ACR Meeting Abstracts

ACR Meeting Abstracts

Session » ACR Convergence 2020

9:00AM-11:00AM
Abstract Number: 0053
¿Comprende? Assessing the Readability of Freely Available Spanish-Language Online Patient Education Materials for Rheumatologic Diseases
9:00AM-11:00AM
Abstract Number: 0090
110 Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Rheumatology Disease Unit: Fracture, Neuropathy, and Pernicious Anemia Are Clues to Recognition
9:00AM-11:00AM
Abstract Number: 0412
2019 Novel Coronavirus Disease (COVID-19) in Patients with Large-Vessels Vasculitis: Single-centre Experience in Paris
9:00AM-11:00AM
Abstract Number: 0073
A Cross-Species Map of Neutrophil Inflammatory Responses
9:00AM-11:00AM
Abstract Number: 0305
A Delphi Consensus Study to Standardize Terminology for the Pre-clinical Phase of Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0399
A Heavy Burden of Calcinosis Reflects Cumulative Disease Damage in Scleroderma
9:00AM-11:00AM
Abstract Number: 0106
A Machine Learning-derived Radiomics Nomogram for Diagnosis of Osteoporosis and Osteopenia
9:00AM-11:00AM
Abstract Number: 0026
A Modified Version of the 2016 ACR Fibromyalgia Criteria Cognitive Items Results in Stronger Correlation Between Subjective and Objective Measures of Cognitive Impairment
9:00AM-11:00AM
Abstract Number: 0201
A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis (RA)
9:00AM-11:00AM
Abstract Number: 0199
A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects
9:00AM-11:00AM
Abstract Number: 0385
A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 0241
A Prospective Analysis of Factors Impacting Medication Adverse Events in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0198
A Prospective Cohort Study of Vehicle Control as a Measure of Driving Performance in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0032
A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0125
A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
9:00AM-11:00AM
Abstract Number: 0216
A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
9:00AM-11:00AM
Abstract Number: 0233
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
9:00AM-11:00AM
Abstract Number: 0314
Accuracy of Physical Examination to Detect Synovial and Extra-synovial Pathologies in Psoriatic Arthritis in Comparison to Ultrasonography
9:00AM-11:00AM
Abstract Number: 0407
Achievement of Early and Sustained Complete Response of Oral Ulcers with Apremilast Compared with Placebo in Patients with Active Behçet’s Syndrome
9:00AM-11:00AM
Abstract Number: 0379
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in DMARD-Naive Patients Treated with Apremilast
9:00AM-11:00AM
Abstract Number: 0353
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
9:00AM-11:00AM
Abstract Number: 0239
Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials
9:00AM-11:00AM
Abstract Number: 0047
Administrative Barriers to Enrollment of Ethnic Minorities in Clinical Research of Rheumatic/Immune-Mediated Diseases
9:00AM-11:00AM
Abstract Number: 0395
African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 0144
Age, Income, Education, and Health Conditions Are Associated with Patient Empowerment Among US Adults with Arthritis, but Race and Geography Are Not
9:00AM-11:00AM
Abstract Number: 0393
Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS)
9:00AM-11:00AM
Abstract Number: 0138
Alignment and Discordances in Treatment Perceptions and Shared Decision-Making Among RA Patients and Rheumatology Care Teams
9:00AM-11:00AM
Abstract Number: 0387
Altered Iron Homeostasis and Pulmonary Haemodynamics in Systemic Sclerosis Associated Pulmonary Arterial Hypertension
9:00AM-11:00AM
Abstract Number: 0066
AMP Deaminase 2 Is Expressed on the Surface of Human Immune Cells as a Novel Regulator of Extracellular Adenosine Metabolism
9:00AM-11:00AM
Abstract Number: 0024
An International Delphi Consensus on Non-pharmacological Interventions for Fibromyalgia
9:00AM-11:00AM
Abstract Number: 0286
An SLE-linked ITGAM Gene Variant Changes Mac-1 Structure, Signaling, and Surface Expression and Enhances IFNg Production and Antigen Presentation by B Cells
9:00AM-11:00AM
Abstract Number: 0079
Analysis of COVID-19 and Rheumatology Twitter Activity During the Pandemic Months
9:00AM-11:00AM
Abstract Number: 0131
Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis
9:00AM-11:00AM
Abstract Number: 0281
ANCA in SLE: Prevalence and Predictor Factors
9:00AM-11:00AM
Abstract Number: 0060
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
9:00AM-11:00AM
Abstract Number: 0424
Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 0007
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
9:00AM-11:00AM
Abstract Number: 0010
Antirheumatic Disease Therapies in Patients with COVID-19: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 0336
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
9:00AM-11:00AM
Abstract Number: 0257
Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records
9:00AM-11:00AM
Abstract Number: 0124
Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
9:00AM-11:00AM
Abstract Number: 0123
Aromatase Inhibitor-Associated Bone Loss: Screening and Prevention
9:00AM-11:00AM
Abstract Number: 0397
Assessing Adherence to Screening of Systemic Sclerosis-Related Lung Disease
9:00AM-11:00AM
Abstract Number: 0003
Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations
9:00AM-11:00AM
Abstract Number: 0111
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 0320
Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0248
Assessment of Lupus Knowledge Through Creation of the Lupus Knowledge Assessment Test (LKAT)
9:00AM-11:00AM
Abstract Number: 0022
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0177
Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0121
Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women
9:00AM-11:00AM
Abstract Number: 0041
Association of the RPA3-UMAD1 Locus with Interstitial Lung Diseases Complicated with Rheumatoid Arthritis in Japanese
9:00AM-11:00AM
Abstract Number: 0178
Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry
9:00AM-11:00AM
Abstract Number: 0242
Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 0317
Axial Involvement in Psoriatic Arthritis in a Comprehensive Rapid Diagnosis Program (Reuma-check PsA). Analysis of Its Characteristics
9:00AM-11:00AM
Abstract Number: 0390
Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry
9:00AM-11:00AM
Abstract Number: 0356
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
9:00AM-11:00AM
Abstract Number: 0127
Biochemical Algorithm to Identify Individuals with ALPL Variants Between Subjects with Persistent Hypophosphatasaemia
9:00AM-11:00AM
Abstract Number: 0348
Biologics History and Sex Are Linked to Golimumab Discontinuation in Axial Spondyloarthritis: A Sub-Analysis of the Post-Registration GO-Practice Study
9:00AM-11:00AM
Abstract Number: 0104
Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0102
Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study
9:00AM-11:00AM
Abstract Number: 0098
CCL2 and CCR2 in Adult Onset Still’s Disease
9:00AM-11:00AM
Abstract Number: 0295
CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia
9:00AM-11:00AM
Abstract Number: 0075
CD209+/CD14+ Dendritic Cells Characterization in Rheumatoid versus Psoriasis Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0155
Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry
9:00AM-11:00AM
Abstract Number: 0415
Characteristics of Arthritis in Adult IgA Vasculitis
9:00AM-11:00AM
Abstract Number: 0306
Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
9:00AM-11:00AM
Abstract Number: 0020
Characteristics of Rheumatology Outpatients with Suspected or Confirmed COVID-19 During the Pandemic in New York City
9:00AM-11:00AM
Abstract Number: 0176
Characterization and Molecular Mechanism Underlying NEMO Deleted Exon 5 Autoinflammatory Syndrome (NDAS)
9:00AM-11:00AM
Abstract Number: 0044
Characterization of Racial Disparities in Rheumatoid Arthritis Treatment Choice and Location of Care
9:00AM-11:00AM
Abstract Number: 0234
Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0072
Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0398
Chest CT Ordering Practices at Expert Scleroderma Centers in the United States
9:00AM-11:00AM
Abstract Number: 0182
Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists
9:00AM-11:00AM
Abstract Number: 0083
Chronic Nonbacterial Osteomyelitis Is Associated with HLA-B*27
9:00AM-11:00AM
Abstract Number: 0085
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
9:00AM-11:00AM
Abstract Number: 0025
Clinical and Psychological Assessment of Rheumatoid Arthritis Patients with Fibromyalgia: A Real World Study
9:00AM-11:00AM
Abstract Number: 0414
Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis
9:00AM-11:00AM
Abstract Number: 0084
Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort
9:00AM-11:00AM
Abstract Number: 0359
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
9:00AM-11:00AM
Abstract Number: 0409
Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size
9:00AM-11:00AM
Abstract Number: 0218
Clinical Outcomes of Earlier versus Delayed Treatment of Iraqi Patients with Rheumatoid Arthritis with Etanercept
9:00AM-11:00AM
Abstract Number: 0180
Clinicopathological Characteristics of Lymphoproliferative Disorders in 232 Patients with Rheumatoid Arthritis in Japan
9:00AM-11:00AM
Abstract Number: 0343
Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0013
Colchicine to Weather the Storm in Hospitalized Patients with COVID-19
9:00AM-11:00AM
Abstract Number: 0355
Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial
9:00AM-11:00AM
Abstract Number: 0368
Comparable Impact and Burden of Disease of Psoriatic Arthritis Patients with Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Treated with Apremilast
9:00AM-11:00AM
Abstract Number: 0333
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0334
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis
9:00AM-11:00AM
Abstract Number: 0324
Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials
9:00AM-11:00AM
Abstract Number: 0403
Comparison of Immediate Post-Operative and Long-Term Outcomes in Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair
9:00AM-11:00AM
Abstract Number: 0280
Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application
9:00AM-11:00AM
Abstract Number: 0100
Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 0293
Contraction of the Stool Taxa Clostridia Is Associated with the Development of Clinical Disease Among Anti-Ro+ Mothers of Children with Neonatal Lupus
9:00AM-11:00AM
Abstract Number: 0413
Coronavirus Infection and Vasculitis: Identifying Associations Mining the Biomedical Literature
9:00AM-11:00AM
Abstract Number: 0252
Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis
9:00AM-11:00AM
Abstract Number: 0163
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
9:00AM-11:00AM
Abstract Number: 0153
Counseling on Safe Driving Strategies in Patients with Osteoarthritis and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0015
COVID -19 Lung Inflammation – What Have We Learnt so Far ?
9:00AM-11:00AM
Abstract Number: 0008
COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review
9:00AM-11:00AM
Abstract Number: 0051
COVID-Related Distress and Mental Health in Adult Rheumatology Patients During the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 0285
CXCL13 Neutralization Reduces Neuropsychiatric Manifestations in MRL/lpr Mice
9:00AM-11:00AM
Abstract Number: 0027
CYP2D6 Genotype and Reduced Codeine Analgesic Effect in Real-World Clinical Practice
9:00AM-11:00AM
Abstract Number: 0312
Dactylitis Is Associated with Greater Disease Severity, Ultrasound Synovitis, and Erosive Damage, in Very Early DMARD Naïve Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0423
Defining Ear Chondritis: Data from 685 Patients with Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 0391
Defining the Optimal Disease Duration of Early Diffuse Systemic Sclerosis for Clinical Trial Design
9:00AM-11:00AM
Abstract Number: 0308
Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study
9:00AM-11:00AM
Abstract Number: 0050
Demographic Disparities in the Medically Underserved Populations of Southern California: A Rheumatology Cohort of Cytokine Release Syndrome Patients Due to COVID-19
9:00AM-11:00AM
Abstract Number: 0174
Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0194
Depression Symptoms but Not Clinically Diagnosed Depression Predict Mortality in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0112
Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy
9:00AM-11:00AM
Abstract Number: 0048
Determinants of Participation in Clinical Trials Among Patients with Lupus in the United States
9:00AM-11:00AM
Abstract Number: 0189
Determining the Relationship Between Mycobacterium Avium Subspecies Paratuberculosis Serostatus, Dietary Habits, Medication Regimen, and Joint Pain in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0322
Development and Preliminary Validation of Smartphone Sensor-based Measurement Tools for Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0117
Development of an In Vitro Trabecular Human Bone Model to Recapitulate Features of Glucocorticoid-induced Osteoporosis
9:00AM-11:00AM
Abstract Number: 0092
Diagnosis of Behçet’s Disease: Comparison of Two Sets of Classification Criteria. Application in 111 Patients of a Well-defined Population
9:00AM-11:00AM
Abstract Number: 0309
Diagnostic Delay in Psoriatic Arthritis: A Population Based Study
9:00AM-11:00AM
Abstract Number: 0417
Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes
9:00AM-11:00AM
Abstract Number: 0016
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
9:00AM-11:00AM
Abstract Number: 0082
Diffuse Sclerosing Osteomyelitis of the Jaw: An Underdiagnosed Disease in Maxillofacial Surgery Department
9:00AM-11:00AM
Abstract Number: 0405
Disease Activity and Quality-of-Life Outcomes in Patients with Behçet’s Syndrome Who Achieved and Maintained Oral Ulcer Complete Response with Apremilast Treatment
9:00AM-11:00AM
Abstract Number: 0049
Disparities in Patient Portal Use Among Patients with Rheumatic and Musculoskeletal Diseases in a Large Academic Medical Center
9:00AM-11:00AM
Abstract Number: 0035
Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides
9:00AM-11:00AM
Abstract Number: 0030
Distinct DNA Methylation Patterns of Rheumatoid Arthritis Peripheral Blood and Synovial Tissue T Cells
9:00AM-11:00AM
Abstract Number: 0260
Does Higher Quality of Care in SLE Improve Quality of Life?
9:00AM-11:00AM
Abstract Number: 0358
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
9:00AM-11:00AM
Abstract Number: 0360
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study
9:00AM-11:00AM
Abstract Number: 0097
Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with FMF?
9:00AM-11:00AM
Abstract Number: 0014
Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?
9:00AM-11:00AM
Abstract Number: 0110
Does Urate Directly Influence Bone Turnover? Randomized Controlled Trial of Inosine Supplementation
9:00AM-11:00AM
Abstract Number: 0058
Drug Retention and Discontinuation of Biological DMARDs and Novel Small Molecules: Data from the Singapore National Biologics Registry
9:00AM-11:00AM
Abstract Number: 0251
Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort
9:00AM-11:00AM
Abstract Number: 0157
Early Arthritis Global Assesment: What Differences Exist Between Patients and Physicians?
9:00AM-11:00AM
Abstract Number: 0172
Early Treatment and IL1RN Single Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0230
Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial
9:00AM-11:00AM
Abstract Number: 0255
Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint
9:00AM-11:00AM
Abstract Number: 0369
Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs
9:00AM-11:00AM
Abstract Number: 0345
Effectiveness and Safety of Apremilast in Biologic-Naive versus Biologic-Experienced Patients with Psoriatic Arthritis in Real-World Clinical Practice Settings in Germany: Interim Analysis of an Ongoing, Multicenter, Prospective, Non-interventional Study
9:00AM-11:00AM
Abstract Number: 0107
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
9:00AM-11:00AM
Abstract Number: 0208
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results
9:00AM-11:00AM
Abstract Number: 0217
Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results
9:00AM-11:00AM
Abstract Number: 0380
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
9:00AM-11:00AM
Abstract Number: 0352
Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results
9:00AM-11:00AM
Abstract Number: 0211
Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs
9:00AM-11:00AM
Abstract Number: 0375
Efficacy of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 0363
Efficacy of Ixekizumab on Disease Activity and Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis and Objective Signs of Inflammation, Stratified by Baseline CRP/Sacroiliac Joint MRI Status
9:00AM-11:00AM
Abstract Number: 0224
Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0381
Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0059
EHR-Supported Staff Protocol Improves Smoking Cessation in a Diverse Rheumatology Clinic: Results of Quit Connect Dissemination Project
9:00AM-11:00AM
Abstract Number: 0289
Endogenous Interferon-β and Low IL-4R on Transitional B Cells Promotes Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 0428
Enrichment of Clinical Trial Recruitment Using Advanced Molecular Imaging in Takayasu’s Arteritis
9:00AM-11:00AM
Abstract Number: 0195
Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV
9:00AM-11:00AM
Abstract Number: 0408
Epidemiology and Treatment of Behçet’s Disease Insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry
9:00AM-11:00AM
Abstract Number: 0377
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
9:00AM-11:00AM
Abstract Number: 0265
Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort
9:00AM-11:00AM
Abstract Number: 0292
Exhausted pSTAT5-IFNα Signaling Pathways in SLE Patients Are Correlated with Age-associated B Cells and Disease Activity
9:00AM-11:00AM
Abstract Number: 0365
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
9:00AM-11:00AM
Abstract Number: 0012
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 0410
Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis
9:00AM-11:00AM
Abstract Number: 0300
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
9:00AM-11:00AM
Abstract Number: 0282
Expression of the cGAMP Transporter SLC19A1 Is Altered in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0271
External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0246
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
9:00AM-11:00AM
Abstract Number: 0263
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0388
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
9:00AM-11:00AM
Abstract Number: 0206
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
9:00AM-11:00AM
Abstract Number: 0142
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
9:00AM-11:00AM
Abstract Number: 0141
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study
9:00AM-11:00AM
Abstract Number: 0143
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study
9:00AM-11:00AM
Abstract Number: 0136
Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies
9:00AM-11:00AM
Abstract Number: 0326
Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe
9:00AM-11:00AM
Abstract Number: 0119
Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes
9:00AM-11:00AM
Abstract Number: 0422
Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 0067
Functionally Mature CD1c+ Dendritic Cells Contribute to Synovial Inflammation in Rheumatoid Arthritis via STAT3
9:00AM-11:00AM
Abstract Number: 0267
Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
9:00AM-11:00AM
Abstract Number: 0034
Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0301
Genetic Associations and Polygenic Risk Assessment in Incomplete Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0283
Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis
9:00AM-11:00AM
Abstract Number: 0086
Geographic Distribution of Eosinophilic Fasciitis Cases in Massachusetts and Associated Environmental Triggers
9:00AM-11:00AM
Abstract Number: 0043
Geographical Disparity in Rheumatoid Arthritis Disease Burden Independent of Race/Ethnicity
9:00AM-11:00AM
Abstract Number: 0005
Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists
9:00AM-11:00AM
Abstract Number: 0238
Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
9:00AM-11:00AM
Abstract Number: 0129
Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density
9:00AM-11:00AM
Abstract Number: 0109
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
9:00AM-11:00AM
Abstract Number: 0259
Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis
9:00AM-11:00AM
Abstract Number: 0332
Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
9:00AM-11:00AM
Abstract Number: 0367
Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
9:00AM-11:00AM
Abstract Number: 0370
Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1
9:00AM-11:00AM
Abstract Number: 0045
Healthcare Practitioner Confidence Assessing Rashes in Patients of Skin of Color with Lupus
9:00AM-11:00AM
Abstract Number: 0328
Healthcare Utilization and Costs Among Patients with Psoriatic Arthritis and Psoriasis in the United States – a Retrospective Study of Claims Data from 2009 to 2020
9:00AM-11:00AM
Abstract Number: 0329
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0091
Helicobacter Pylori Infection, Autoimmune Disease and Paraproteinemia Influence the Presentation of a Cohort of 150 Pernicious Anemia Patients Diagnosed in a Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 0087
Hemophagocytic Syndrome. Clinical Characteristics and Prognostic Factors of a Series of 30 Clinical Cases
9:00AM-11:00AM
Abstract Number: 0190
Hepatic Steatosis in Rheumatoid Arthritis: Frequency and Disease-Related Contributors
9:00AM-11:00AM
Abstract Number: 0316
High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0376
Higher Intake of Carbohydrates and Free Sugar Are Associated with Higher Disease Activity in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0354
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
9:00AM-11:00AM
Abstract Number: 0149
How Stable Are Medication Necessity Beliefs and Safety Concerns in the First Year of RA?
9:00AM-11:00AM
Abstract Number: 0002
Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era
9:00AM-11:00AM
Abstract Number: 0023
Hypophosphatasia May Be Misdiagnosed as Fibromyalgia: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 0039
Identification of a Regulatory Pathway Governing Expression of TRAF1 via a JIA-associated Non-coding Variant
9:00AM-11:00AM
Abstract Number: 0069
Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis
9:00AM-11:00AM
Abstract Number: 0179
Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning
9:00AM-11:00AM
Abstract Number: 0175
Identifying Immuno-phenotypes in Juvenile Localized Scleroderma with RNA Sequencing
9:00AM-11:00AM
Abstract Number: 0371
Identifying Inadequate Response Among Ankylosing Spondylitis Patients Prescribed Biologics in a Real-world Commercially Insured Adult Population in the United States
9:00AM-11:00AM
Abstract Number: 0162
Identifying Sleep Problems in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients with Patient-reported Outcomes (PRO) Questionnaires
9:00AM-11:00AM
Abstract Number: 0416
IgG4-related Retroperitoneal Fibrosis. Retrospective Cohort
9:00AM-11:00AM
Abstract Number: 0126
Immunophenotyping of Peripheral Blood Highlights an Association of Dysregulated Lymphocytes with Patients with Glucocorticoid-induced Osteonecrosis
9:00AM-11:00AM
Abstract Number: 0168
Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
9:00AM-11:00AM
Abstract Number: 0220
Impact of Concomitant Glucocorticoids on the Clinical Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: An Ad Hoc Analysis of Data from Three Phase 3 Studies
9:00AM-11:00AM
Abstract Number: 0017
Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Immunosuppressive Medications
9:00AM-11:00AM
Abstract Number: 0268
Impact of Flares on Healthcare Resource Usage and PROs in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 0228
Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
9:00AM-11:00AM
Abstract Number: 0113
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
9:00AM-11:00AM
Abstract Number: 0115
Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project
9:00AM-11:00AM
Abstract Number: 0347
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
9:00AM-11:00AM
Abstract Number: 0215
Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program
9:00AM-11:00AM
Abstract Number: 0277
Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria
9:00AM-11:00AM
Abstract Number: 0114
Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to Precision Error
9:00AM-11:00AM
Abstract Number: 0183
Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry
9:00AM-11:00AM
Abstract Number: 0191
Increased Frequency of Lower Limb Arterial Obstruction in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0382
Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis
9:00AM-11:00AM
Abstract Number: 0338
Increased Risk of Lymphoproliferative Disorders in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0057
Increased Susceptibility to Measles in Patients from Central America and Mexico in a U.S. Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 0118
Indicators of Effectiveness After 6 Years of Follow-up in a Fracture Liaison Service
9:00AM-11:00AM
Abstract Number: 0406
Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients
9:00AM-11:00AM
Abstract Number: 0192
Influence of Inflammatory and Non-inflammatory Rheumatic Disorders on the Clinical and Biological Profile of Adult-onset Diabetes
9:00AM-11:00AM
Abstract Number: 0229
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years
9:00AM-11:00AM
Abstract Number: 0171
Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI
9:00AM-11:00AM
Abstract Number: 0099
Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis
9:00AM-11:00AM
Abstract Number: 0335
Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0296
Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals
9:00AM-11:00AM
Abstract Number: 0219
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
9:00AM-11:00AM
Abstract Number: 0339
Is Sex-adjusted Treatment in Early-PsA Justified?
9:00AM-11:00AM
Abstract Number: 0404
Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management
9:00AM-11:00AM
Abstract Number: 0378
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
9:00AM-11:00AM
Abstract Number: 0019
Lasting COVID-19 Impacts on US Rheumatology Practices
9:00AM-11:00AM
Abstract Number: 0037
Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 0254
LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort
9:00AM-11:00AM
Abstract Number: 0298
Local Genetic Ancestry Associations with Clinical Features of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0052
Loneliness and Social Isolation Are Important Social Determinants Among Patients from Minority Communities with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 0212
Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks
9:00AM-11:00AM
Abstract Number: 0210
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibitors
9:00AM-11:00AM
Abstract Number: 0240
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Inhibitor Failures
9:00AM-11:00AM
Abstract Number: 0307
Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0302
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
9:00AM-11:00AM
Abstract Number: 0247
Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0250
Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
9:00AM-11:00AM
Abstract Number: 0273
Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
9:00AM-11:00AM
Abstract Number: 0184
Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study
9:00AM-11:00AM
Abstract Number: 0425
MAGIC Syndrome in a Cohort of Patients with Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 0001
Management of Rheumatic Diseases During COVID-19: A National Veterans Affairs Survey of Rheumatologists
9:00AM-11:00AM
Abstract Number: 0140
Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-To- Severe Osteoarthritis
9:00AM-11:00AM
Abstract Number: 0373
Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study
9:00AM-11:00AM
Abstract Number: 0341
Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity
9:00AM-11:00AM
Abstract Number: 0031
Metabolomics Profiling Predicts Outcome of Tocilizumab in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0205
Methotrexate Therapy Is Not Associated with an Increased Risk of Liver Fibrosis Assessed by the Fibrosis-4 Index
9:00AM-11:00AM
Abstract Number: 0181
Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study
9:00AM-11:00AM
Abstract Number: 0077
Mimickers of Immunoglobulin G4-Related Disease
9:00AM-11:00AM
Abstract Number: 0036
Molecular Phenotyping of Late-Stage Knee Osteoarthritis Synovium Through Total RNA-Sequencing
9:00AM-11:00AM
Abstract Number: 0151
More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)
9:00AM-11:00AM
Abstract Number: 0173
mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice
9:00AM-11:00AM
Abstract Number: 0342
Multimorbidity Clusters in Psoriatic Arthritis: A Population-Based Study
9:00AM-11:00AM
Abstract Number: 0330
Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors
9:00AM-11:00AM
Abstract Number: 0374
Neo-epitopes of Type I Collagen Can Be Utilized as Translational Biomarkers for Skin and Joint Turnover in Patients with Psoriasis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0340
Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity
9:00AM-11:00AM
Abstract Number: 0064
Neutrophil Extracellular Traps Are Sufficient to Activate the Alternative Pathway of Complement
9:00AM-11:00AM
Abstract Number: 0070
Neutrophils Transiting Through Megakaryocytes During Emperipolesis Exhibit Distinct Fates and Acquire the Capacity to Guide Other Neutrophils via MK Trails
9:00AM-11:00AM
Abstract Number: 0063
Novel Repurposed Drugs Against Joint Inflammation Reveal Potential Use for Gout Treatment: An In Silico, In Vitro and Clinical Study
9:00AM-11:00AM
Abstract Number: 0196
Objectively-Measured Obstructive Sleep Apnea Is Frequent Among Individuals with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0402
Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 0389
Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 0122
Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry
9:00AM-11:00AM
Abstract Number: 0321
Outcome Measures in Psoriatic Arthritis Registries Are Very Heterogeneous: A Systematic Literature Review of 27 Registries, or 16183 Patients
9:00AM-11:00AM
Abstract Number: 0400
Outcomes of Systemic Sclerosis Hospitalizations by Hospital Teaching Status: Analysis of the National Inpatient Sample
9:00AM-11:00AM
Abstract Number: 0284
Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model
9:00AM-11:00AM
Abstract Number: 0318
Oxylipin Profile Is Associated with Skin Disease and Enthesitis in Psoriatic Disease
9:00AM-11:00AM
Abstract Number: 0028
Pain in the Time of Corona: Impact of COVID 19 Outbreak on Fibromyalgia Patients
9:00AM-11:00AM
Abstract Number: 0275
Paradoxical Relationship Between Disease Activity and Satisfaction with Care in Lupus
9:00AM-11:00AM
Abstract Number: 0256
Patient Perspective of the Type 1 and 2 SLE Model: A Qualitative Study
9:00AM-11:00AM
Abstract Number: 0159
Patient-Reported Data Show the Impact of Time to Diagnosis in RA
9:00AM-11:00AM
Abstract Number: 0169
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0011
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
9:00AM-11:00AM
Abstract Number: 0193
Patients with Asthma Have a Higher Risk of Rheumatoid Arthritis: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 0362
Patients with Psoriatic Arthritis Treated with Guselkumab Achieved Psoriasis-Related Symptom-Free State and Had No Skin Condition Impact on Their Health Related Quality of Life
9:00AM-11:00AM
Abstract Number: 0146
Patients’ Perceptions and Expectations Towards the Role of Rheumatologists in the Recommendations of Physical Activity’s Practice – A Cross-sectional Study Involving 308 Patients Living with Rheumatoid Arthritis in France
9:00AM-11:00AM
Abstract Number: 0148
Perspectives on Treatment Burden for Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis Patients: A Qualitative Study
9:00AM-11:00AM
Abstract Number: 0133
Pharmacist-Driven Clinic Development for Patients with Incidental Vertebral or Hip Fractures
9:00AM-11:00AM
Abstract Number: 0204
Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects
9:00AM-11:00AM
Abstract Number: 0386
Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ Hematopoietic Stem Cells Without G-CSF
9:00AM-11:00AM
Abstract Number: 0421
Polymyalgia Rheumatica Is Associated with Later Menopause: An Observational Study
9:00AM-11:00AM
Abstract Number: 0349
Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
9:00AM-11:00AM
Abstract Number: 0033
Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy
9:00AM-11:00AM
Abstract Number: 0200
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
9:00AM-11:00AM
Abstract Number: 0261
Predictors of Future Repeat Renal Biopsies in Patients with Lupus Nephritis and Influence of Repeat Biopsy in Flare Management: A Retrospective Study
9:00AM-11:00AM
Abstract Number: 0401
Prevalence and Characteristics of Systemic Sclerosis Patients Fulfilling the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0166
Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
9:00AM-11:00AM
Abstract Number: 0225
Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study
9:00AM-11:00AM
Abstract Number: 0264
Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0392
Prevalence and Survival of Systemic Sclerosis (SSc) and Associated Interstitial Lung Disease (ILD) in Ontario, Canada over 10 Years
9:00AM-11:00AM
Abstract Number: 0394
Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors
9:00AM-11:00AM
Abstract Number: 0009
Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases
9:00AM-11:00AM
Abstract Number: 0185
Prevalence of Migraine and Neuropathic Pain in Rheumatic Disease
9:00AM-11:00AM
Abstract Number: 0132
Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment
9:00AM-11:00AM
Abstract Number: 0081
Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome
9:00AM-11:00AM
Abstract Number: 0418
Prevalence of Thyroid Disease Among Patients with Vasculitis
9:00AM-11:00AM
Abstract Number: 0021
Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned
9:00AM-11:00AM
Abstract Number: 0018
PROMIS-29 and Health Related Quality of Life in Rheumatology Outpatients During the COVID-19 Pandemic in New York City
9:00AM-11:00AM
Abstract Number: 0137
PROMIS-29 Scores Are Significantly Higher in Patients with Rheumatoid Arthritis Who Meet Criteria for Co-morbid Fibromyalgia (FM) Than in Those with Rheumatoid Arthritis and No FM
9:00AM-11:00AM
Abstract Number: 0420
Prospective Analysis of the Prevalence of Giant Cell Arteritis in Consecutive Newly Diagnosed Patients with Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 0038
Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study
9:00AM-11:00AM
Abstract Number: 0279
Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0006
Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
9:00AM-11:00AM
Abstract Number: 0042
Racial and Ethnic Differences in a Multiple Biochemical Measure of Rheumatoid Arthritis Disease Activity
9:00AM-11:00AM
Abstract Number: 0055
Racial and Sex-based Disparities in Health Care Utilization: Eye Inflammation as a Paradigm
9:00AM-11:00AM
Abstract Number: 0227
Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
9:00AM-11:00AM
Abstract Number: 0187
Regional and Widespread Patterns of Non-articular Pain Are Common at RA Diagnosis and Contribute to Poor Outcomes at 12 Months: A Prospective Study of Pain Patterns in Canadians with RA
9:00AM-11:00AM
Abstract Number: 0158
Relationships Between Disease Patterns in RA and Rheumatology Treatment
9:00AM-11:00AM
Abstract Number: 0323
Residual Symptoms in Patients with PsA Who Are in Very Low Disease Activity According to Physician Assessments
9:00AM-11:00AM
Abstract Number: 0361
Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration
9:00AM-11:00AM
Abstract Number: 0078
Retrospective Analysis of Clinical Characteristics and Classification Criteria Performance in a Single Center Cohort of 114 Patients Diagnosed with IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 0093
Review of Gastrointestinal Manifestations of Kohlmeier-Degos Disease
9:00AM-11:00AM
Abstract Number: 0167
Rheumatoid Arthritis Patient Phenotypes from a Digital Health Coaching Engagement Program
9:00AM-11:00AM
Abstract Number: 0061
Rheumatologists’ Attitudes Toward Palliative Care and Medical Assistance in Dying
9:00AM-11:00AM
Abstract Number: 0120
Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases
9:00AM-11:00AM
Abstract Number: 0287
RNA Externalized by Neutrophil Extracellular Traps Promotes Inflammatory Pathways in Endothelial Cells
9:00AM-11:00AM
Abstract Number: 0290
Role of Protein Tyrosine Phosphatase 1B (PTP1B) in Endothelial-to-Mesenchymal Transition (EndoMT) Promoted by Inflammation: Implications for SLE
9:00AM-11:00AM
Abstract Number: 0056
Role of Socioeconomic and Cultural Factors in Racial Disparities in Disease Severity and Health Status of Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0101
Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass
9:00AM-11:00AM
Abstract Number: 0139
Routine Assessment of Patient Index Data (RAPID) 3 as a Predictor of Weight Reduction in Rheumatology Patients Undergoing Bariatric Surgery
9:00AM-11:00AM
Abstract Number: 0235
Safety and Biological Activity of Rozibafusp Alfa in Subjects with Rheumatoid Arthritis: Final Results of a Phase 1b Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study
9:00AM-11:00AM
Abstract Number: 0232
Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN
9:00AM-11:00AM
Abstract Number: 0396
Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
9:00AM-11:00AM
Abstract Number: 0236
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
9:00AM-11:00AM
Abstract Number: 0203
Safety of Baricitinib in Patients with Rheumatoid Arthritis: Interim Report from All-Case Post‑Marketing Study in Clinical Use
9:00AM-11:00AM
Abstract Number: 0223
Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB)
9:00AM-11:00AM
Abstract Number: 0202
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis
9:00AM-11:00AM
Abstract Number: 0237
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0346
Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0411
Serial Vessel Wall Enhancement Change on High-Resolution MRI Vessel Wall Imaging in Primary Central Nervous System Vasculitis
9:00AM-11:00AM
Abstract Number: 0253
Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 0384
Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 0383
Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials
9:00AM-11:00AM
Abstract Number: 0128
Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck
9:00AM-11:00AM
Abstract Number: 0221
Should We Use BioDMARDS in First Intention in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
9:00AM-11:00AM
Abstract Number: 0071
Significant Enrichment of Transcriptionally Distinct CD206+CD163+ Macrophage Population in Rheumatoid Arthritis Synovial Tissue
9:00AM-11:00AM
Abstract Number: 0226
Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0337
Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
9:00AM-11:00AM
Abstract Number: 0068
Single Cell RNA-seq to Characterize Monocyte Subtypes in the Autoinflammatory Interferonopathy, SAVI and the Inflammasomopathy, NOMID
9:00AM-11:00AM
Abstract Number: 0327
Skin Involvement in Psoriatic Arthritis (PsA) – The Incremental Impact of Psoriasis on Quality of Life, Disability and Work Productivity: Real-world Survey in US and Europe
9:00AM-11:00AM
Abstract Number: 0291
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0303
SLE Patients Stratify into Distinct Clusters Based on Their Peripheral Blood Immunologic Phenotype During Acute Flare
9:00AM-11:00AM
Abstract Number: 0262
SLE Pregnancies: C4 as Predictor of Flares and Adverse Pregnancy Outcomes
9:00AM-11:00AM
Abstract Number: 0046
Socioeconomic Disparities in Functional Status Among RA Patients: A Longitudinal Analysis Using RISE Data
9:00AM-11:00AM
Abstract Number: 0364
Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
9:00AM-11:00AM
Abstract Number: 0272
Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
9:00AM-11:00AM
Abstract Number: 0357
Suppressing Inflammation Rather Than Lowering the Disease Activity Score Should Be Targeted During TNF Inhibitor Treatment to Slow Radiographic Changes in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 0419
Survival and Prevalent Comorbidities in Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 0214
Sustainability of Response Between Upadacitinib and Adalimumab Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
9:00AM-11:00AM
Abstract Number: 0213
Sustainability of Response to Upadacitinib as Monotherapy or in Combination Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Conventional Synthetic DMARDs
9:00AM-11:00AM
Abstract Number: 0313
Swollen Joints but Not Tender Joints Are Associated with Ultrasound Power Doppler Synovitis in Very Early DMARD Naive Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0366
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
9:00AM-11:00AM
Abstract Number: 0095
Systematic Evaluation of Nine Monogenic Autoinflammatory Diseases Reveals Common and Disease-Specific Correlations with Allergy-Associated Features
9:00AM-11:00AM
Abstract Number: 0245
Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record
9:00AM-11:00AM
Abstract Number: 0269
Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality
9:00AM-11:00AM
Abstract Number: 0426
T-Cell Receptor (TCR) Sequencing Reveals Decreased Diversity and Clonotypic Expansion of T-cells in Relapsing Polychondritis (RP)
9:00AM-11:00AM
Abstract Number: 0319
Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24
9:00AM-11:00AM
Abstract Number: 0288
Targeted Sequencing Revealed Novel Candidate Genetic Contributions to Lupus Nephritis in a Cohort of Swedish Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0103
The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative
9:00AM-11:00AM
Abstract Number: 0096
The Bicipital Stress Test: A Maneuver to More Accurately Diagnose Bicipital Tendinitis and Its Referred Pain Patterns
9:00AM-11:00AM
Abstract Number: 0197
The Clinical and Laboratory Features of Seronegative Rheumatoid Arthritis with and Without Malignancy
9:00AM-11:00AM
Abstract Number: 0266
The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0065
The Energy-dependent Hierarchy of Immune Functions in Human Monocytes
9:00AM-11:00AM
Abstract Number: 0350
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 0134
The Impact of Exercise on Sleep in People with Rheumatoid Arthritis: A Pilot Randomised Controlled Trial
9:00AM-11:00AM
Abstract Number: 0325
The Impact of PsA Disease Control Status on Patient Treatment Satisfaction: Real-world Survey in US and Europe
9:00AM-11:00AM
Abstract Number: 0004
The Impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases: A Study in 15 Arab Countries
9:00AM-11:00AM
Abstract Number: 0116
The in Vitro 3D Fracture Gap Model: A Tool for Preclinical Testing
9:00AM-11:00AM
Abstract Number: 0147
The Interpretation of Patient-reported Outcomes in Rheumatoid Arthritis: Do Clinical Trials Adequately Evaluate Meaningful Improvements for Patients?
9:00AM-11:00AM
Abstract Number: 0074
The Intracellular DNA Sensor STING Protects Against Bone Loss Through Regulation of Type I Interferons
9:00AM-11:00AM
Abstract Number: 0311
The Link Between Joints and Entheses in Psoriatic Arthritis: An Ultrasound Study Supporting the Synovio-entheseal Complex Theory
9:00AM-11:00AM
Abstract Number: 0299
The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0270
The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE
9:00AM-11:00AM
Abstract Number: 0186
The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0310
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report
9:00AM-11:00AM
Abstract Number: 0150
The Preparation Experience for Total Knee Arthroplasty of Patients with Osteoarthritis: A Cross-Sectional Survey
9:00AM-11:00AM
Abstract Number: 0130
The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review
9:00AM-11:00AM
Abstract Number: 0108
The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0274
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
9:00AM-11:00AM
Abstract Number: 0089
The Risk Factors of Recurrence in Relapsing Polychondritis; A Study of 41 Cases
9:00AM-11:00AM
Abstract Number: 0188
The Risk of Fractures in a Community-based Cohort of Patients with Rheumatoid Arthritis Compared with the Background Population
9:00AM-11:00AM
Abstract Number: 0243
The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus
9:00AM-11:00AM
Abstract Number: 0156
The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis
9:00AM-11:00AM
Abstract Number: 0076
The Role of Interferon Kappa in Psoriasis
9:00AM-11:00AM
Abstract Number: 0062
The Role of PGLYRP1 in the Pathogenesis of Lyme Disease
9:00AM-11:00AM
Abstract Number: 0315
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia
9:00AM-11:00AM
Abstract Number: 0088
The Spectrum of Hemophagocytic Lymphohistiocytosis: Autoimmunity vs. Malignancy
9:00AM-11:00AM
Abstract Number: 0294
Tired T-Cells and Monocytes with Malaise: Investigating the Links Between Cellular Iron Deficiency and Mitochondrial Dysfunction in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0297
Towards a Glucocorticoid Exposure Signature in SLE: Effects of Type I Interferon
9:00AM-11:00AM
Abstract Number: 0145
Treat-to-Target in Rheumatoid Arthritis: Rates of Treatment Changes in Patients Engaged with Care Management Services Compared to Historically Reported National Registry Based Estimates
9:00AM-11:00AM
Abstract Number: 0154
Treatment Decision Making Among Axial Spondyloarthritis Patients: Real-World Data from the ArthritisPower Registry
9:00AM-11:00AM
Abstract Number: 0231
Treatment Patterns of Biologic/Targeted Synthetic DMARDs for the Management of Rheumatoid Arthritis in Australia: An Analysis of the OPAL Dataset
9:00AM-11:00AM
Abstract Number: 0278
Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study
9:00AM-11:00AM
Abstract Number: 0222
tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to bDMARDs Both in Bionaive and Bioexperienced Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0372
Tumor Necrosis Factor-α Receptor 2 Polymorphisms and Response to TNF Inhibitor Therapy in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0276
Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy
9:00AM-11:00AM
Abstract Number: 0304
Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids
9:00AM-11:00AM
Abstract Number: 0080
Understanding Ankylosing Spondylitis –
9:00AM-11:00AM
Abstract Number: 0135
Understanding the Rheumatologist-Patient Relationship in Treating Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0209
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks
9:00AM-11:00AM
Abstract Number: 0207
Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks
9:00AM-11:00AM
Abstract Number: 0029
Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 0105
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
9:00AM-11:00AM
Abstract Number: 0160
Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
9:00AM-11:00AM
Abstract Number: 0344
Use of the BASDAI in Psoriatic Arthritis Patients with and Without Axial Disease
9:00AM-11:00AM
Abstract Number: 0258
Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous
9:00AM-11:00AM
Abstract Number: 0351
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
9:00AM-11:00AM
Abstract Number: 0170
Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0161
Validation of Patient-reported Outcomes (PRO) Lung Questionnaires for Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Risk for Lung Disease
9:00AM-11:00AM
Abstract Number: 0427
Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 0249
Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
9:00AM-11:00AM
Abstract Number: 0094
Validation Study of Proposed Diagnostic Criteria for Sympathetic Joint Effusion
9:00AM-11:00AM
Abstract Number: 0152
Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals
9:00AM-11:00AM
Abstract Number: 0244
What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?
9:00AM-11:00AM
Abstract Number: 0164
What’s in a Name? Patient and Family Perspectives on the Naming of Systemic Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0040
Whole Blood RNA Expression in Clinically Suspected Arthralgia Patients Shows a Potential Value in Prediction of Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 0331
Work Absenteeism and Disability Associated with Psoriatic Arthritis and Psoriasis in the United States – A Retrospective Study of Claims Data from 2009 to 2020
9:00AM-11:00AM
Abstract Number: 0165
Work Disability and Predictors of Poor Work Outcome in Patients with Axial Spondyloarthritis
10:00AM-10:50AM
Abstract Number: 0454
Anticytokine Therapies for Inflammatory Rheumatic Disease (IRD) Are Associated with Reduced Hospitalisation Following Community COVID-19 Infection; Results of the Trinity Rheumatology and Covid-19 Registry – TRACR
10:00AM-10:50AM
Abstract Number: 0474
Assessment of Teaching Behavior and Knowledge Among Faculty to Inform an Active Teaching Intervention Within a Rheumatology Fellowship Curriculum
10:00AM-10:50AM
Abstract Number: 0459
Autologous Hematopoietic Stem Cell Transplantation for Behçet’s Disease: A Retrospective Survey of Patients Treated in Europe, on the Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Bone Marrow Transplantation
10:00AM-10:50AM
Abstract Number: 0444
Chronological Order of Decrease of Synovitis, Osteitis and Tenosynovitis in Early Arthritis Patients Receiving First DMARD-treatment
10:00AM-10:50AM
Abstract Number: 0448
Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A mutlicenter study with 806 patients.
10:00AM-10:50AM
Abstract Number: 0445
Dual-Energy CT in Gout Patients: Do All Color-Coded Lesions Actually Represent Monosodium Urate Crystals?
10:00AM-10:50AM
Abstract Number: 0461
High-Throughput Single-Cell Analysis Reveals Unique Lung Cellular Subsets in a Murine Model of Rheumatoid Arthritis-Inflammatory Lung Disease
10:00AM-10:50AM
Abstract Number: 0455
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
10:00AM-10:50AM
Abstract Number: 0457
Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients
10:00AM-10:50AM
Abstract Number: 0478
Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program
10:00AM-10:50AM
Abstract Number: 0462
Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome
10:00AM-10:50AM
Abstract Number: 0460
Lymphocyte Clonal Expansion Distinguishes Different Forms of Uveitis
10:00AM-10:50AM
Abstract Number: 0447
Magnetic Resonance Imaging Characteristics in Patients with Spondyloarthritis and Clinical Diagnosis of Heel Enthesitis: Screening Data from a Phase 3 Trial
10:00AM-10:50AM
Abstract Number: 0463
Molecular Diagnosis of Childhood Immunodysregulation, Endocrinopathy and Enteropathy X-linked (IPEX)-Like Syndrome and Implications for Clinical Management
10:00AM-10:50AM
Abstract Number: 0446
Novel Ultrasound Image Acquisition Protocol and Scoring System for the Pediatric Ankle
10:00AM-10:50AM
Abstract Number: 0458
Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force
10:00AM-10:50AM
Abstract Number: 0456
Reduced Risk of Serious Pneumococcal Infection up to 10 Years After Immunization with 7-valent Conjugated Pneumococcal Vaccine in Patients with Inflammatory Arthritis
10:00AM-10:50AM
Abstract Number: 0477
Rheumatology Fellowship Program Directors in the United States: Analysis of Demographics, Educational and Scholarly Achievements
10:00AM-10:50AM
Abstract Number: 0475
To Attend or Note to Attend; The Medical Student’s Dilemma
10:00AM-10:50AM
Abstract Number: 0476
Using Consensus Building to Guide Rheumatology Curriculum Development for Internal Medicine Residents
11:30AM-1:00PM
Abstract Number: 0431
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
11:30AM-1:00PM
Abstract Number: 0430
Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network
11:30AM-1:00PM
Abstract Number: 0429
Prothrombotic Antiphospholipid Antibodies in COVID-19
11:30AM-1:00PM
Abstract Number: 0433
Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus
11:30AM-1:00PM
Abstract Number: 0432
The Effect on Renal Function of the Complement C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
3:00PM-3:50PM
Abstract Number: 0483
Can a Clinical Disease Activity Index Based on Patient-Reported Joint Counts (PT-CDAI) Be Used to Inform Target-Based Care in Telemedicine? An Analysis of 2 Early RA Cohort Studies
3:00PM-3:50PM
Abstract Number: 0509
Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1
3:00PM-3:50PM
Abstract Number: 0507
Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study
3:00PM-3:50PM
Abstract Number: 0449
Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca
3:00PM-3:50PM
Abstract Number: 0482
Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
3:00PM-3:50PM
Abstract Number: 0479
Early DAS Response After DMARD-start Increases Probability of Achieving Sustained DMARD-free Remission in Rheumatoid Arthritis
3:00PM-3:50PM
Abstract Number: 0506
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
3:00PM-3:50PM
Abstract Number: 0504
Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
3:00PM-3:50PM
Abstract Number: 0512
Efficacy of Apremilast for the Treatment of Manifestations of Behçet’s Syndrome Other Than Oral Ulcers, Including Skin Lesions and Arthritis
3:00PM-3:50PM
Abstract Number: 0511
ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses
3:00PM-3:50PM
Abstract Number: 0510
Expression and Functional Activity of the Angiotensin II System in Temporal Artery Lesions from Patients with Giant Cell Arteritis
3:00PM-3:50PM
Abstract Number: 0480
Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
3:00PM-3:50PM
Abstract Number: 0450
In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition
3:00PM-3:50PM
Abstract Number: 0508
Maintenance or Achievement of Minimal Disease Activity Following Therapy Optimization with Adalimumab or Methotrexate in Patients with Psoriatic Arthritis: Results from Part 2 of a Randomized, Open-Label Phase 4 Study
3:00PM-3:50PM
Abstract Number: 0513
Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade
3:00PM-3:50PM
Abstract Number: 0453
Monitoring of BK Reactivation and Long-term Safety on JAK1/2 Inhibition with Baricitinib
3:00PM-3:50PM
Abstract Number: 0451
Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis
3:00PM-3:50PM
Abstract Number: 0452
Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients
3:00PM-3:50PM
Abstract Number: 0505
Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial
3:00PM-3:50PM
Abstract Number: 0481
Subclinical Synovitis in Arthralgia: How Often Does It Result in Clinical Arthritis? A Longitudinal Study to Reflect on Starting Points for DMARD Treatment
4:00PM-4:50PM
Abstract Number: 0515
A Proof of Concept Study to Assess the Efficacy of Tocilizumab in Combination with Ultra-Short Glucocorticoid Administration to Treat Newly Diagnosed Giant Cell Arteritis – a 24 Week Analysis
4:00PM-4:50PM
Abstract Number: 0487
Association Between an Extended Lifestyle Score and Adverse Health-related Outcomes in People with Rheumatoid Arthritis: A Study of 5295 UK Biobank Participants
4:00PM-4:50PM
Abstract Number: 0434
Changes in Mental Health During the COVID-19 Pandemic Among Individuals with Rheumatic Disease
4:00PM-4:50PM
Abstract Number: 0516
Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial
4:00PM-4:50PM
Abstract Number: 0486
Differences in Low-density Lipoprotein (LDL) Particle Composition and Oxidation May Underlie the Paradoxical Association of Low LDL with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis
4:00PM-4:50PM
Abstract Number: 0442
Disparities in CoronaViridae Infection Are Readily Apparent in Rheumatology Patients Despite Use of Hydroxychloquine And/or Methotrexate
4:00PM-4:50PM
Abstract Number: 0514
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
4:00PM-4:50PM
Abstract Number: 0439
Hurried Communication and Low Patient Self-Efficacy Are Associated with Persistent Non-Adherence to SLE Medications
4:00PM-4:50PM
Abstract Number: 0443
Impact of the COVID-19 Pandemic on Racial and Ethnic Minority Groups Diagnosed with Rheumatic Diseases
4:00PM-4:50PM
Abstract Number: 0488
Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database
4:00PM-4:50PM
Abstract Number: 0437
Integrating Reproductive Health in Systemic Lupus Erythematosus in a Tertiary Care Setting
4:00PM-4:50PM
Abstract Number: 0435
Low Incidence of Coronavirus Disease 2019 (COVID-19) Infection in Patients on Biologic Infusion Therapies at a Community Rheumatology Practice
4:00PM-4:50PM
Abstract Number: 0485
Non-obese Rheumatoid Arthritis Patients with Low Low-density Lipoprotein Have Higher Coronary Atherosclerosis Burden, Greater Plaque Progression and Cardiovascular Event Risk
4:00PM-4:50PM
Abstract Number: 0438
Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Large Private Rheumatology Practice
4:00PM-4:50PM
Abstract Number: 0484
Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib
4:00PM-4:50PM
Abstract Number: 0440
Representation of Women as Authors of Rheumatology Research Articles
4:00PM-4:50PM
Abstract Number: 0436
The Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Community Recommendations to Address Major Challenges in Lupus Diagnosis, Care, Treatment and Research
4:00PM-4:50PM
Abstract Number: 0518
The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis
4:00PM-4:50PM
Abstract Number: 0517
Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study
4:00PM-4:50PM
Abstract Number: 0441
Use of an Integrated Care Management Program to Uncover and Address Social Determinants of Health for Individuals with Lupus
5:00PM-5:50PM
Abstract Number: 0496
A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease
5:00PM-5:50PM
Abstract Number: 0472
ApoB:ApoA1 Ratio Could Predict Atherosclerotic Risk in Juvenile-SLE Patients Associated with Altered Interferon Signalling in CD8+ T-cells
5:00PM-5:50PM
Abstract Number: 0464
Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic Musculoskeletal Diseases in Europe. Preliminary Results from the REUMAVID Study
5:00PM-5:50PM
Abstract Number: 0493
Automatic Joint Space Assessment in Hand Radiographs with Deep Learning Among Patients with Rheumatoid Arthritis
5:00PM-5:50PM
Abstract Number: 0473
Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
5:00PM-5:50PM
Abstract Number: 0468
Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician Network
5:00PM-5:50PM
Abstract Number: 0466
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
5:00PM-5:50PM
Abstract Number: 0495
Epstein Barr Virus (EBV), an Etiologic Factor for Systemic Lupus Erythematosus (SLE), Interacts with SLE Risk Loci Through EBV-encoded Transcription Co-factors (co-TFs)
5:00PM-5:50PM
Abstract Number: 0498
Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE Pathogenesis
5:00PM-5:50PM
Abstract Number: 0490
Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
5:00PM-5:50PM
Abstract Number: 0494
Genetic-epigenetic Interaction and the Relationship Between DNA Methylation Patterns and Disease Activity in a Longitudinal Cohort of Lupus Patients
5:00PM-5:50PM
Abstract Number: 0500
Genomic, Phenomic, Proteomic Predictors of Psoriatic Arthritis
5:00PM-5:50PM
Abstract Number: 0469
IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome
5:00PM-5:50PM
Abstract Number: 0467
Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab
5:00PM-5:50PM
Abstract Number: 0502
Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis
5:00PM-5:50PM
Abstract Number: 0497
Interleukin-23 Acts Directly on Podocytes and Contributes to the Development of Glomerulonephritis
5:00PM-5:50PM
Abstract Number: 0492
Microbiota-induced Intestinal Barrier Dysfunction Initiates the Shuttling of Immune Cells from the Gut to the Joints
5:00PM-5:50PM
Abstract Number: 0489
Prevalence, Incidence, and Cause-Specific Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Older Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
5:00PM-5:50PM
Abstract Number: 0491
Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
5:00PM-5:50PM
Abstract Number: 0471
Splice Site Variants in IKBKG, Encoding NEMO, Detected by a Customized Analysis of Next-Generation Sequencing Data Cause an Early-onset Autoinflammatory Syndrome of Panniculitis and Cytopenias in Male and Female Patients
5:00PM-5:50PM
Abstract Number: 0501
Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis – A Prospective Cohort Study
5:00PM-5:50PM
Abstract Number: 0503
Targeted Metabolomic Profiling and Prediction of Cardiovascular Events: A Prospective Study of Patients with Psoriatic Arthritis and Psoriasis
5:00PM-5:50PM
Abstract Number: 0470
Th1 Polarization Defines the T Cell Compartment in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
5:00PM-5:50PM
Abstract Number: 0465
The COVID-19 Pandemic and Its Effect on Patients with Chronic Rheumatologic Disease Regarding the Value of Vaccination Recommendations
5:00PM-5:50PM
Abstract Number: 0499
WITHDRAWN
9:00AM-11:00AM
Abstract Number: 0646
“An Apple Pie a Day Does Not Keep the Doctor Away”. Fictional Depictions of Gout in Contemporary Film and Television
9:00AM-11:00AM
Abstract Number: 0814
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 0737
“It’ll Go Away. There’s Nothing Wrong with you:” the Experience of Pain-Related Stigma Among Adolescents with Pain Amplification Syndrome
9:00AM-11:00AM
Abstract Number: 0630
“No Benefit from a Strict Immobilization in Vertebral Osteomyelitis” Vertebral Immobilization and Neurological Complication in Acute Pyogenic Vertebral Osteomyelitis: SPONDIMMO, a Prospective Cohort of 250 Patients
9:00AM-11:00AM
Abstract Number: 0786
A Combination of Dimensionality Reduction Techniques Reveals Novel HLA-DR+ ‘Candidate’ Antigen-Presenting Cell Subsets (cAPC) in Patients with Rheumatoid Arthritis (RA)
9:00AM-11:00AM
Abstract Number: 0725
A Data Science Evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Questionnaire for Improving Management of JIA Patients
9:00AM-11:00AM
Abstract Number: 0874
A Multi-Center, Randomized, Double-blind, Placebo-controlled Dose-ranging Study Evaluating Efficacy and Safety of SHR-1314 in Subjects with Moderate-to-Severe Plaque Psoriasis
9:00AM-11:00AM
Abstract Number: 0677
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
9:00AM-11:00AM
Abstract Number: 0649
A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients with Uncontrolled Gout Who Have Undergone Kidney Transplantation: Early Data Report
9:00AM-11:00AM
Abstract Number: 0581
A Proposed Economic Framework to Model the Consequences of Psoriatic Arthritis Disease Domains
9:00AM-11:00AM
Abstract Number: 0529
A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies
9:00AM-11:00AM
Abstract Number: 0798
A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
9:00AM-11:00AM
Abstract Number: 0800
A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0592
A Rheumatology-Driven Protocol and Treatment Algorithm of SARS-CoV-2 Cytokine Release Syndrome and Its Associated Outcomes
9:00AM-11:00AM
Abstract Number: 0656
A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis
9:00AM-11:00AM
Abstract Number: 0606
A Systematic Review Exploring Pre-COVID-19 Telehealthcare Models Used in the Management of Patients with Rheumatological Disease
9:00AM-11:00AM
Abstract Number: 0590
A Web-Based Data Capture System Can Successfully Collect Detailed and Quantifiable Physical Therapy Intervention Data Post Total Knee Replacement
9:00AM-11:00AM
Abstract Number: 0569
Ability and Willingness to Utilize Telemedicine Among Rheumatology Patients – a Cross Sectional Survey
9:00AM-11:00AM
Abstract Number: 0878
Absolute Lymphocyte Count Is Negatively Correlated with Atherosclerotic Cardiovascular Disease Risk Score and Red Cell Distribution Width in Psoriatic Arthritis and Increases with TNF-Inhibitor Therapy
9:00AM-11:00AM
Abstract Number: 0900
Achievement of Low Disease Activity According to BASDAI with Ixekizumab in Patients with Axial Spondyloarthritis: 16-Week Results from the COAST Trials
9:00AM-11:00AM
Abstract Number: 0886
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 0766
ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
9:00AM-11:00AM
Abstract Number: 0706
Adenosine A2A Receptor Activation Reduces Markers of Chondrocyte Senescence and Cartilage Inflammation Associated with Osteoarthritis
9:00AM-11:00AM
Abstract Number: 0933
Advanced Multiparametric Magnetic Resonance Imaging of Muscle for Detection and Quantification of Muscle Disease in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 0857
Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory
9:00AM-11:00AM
Abstract Number: 0711
Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
9:00AM-11:00AM
Abstract Number: 0840
Amelioration of Immune Complex-Mediated Glomerulonephritis via CD6 Modulation
9:00AM-11:00AM
Abstract Number: 0663
Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation
9:00AM-11:00AM
Abstract Number: 0709
Anatomical Distribution of Mrgprd-expressing Nonpeptidergic C-fibers in the Mouse Knee
9:00AM-11:00AM
Abstract Number: 0767
Anti-acetylated Protein Antibodies in Rheumatoid Arthritis (RA): Clues for the Starting Point of Autoantibody Responses in RA
9:00AM-11:00AM
Abstract Number: 0719
Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study
9:00AM-11:00AM
Abstract Number: 0758
Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0761
Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Risk of Progression to Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0762
Anti-Protein-Arginine Deiminase (PAD) 1 IgG Is a Promising Novel Autoantigen in Rheumatoid Arthritis (RA) and Increases Diagnostic Performance in Combination with Anti-PAD4 IgG Using a Composite Biomarker Score
9:00AM-11:00AM
Abstract Number: 0779
Antibody Responses to Epstein-Barr Virus Are Altered in the Pre-Clinical Period of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0520
Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward
9:00AM-11:00AM
Abstract Number: 0724
Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) Correlate with Pain and Stress Using Patient-Reported Outcomes Measurement Information System (PROMIS®)
9:00AM-11:00AM
Abstract Number: 0879
Application of Treat-to-Target in Axial Spondyloarthritis in Daily Practice
9:00AM-11:00AM
Abstract Number: 0690
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate in Patients with Gout in a Phase 2a Study
9:00AM-11:00AM
Abstract Number: 0675
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers
9:00AM-11:00AM
Abstract Number: 0624
Association of Regional Body Composition and Physical Function Using the Short Physical Performance Battery Among Peruvian Women with HIV
9:00AM-11:00AM
Abstract Number: 0538
Autoimmune Disease Outcomes of Women with Breast Implants: A Population-Based Study
9:00AM-11:00AM
Abstract Number: 0521
Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?
9:00AM-11:00AM
Abstract Number: 0778
Bacterial Families Lachnospiraceae/Ruminococcaceae Are Immunologically Targeted in Individuals At-risk for RA and a Specific Strain Is Arthritogenic in Monocultured Gnotobiotic Mice
9:00AM-11:00AM
Abstract Number: 0587
Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 0698
Baseline Factors Are Not Associated with Rehabilitation Dose over Six Months Among Adults with RA
9:00AM-11:00AM
Abstract Number: 0906
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
9:00AM-11:00AM
Abstract Number: 0859
Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 0669
Calcium Pyrophosphate Crystal Deposition in Gouty Tophi
9:00AM-11:00AM
Abstract Number: 0922
Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex
9:00AM-11:00AM
Abstract Number: 0740
Card9 Promotes Th17-mediated Arthritis and Spondylitis via Control of Acute Pathogenic Neutrophil Responses in SKG Mice
9:00AM-11:00AM
Abstract Number: 0927
Care Gap in Patients with Systemic Sclerosis with CXR Findings Suggestive of Fibrosis
9:00AM-11:00AM
Abstract Number: 0662
Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study
9:00AM-11:00AM
Abstract Number: 0841
CD6 Modulation Ameliorates Kidney and Skin Disease in a Spontaneous Murine Lupus Model
9:00AM-11:00AM
Abstract Number: 0610
Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak
9:00AM-11:00AM
Abstract Number: 0652
Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout
9:00AM-11:00AM
Abstract Number: 0732
Changing Evidence over Time: Updated Meta-analysis Regarding Anti-TNF Efficacy in Childhood Chronic Uveitis
9:00AM-11:00AM
Abstract Number: 0903
Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Arthritis: An Analysis of the OPAL Dataset
9:00AM-11:00AM
Abstract Number: 0523
Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members
9:00AM-11:00AM
Abstract Number: 0533
Characterization of Older Male Patients with a Fragility Fracture
9:00AM-11:00AM
Abstract Number: 0644
Characterizations of Cytokine Storm Associated with COVID19
9:00AM-11:00AM
Abstract Number: 0695
Chronic Inflammatory Back Pain Occurring Later in Life: A Neglected Concept
9:00AM-11:00AM
Abstract Number: 0744
Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations with Disease Characteristics, Body Composition, and Physical Functioning
9:00AM-11:00AM
Abstract Number: 0777
CLEC12A Expression as a Potential Predictor of Disease Activity in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0596
Clinical Academic Rheumatology: A Boon for Health Systems
9:00AM-11:00AM
Abstract Number: 0828
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
9:00AM-11:00AM
Abstract Number: 0637
Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time
9:00AM-11:00AM
Abstract Number: 0915
Clinical Bedside Tools to Assess Systemic Sclerosis Vasculopathy: Can Digital Thermal Monitoring and Sublingual Microscopy Identify Patients with Current or past Digital Ulcers?
9:00AM-11:00AM
Abstract Number: 0631
Clinical Manifestations and Outcomes in DMARD-Naïve Patients with Chronic Chikungunya Arthritis
9:00AM-11:00AM
Abstract Number: 0728
Clinical Outcomes of Juvenile Arthritis in Adulthood: A Systematic Review
9:00AM-11:00AM
Abstract Number: 0826
Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Dose De-Escalation, in Patients with Early, MTX-Naïve, ACPA+ RA: Results from a Phase IIIb Study
9:00AM-11:00AM
Abstract Number: 0568
Clinical Timelines and Management Delays in Suspected Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 0641
Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection?
9:00AM-11:00AM
Abstract Number: 0827
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
9:00AM-11:00AM
Abstract Number: 0809
Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study
9:00AM-11:00AM
Abstract Number: 0731
Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U
9:00AM-11:00AM
Abstract Number: 0884
Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
9:00AM-11:00AM
Abstract Number: 0797
Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
9:00AM-11:00AM
Abstract Number: 0627
Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series
9:00AM-11:00AM
Abstract Number: 0741
Constitutive Inhibitor Kappa B (IκB) Kinase 2 (IKK2) Activation Induces an Inflammatory State in Fibroblast-Like Synoviocytes
9:00AM-11:00AM
Abstract Number: 0707
Contribution of NOTUM and Glypicans to the Development of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 0616
Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0583
Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0585
Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0629
COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study
9:00AM-11:00AM
Abstract Number: 0640
Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence
9:00AM-11:00AM
Abstract Number: 0642
COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
9:00AM-11:00AM
Abstract Number: 0923
Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Patients?
9:00AM-11:00AM
Abstract Number: 0623
Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort
9:00AM-11:00AM
Abstract Number: 0918
Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
9:00AM-11:00AM
Abstract Number: 0837
Deletion of miR-223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Faslpr/lpr Mice
9:00AM-11:00AM
Abstract Number: 0848
Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial
9:00AM-11:00AM
Abstract Number: 0691
Denosumab Did Not Improve Computerized Tomography Erosion Scores When Added to Intensive Urate-Lowering Therapy in Gout: Results from a Pilot Study
9:00AM-11:00AM
Abstract Number: 0919
Determinants of Health-related Quality of Life in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 0524
Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases
9:00AM-11:00AM
Abstract Number: 0549
Developing an Algorithm for Identifying Mortality in MarketScan Claims Data Using Machine Learning
9:00AM-11:00AM
Abstract Number: 0796
Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables
9:00AM-11:00AM
Abstract Number: 0745
Development of Functional Assays to Pre-qualify Human Mesenchymal Stem Cells for Rheumatoid Arthritis Treatment
9:00AM-11:00AM
Abstract Number: 0522
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase III Case Collection Results
9:00AM-11:00AM
Abstract Number: 0734
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
9:00AM-11:00AM
Abstract Number: 0612
Differences in 30-Day Rehospitalization Risk and Predictors by Age Group Among Patients with Lupus in Medicare
9:00AM-11:00AM
Abstract Number: 0708
Differences in Treating Knee Osteoarthritis by Clinician Specialty
9:00AM-11:00AM
Abstract Number: 0830
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 0611
Disease Activity and Disability Are Not Associated with Rehabilitation Utilization in African Americans with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0674
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
9:00AM-11:00AM
Abstract Number: 0702
Distinct Murine Cartilage Microbial DNA Signatures Are Seen in High Fat Diet-Induced Obesity and Aging
9:00AM-11:00AM
Abstract Number: 0620
Do Physical Therapists Follow Evidence-Based Practice Recommendations for Treatment of Inflammatory Arthritides?
9:00AM-11:00AM
Abstract Number: 0769
Does the Autoantibody-Response Mature Between Presentation with Arthralgia and Development of Rheumatoid Arthritis? – a Longitudinal Serological Study
9:00AM-11:00AM
Abstract Number: 0917
Drug-Drug Interaction Study of Nintedanib (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
9:00AM-11:00AM
Abstract Number: 0648
Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis
9:00AM-11:00AM
Abstract Number: 0647
Dual-energy CT versus Ultrasound, Alone or in Combination, for the Diagnosis of Gout: A Diagnostic Performance Study
9:00AM-11:00AM
Abstract Number: 0768
Dynamics of Follicular Helper T Cells Subsets in Rheumatoid Arthritis Patients Before and After Treatment
9:00AM-11:00AM
Abstract Number: 0925
Early Hydroxychloroquine Use May Reduce Risk for SSc-Associated Pulmonary Hypertension
9:00AM-11:00AM
Abstract Number: 0626
Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients
9:00AM-11:00AM
Abstract Number: 0710
Early Start of Biological Treatment in Juvenile Idiopathic Arthritis: Does a Therapeutic Window Exist in Real Life?
9:00AM-11:00AM
Abstract Number: 0770
Effect of Citrullination on the Processing and Presentation of Rheumatoid Arthritis Autoantigens
9:00AM-11:00AM
Abstract Number: 0864
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0910
Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2
9:00AM-11:00AM
Abstract Number: 0742
Effect of IA OnabotulinumtoxinA and Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia of Mice with Monoarthritis
9:00AM-11:00AM
Abstract Number: 0693
Effect of Physical Activity on Cartilage Degradation and Inflammation in Individuals with Lumbar Spinal Stenosis
9:00AM-11:00AM
Abstract Number: 0822
Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study
9:00AM-11:00AM
Abstract Number: 0912
Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension
9:00AM-11:00AM
Abstract Number: 0799
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD
9:00AM-11:00AM
Abstract Number: 0621
Effectiveness of Screening in Patients with Rheumatic Disease Before Commencing Biologic Therapy and Risk of Active Tuberculosis
9:00AM-11:00AM
Abstract Number: 0895
Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies
9:00AM-11:00AM
Abstract Number: 0573
Effects of Successive Switches of Two Different Biosimilars of Etanercept on Outcomes in Inflammatory Rheumatic Diseases in Daily Practice
9:00AM-11:00AM
Abstract Number: 0865
Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study
9:00AM-11:00AM
Abstract Number: 0894
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
9:00AM-11:00AM
Abstract Number: 0882
Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial
9:00AM-11:00AM
Abstract Number: 0818
Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0889
Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies
9:00AM-11:00AM
Abstract Number: 0679
Epidemiology of Intra-Articular Mineralization on Knee Dual-Energy Computed Tomography: The Multicenter Osteoarthritis Study
9:00AM-11:00AM
Abstract Number: 0525
Epidemiology of Thromboembolic Complications Among Hospitalized Patients with Antiphospholipid Syndrome in the United States
9:00AM-11:00AM
Abstract Number: 0782
Epigenetic Regulation of Metabolic Transporters in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
9:00AM-11:00AM
Abstract Number: 0722
Evaluation of Flare Rate and Tapering Strategies in Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0599
Evaluation of Telephone Consultations in Germany as an Additional Tool in Outpatient Rheumatology Clinics During the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 0542
Examining the Long-Term and Short-Term Day-To-Day Pain Variability in Inflammatory and Non-Inflammatory Rheumatic and Musculoskeletal Diseases Using Multilevel and Markov Transition Models: Cloudy with a Chance of Pain, a National U.K. Smartphone Study
9:00AM-11:00AM
Abstract Number: 0543
Exercise Among Older Adults Living with Rheumatic Disease: Physical Activity Habits and Patient Reported Outcomes
9:00AM-11:00AM
Abstract Number: 0755
Exploring the Significance of Anti-Nuclear Antibody Positivity in the Medical Management of Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0771
Factors Associated to Clinical and Radiographic Disease Progression in Patients with Early RA and First-degree Relatives: A 1-year Follow-up
9:00AM-11:00AM
Abstract Number: 0628
Factors Associated with Knee Osteoarthritis in an Outpatient HIV-1 Clinic over a 26 Year Interval
9:00AM-11:00AM
Abstract Number: 0804
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
9:00AM-11:00AM
Abstract Number: 0552
Fast Food Habits and Serum Urate Change in Young Adults: 15-Year Prospective Cohort Analysis
9:00AM-11:00AM
Abstract Number: 0588
Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices
9:00AM-11:00AM
Abstract Number: 0696
Femoral Cartilage Ultrasound Echo-Intensity Associates with Arthroscopic Cartilage Damage in People Following Anterior Cruciate Ligament Reconstruction
9:00AM-11:00AM
Abstract Number: 0891
Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
9:00AM-11:00AM
Abstract Number: 0821
Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
9:00AM-11:00AM
Abstract Number: 0876
Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials
9:00AM-11:00AM
Abstract Number: 0661
Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
9:00AM-11:00AM
Abstract Number: 0578
Going Digital Due to COVID 19 Crisis: A Rapid Reorganisation of Medication Clinics
9:00AM-11:00AM
Abstract Number: 0657
Gout and Heart Failure in the US
9:00AM-11:00AM
Abstract Number: 0681
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
9:00AM-11:00AM
Abstract Number: 0600
Gout Increases Length of Stay in Patients Hospitalized for Heart Failure Exacerbation
9:00AM-11:00AM
Abstract Number: 0673
Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure
9:00AM-11:00AM
Abstract Number: 0667
Gout Management Beyond Prescription Writing: The Role of the Pharmacist
9:00AM-11:00AM
Abstract Number: 0853
Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0888
Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naïve Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study
9:00AM-11:00AM
Abstract Number: 0908
Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
9:00AM-11:00AM
Abstract Number: 0746
HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0566
Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries
9:00AM-11:00AM
Abstract Number: 0845
Hematopoietic Specific Deficiency of Rho Kinase Attenuates Neutrophil NETosis and UVB-induced Skin Inflammation
9:00AM-11:00AM
Abstract Number: 0849
Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 0765
High Disease Activity at Baseline and Seropositivity Are Associated with Treatment Response at One Year Post Synovial Biopsy in RA Patients
9:00AM-11:00AM
Abstract Number: 0820
High Remission Rates in RA – Real Life Data from Bariticinib
9:00AM-11:00AM
Abstract Number: 0595
High Satisfaction with Tele-medicine in a New York City Clinic
9:00AM-11:00AM
Abstract Number: 0743
Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis
9:00AM-11:00AM
Abstract Number: 0537
Hip Abductor Strength and Its Association with New or Worsening Knee Pain: The MOST Study
9:00AM-11:00AM
Abstract Number: 0727
Hip Involvement Leads to Poor Outcome in Adulthood in Children with Enthesitis Related Arthritis (ERA) Category of Juvenile Idiopathic Arthritis (JIA)
9:00AM-11:00AM
Abstract Number: 0605
How Did SARS-CoV2/COVID-19 Pandemic Affected Rheumatology Practice in Latin America? A Regional Survey from PANLAR
9:00AM-11:00AM
Abstract Number: 0852
How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis
9:00AM-11:00AM
Abstract Number: 0871
Hydroxychloroquine Dose Reduction and SLE Flares
9:00AM-11:00AM
Abstract Number: 0870
Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vascular Health in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0635
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0861
Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 0867
Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients
9:00AM-11:00AM
Abstract Number: 0851
Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature
9:00AM-11:00AM
Abstract Number: 0806
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
9:00AM-11:00AM
Abstract Number: 0666
Identification of Intracellular Vacuoles in Synovial Fluid with Calcium Pyrophosphate and Monosodium Urate Crystals
9:00AM-11:00AM
Abstract Number: 0785
Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of RA-associated Lung Disease with Potential Role for resolvin-D1 in Reducing Monocyte Inflammatory Responses
9:00AM-11:00AM
Abstract Number: 0736
Identification of Salient Resilience Domains Among Adolescents with Chronic Musculoskeletal Pain and Their Parents
9:00AM-11:00AM
Abstract Number: 0658
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
9:00AM-11:00AM
Abstract Number: 0866
Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies
9:00AM-11:00AM
Abstract Number: 0823
Identifying Physician-Perceived Barriers to a Pragmatic Treatment Trial in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0639
Immunological Abnormalities in a SARS-CoV-2-Cytokine Release Syndrome Rheumatology Cohort
9:00AM-11:00AM
Abstract Number: 0598
Impact of a Dedicated Lupus Nephritis Clinic to Improve Time to Biopsy and Care Quality
9:00AM-11:00AM
Abstract Number: 0614
Impact of COVID-19 Pandemic on the Rheumatology Practice in Mexico: Mexican College of Rheumatology Survey
9:00AM-11:00AM
Abstract Number: 0609
Impact of Depressive Symptoms, Anti-depression Treatment on Direct Medical Costs Among Medicare Beneficiaries with Knee Osteoarthritis (KOA)
9:00AM-11:00AM
Abstract Number: 0902
Impact of Dose Escalation of Secukinumab in Patients with Psoriatic Arthritis in Real-World Setting
9:00AM-11:00AM
Abstract Number: 0911
Impact of Filgotinib on Structural Lesions in the Sacroiliac Joints at 12 Weeks in Patients with Active Ankylosing Spondylitis: Correlation with Clinical Endpoints
9:00AM-11:00AM
Abstract Number: 0885
Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab
9:00AM-11:00AM
Abstract Number: 0847
Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
9:00AM-11:00AM
Abstract Number: 0868
Impact of Proteinuria on the Clearance of Monoclonal Antibodies: Potential Clinical Implications
9:00AM-11:00AM
Abstract Number: 0873
Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
9:00AM-11:00AM
Abstract Number: 0896
Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs
9:00AM-11:00AM
Abstract Number: 0877
Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib
9:00AM-11:00AM
Abstract Number: 0571
Improving Care for Patients with Inflammatory Arthritis by Enabling Physical Therapists to Directly Refer to Rheumatologists: A Qualitative Study
9:00AM-11:00AM
Abstract Number: 0565
In Those with Unilateral Frequent Knee Pain, Between-Limb Differences in Stance Time During Walking Increase the Risk of Frequent Pain in the Other Knee: The MOST Study
9:00AM-11:00AM
Abstract Number: 0898
Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy in a Real-world US Commercially Insured Population
9:00AM-11:00AM
Abstract Number: 0564
Incidence and Progression of Foot Osteoarthritis
9:00AM-11:00AM
Abstract Number: 0548
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up
9:00AM-11:00AM
Abstract Number: 0554
Increased Burden of Painful Arthritis and Rheumatism Following the Chikungunya Epidemic 2006: India Rural Population Survey 2018
9:00AM-11:00AM
Abstract Number: 0756
Increased Risk of Hospitalization in Patients with RA Who Are ACPA Positive and Shared Epitope Positive
9:00AM-11:00AM
Abstract Number: 0604
Increasing the Rate of Pneumococcal Vaccination in an Academic Rheumatology Outpatient Clinic
9:00AM-11:00AM
Abstract Number: 0887
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network
9:00AM-11:00AM
Abstract Number: 0622
Infection-induced MPO-ANCA Associated Vasculitis: A Systematic Review of Published Case Reports
9:00AM-11:00AM
Abstract Number: 0697
Inferior Tendon Structure and Function Seen in Patients with Achilles Tendinopathy and Neovascularization of the Achilles Tendon
9:00AM-11:00AM
Abstract Number: 0634
Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 0815
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0829
International Comparison of Japanese and US Cross Country Utilization of RA Medications
9:00AM-11:00AM
Abstract Number: 0591
Intervention to Improve SLE Medication Adherence Using Surescripts Pharmacy Refill Data
9:00AM-11:00AM
Abstract Number: 0834
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
9:00AM-11:00AM
Abstract Number: 0574
Is Hydroxychloroquine Use a Proxy for Health Care Access? Predictors of First Dispensing Among Medicaid Beneficiaries with Incident Lupus
9:00AM-11:00AM
Abstract Number: 0893
Is It Feasible to Achieve Recommended Therapeutic Target Objective in Patients with Axial Spondyloarthritis in Clinical Practice? Data from the SpA-paz Cohort
9:00AM-11:00AM
Abstract Number: 0747
Isotope-Labeling-LC-MS-based Metabolic Profiling of Multiple Serum Sample Sets for the Discovery of High-confidence Rheumatoid Arthritis Biomarkers
9:00AM-11:00AM
Abstract Number: 0880
Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks
9:00AM-11:00AM
Abstract Number: 0890
Ixekizumab Treatment Improves Fatigue, Spinal Pain, Stiffness, and Sleep in Patients with Nonradiographic Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0715
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
9:00AM-11:00AM
Abstract Number: 0748
Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0602
Labor Impact of SARS-COV-2 Pandemic in Argentine Rheumatologists
9:00AM-11:00AM
Abstract Number: 0858
Leflunomide: A Safe and Effective Alternative in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0700
Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
9:00AM-11:00AM
Abstract Number: 0703
Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect
9:00AM-11:00AM
Abstract Number: 0705
lncRNA H19 and Micro RNA 675-3p Are Altered by Visfatin During Osteogenesis
9:00AM-11:00AM
Abstract Number: 0749
Locating Cellular Subsets in Rheumatoid Arthritis Synovium Using CO-Detection by IndEXing (CODEX)
9:00AM-11:00AM
Abstract Number: 0720
Long Term Efficacy and Safety of Triamcinolone Hexacetonide versus Triamcinolone Acetonide Intraarticular Injection for Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0810
Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data
9:00AM-11:00AM
Abstract Number: 0811
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
9:00AM-11:00AM
Abstract Number: 0907
Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)
9:00AM-11:00AM
Abstract Number: 0892
Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0713
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry
9:00AM-11:00AM
Abstract Number: 0559
Low Frequency of ANA/DFS70 Pattern Positive Result in a Large Cohort of Autoimmune/autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated in a Single Hospital from Colombia
9:00AM-11:00AM
Abstract Number: 0699
Lumbar Spine Stenosis Treatment : Is Surgery Better Than Medical Treatment in Afro-Descendant Populations ?
9:00AM-11:00AM
Abstract Number: 0792
LY294002 Improves the Collagen-induced Arthritis by Inducing Neutrophil Apoptosis
9:00AM-11:00AM
Abstract Number: 0920
Machine Learning Assisted Prediction of Progression in Systemic Sclerosis Patients: An Approach to Concise, Tailored Model Construction Using Outpatient Clinical Data
9:00AM-11:00AM
Abstract Number: 0625
Machine Learning Model to Predict Culture Positivity in Suspected Septic Arthritis
9:00AM-11:00AM
Abstract Number: 0550
Mapping Multimorbidity Using Drug Concept Unique Identifiers (RxCUIs) via the Rx-Risk Comorbidity Index
9:00AM-11:00AM
Abstract Number: 0789
Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients
9:00AM-11:00AM
Abstract Number: 0594
Mechanical and Temperature Stress During Biologic Shipments to Rheumatology Patients
9:00AM-11:00AM
Abstract Number: 0576
Medical Savings of Timely Rheumatoid Arthritis Diagnoses
9:00AM-11:00AM
Abstract Number: 0787
MerTK Synovial Expression Correlates with Disease Activity and Treatment Response in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0846
MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus
9:00AM-11:00AM
Abstract Number: 0795
Minimum Clinically Important Improvement in Patients with Rheumatoid Arthritis Associates with Gut Microbiome
9:00AM-11:00AM
Abstract Number: 0701
miRNome Sequencing Identifies a Unique Profile of Circulating MicroRNAs in Early Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 0613
Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease
9:00AM-11:00AM
Abstract Number: 0772
Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
9:00AM-11:00AM
Abstract Number: 0729
Morbidity of JIA-associated Uveitis: Half of Patients Despite Systemic Treatment Still Show Ocular Damage During a Long-term Follow-up
9:00AM-11:00AM
Abstract Number: 0854
Mortality and Adverse Events of Special Interest in Adult Patients with Systemic Lupus Erythematosus Receiving Intravenous Belimumab: A Post Hoc Descriptive Summary of Serious Psychiatric Events
9:00AM-11:00AM
Abstract Number: 0582
Mortality and Cost of Hospitalization: Do Hospitals Caring for More SLE Patients Perform Better?
9:00AM-11:00AM
Abstract Number: 0560
Mortality Burden of Immune-Mediated Inflammatory Diseases (IMID): Race/Ethnicity, Sex, and Geographic Variation in the United States
9:00AM-11:00AM
Abstract Number: 0842
mTOR Signaling Pathway Blockade and Rab4 Expression Affects Metabolism of Lupus T Cells
9:00AM-11:00AM
Abstract Number: 0603
Multisite Study of the Impact of COVID-19 Era Telemedicine Expansion on Reduction in No-Show Rates
9:00AM-11:00AM
Abstract Number: 0687
Musculoskeletal Manifestations in Patients with CD73 Deficiency
9:00AM-11:00AM
Abstract Number: 0534
National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use
9:00AM-11:00AM
Abstract Number: 0883
Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0774
Nr4a1-high Arthritogenic T Cells from SKG Mice Are Associated with Markers of Recent and Chronic Antigen-stimulation and an Altered T Cell Receptor Repertoire
9:00AM-11:00AM
Abstract Number: 0750
Nuclei Detection in Rheumatoid Arthritis Synovial Tissue Using Artificial Intelligence
9:00AM-11:00AM
Abstract Number: 0653
Nutrient Content of Gout Flare Trigger Foods
9:00AM-11:00AM
Abstract Number: 0718
Obesity Impairs Achievement of Clinical Inactive Disease (CID) in Patients with Juvenile Idiopathic Arthritis (JIA) Treated with TNF Inhibitors
9:00AM-11:00AM
Abstract Number: 0833
Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics
9:00AM-11:00AM
Abstract Number: 0931
Oropharyngeal Dysfunction in Patients with Systemic Sclerosis – Results of a Monocentric Clinical Study
9:00AM-11:00AM
Abstract Number: 0668
Outcomes and Resource Utilization After Total Knee Arthroplasty in Calcium Pyrophosphate Crystal Deposition Disease Patients: Insights from the National Inpatient Sample Database
9:00AM-11:00AM
Abstract Number: 0735
Paediatric Sarcoidosis: Phenotype of a Retrospective Cohort of Biopsy-proven Patients
9:00AM-11:00AM
Abstract Number: 0835
Pathogenic Effect of Chronic Stress-induced interleukin-12/23p40 on Neuropsychiatric System in Lupus-prone Mouse
9:00AM-11:00AM
Abstract Number: 0608
Patient and Parent Perspectives in a Academic Pediatric Rheumatology Transition Clinic
9:00AM-11:00AM
Abstract Number: 0593
Patient Characteristics and Factors Affecting Decision-Making Regarding Total Knee Replacement by Different Types of Physicians Treating Patients with Knee OA
9:00AM-11:00AM
Abstract Number: 0678
Patient Characteristics and Patterns of Urate-lowering Treatments in Older Patients with Incident Gout
9:00AM-11:00AM
Abstract Number: 0526
Patient-Reported Outcomes in Antiphospholipid Syndrome
9:00AM-11:00AM
Abstract Number: 0530
Pediatric APS: Clinical Features, Therapeutic Interventions, and Damage in a Series of 22 Cases
9:00AM-11:00AM
Abstract Number: 0791
Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
9:00AM-11:00AM
Abstract Number: 0586
Performance Characteristics of ANA by Elisa and Immunofluorescence
9:00AM-11:00AM
Abstract Number: 0794
Peripheral Blood T and B Lymphocyte Subsets in Arthritis in the Elderly
9:00AM-11:00AM
Abstract Number: 0619
Pharmacist Intervention: Reducing Insurance Denials of Specialty Medications
9:00AM-11:00AM
Abstract Number: 0683
Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate
9:00AM-11:00AM
Abstract Number: 0781
Phenotypic and Functional Characterisation of Synovial Fluid-derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0551
Physical Performance as a Mediator of the Association Between Depression and Pain in Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 0763
Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0659
Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1
9:00AM-11:00AM
Abstract Number: 0733
Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis
9:00AM-11:00AM
Abstract Number: 0692
Pre-Operative Opioid Usage Increases Length of Stay for Rheumatoid Arthritis Patients Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty
9:00AM-11:00AM
Abstract Number: 0717
Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies
9:00AM-11:00AM
Abstract Number: 0759
Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Development in a Population at Risk for Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0860
PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE
9:00AM-11:00AM
Abstract Number: 0645
Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis
9:00AM-11:00AM
Abstract Number: 0905
Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0901
Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence
9:00AM-11:00AM
Abstract Number: 0832
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
9:00AM-11:00AM
Abstract Number: 0672
Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares
9:00AM-11:00AM
Abstract Number: 0535
Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists
9:00AM-11:00AM
Abstract Number: 0577
Qualitative Review of Unsuccessful Pilot Study of Super-Utilizer Systemic Lupus Erythematosus (SLE) Patients Enrollment into Team Based Program to Improve Patient Outcomes
9:00AM-11:00AM
Abstract Number: 0843
Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0844
Rab4A Regulates Glomerulonephritis and Tryptophan Metabolism in Sle1.2.3. Lupus-prone Mice via Recycling of CD98
9:00AM-11:00AM
Abstract Number: 0651
Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares
9:00AM-11:00AM
Abstract Number: 0802
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
9:00AM-11:00AM
Abstract Number: 0803
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety
9:00AM-11:00AM
Abstract Number: 0812
Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US
9:00AM-11:00AM
Abstract Number: 0556
Recent Use, Missed Doses and Discontinuation of Infliximab in New-users: Comparisons of Biosimilar and Originator Exposures
9:00AM-11:00AM
Abstract Number: 0881
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study
9:00AM-11:00AM
Abstract Number: 0563
Relation of Pain Sensitization to Isokinetic Knee Extension Torque: The MOST Study
9:00AM-11:00AM
Abstract Number: 0694
Relationships Among Adherence and Patient Outcomes in a Cognitive Behavioral Plus Physical Activity Intervention for Older Adults with Osteoarthritis and Hypertension
9:00AM-11:00AM
Abstract Number: 0686
Renal Evolution During the First Year of Urate-lowering Therapy According to Sonographic Joint Deposition: Data from the Lille-Alicante Inception Cohort
9:00AM-11:00AM
Abstract Number: 0909
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
9:00AM-11:00AM
Abstract Number: 0863
Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States
9:00AM-11:00AM
Abstract Number: 0714
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
9:00AM-11:00AM
Abstract Number: 0904
Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks
9:00AM-11:00AM
Abstract Number: 0869
Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine
9:00AM-11:00AM
Abstract Number: 0567
Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care
9:00AM-11:00AM
Abstract Number: 0615
Rheumatology Going Digital: Developing a Rheumatology App for Use by All Patients Attending Our Department to Aid Remote Working and Self-management
9:00AM-11:00AM
Abstract Number: 0636
Rheumatology Patient Experience and Trends During the SARS-COV-2 Pandemic
9:00AM-11:00AM
Abstract Number: 0788
Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery
9:00AM-11:00AM
Abstract Number: 0561
Risk Factors for Falls Among Individuals with Knee OA: A Longitudinal Community-based Study
9:00AM-11:00AM
Abstract Number: 0926
Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort
9:00AM-11:00AM
Abstract Number: 0544
Risk Factors for Lumbar Vertebral Osteoporosis Do Not Reflect Factors Traditionally Associated with Osteoporosis at the Hip
9:00AM-11:00AM
Abstract Number: 0670
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
9:00AM-11:00AM
Abstract Number: 0579
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0540
Risk of Hydroxychloroquine Retinopathy in the Community
9:00AM-11:00AM
Abstract Number: 0580
Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting
9:00AM-11:00AM
Abstract Number: 0650
Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout
9:00AM-11:00AM
Abstract Number: 0527
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
9:00AM-11:00AM
Abstract Number: 0783
Role of Glutamine Metabolism in Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressive Phenotype
9:00AM-11:00AM
Abstract Number: 0682
Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout
9:00AM-11:00AM
Abstract Number: 0807
Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 0899
Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial
9:00AM-11:00AM
Abstract Number: 0875
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study
9:00AM-11:00AM
Abstract Number: 0914
Serious Infections in People with Systemic Sclerosis: A National U.S. Study
9:00AM-11:00AM
Abstract Number: 0638
Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service
9:00AM-11:00AM
Abstract Number: 0751
Serum Interferon-Alpha Levels Could Help Identify a Subgroup of Rheumatoid Arthritis with Poorer Physical Function and Higher Physician Global Assessment
9:00AM-11:00AM
Abstract Number: 0752
Serum Proteomics Implicates Neutrophil Degranulation in Rheumatoid Arthritis Disease Activity
9:00AM-11:00AM
Abstract Number: 0825
Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials
9:00AM-11:00AM
Abstract Number: 0930
Sexual Health Impairment in 90 Female Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 0836
SH3BP2 Deficiency Ameliorates Murine Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0839
Single-Cell Transcriptomics of Mouse and Human Lupus Nephritis Identifies Conserved Myeloid Populations Across Species
9:00AM-11:00AM
Abstract Number: 0932
Skeletal Muscle Involvement in Systemic Sclerosis Predisposes to Severe Gastrointestinal Tract and Cardiac Muscle Disease
9:00AM-11:00AM
Abstract Number: 0723
Social Determinants of Health and Time to First Pediatric Rheumatology Appointment in Polyarticular Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0831
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 0660
Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin
9:00AM-11:00AM
Abstract Number: 0539
Sports with a Bat or Racket Are Not Associated with Thumb-base Osteoarthritis: Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 0532
State-Specific Percentage of Adults with Arthritis Who Report Both Severe Joint Pain and Physical Inactivity and Their Characteristics, United States, Behavioral Risk Factor Surveillance System, 2017
9:00AM-11:00AM
Abstract Number: 0558
Statin Use Pattern in Patients with Inflammatory Joint Disease in a Single Site VA Medical Center
9:00AM-11:00AM
Abstract Number: 0546
Stepping up for Inflammatory Arthritis (SUFIA): A Pilot Trial to Test Behavioral Economics Strategy to Increase Physical Activity in Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 0671
Structured Cardiovascular Assessment in Gout Incorporating Carotid Ultrasound: Analysis of Subsequent Events in the Follow-Up
9:00AM-11:00AM
Abstract Number: 0541
Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan
9:00AM-11:00AM
Abstract Number: 0780
Subsets of Synovial Fluid Derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0757
Sunlight Exposure, Sun-protective Behaviour, and Anti-citrullinated Protein Antibody Positivity: A General Population-based Study in Quebec, Canada
9:00AM-11:00AM
Abstract Number: 0617
Support Methodologies for African American Women with Lupus – Comparing Two Study’s Effects on Patient Activation
9:00AM-11:00AM
Abstract Number: 0676
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
9:00AM-11:00AM
Abstract Number: 0680
Sustained Treat to Target Uric Acid Lowering Therapy Markedly Lowers Fatty Acids Levels in Gout Patients
9:00AM-11:00AM
Abstract Number: 0712
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 0753
Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort
9:00AM-11:00AM
Abstract Number: 0536
Systematic Geriatric Assessment in Older Patients with Rheumatic Diseases – The RheuMAGIC Pilot Study
9:00AM-11:00AM
Abstract Number: 0738
Systemic Administration of Novel Hydroxyl Dendrimers to Target Inflammation in Arthritic Tissues
9:00AM-11:00AM
Abstract Number: 0913
Systemic Sclerosis Portends a Higher Risk of Conduction and Rhythm Disorders at Diagnosis and During Disease Course: Results from a US Population Based Study
9:00AM-11:00AM
Abstract Number: 0928
Systemic Sclerosis Progression and Pregnancy: A Hopeful Message from the Canadian Scleroderma Registry Database
9:00AM-11:00AM
Abstract Number: 0632
Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 0775
T and B Cell Responses to Common Tenascin-C Peptides in RA
9:00AM-11:00AM
Abstract Number: 0838
T Cell–Specific CaMKIV Deficiency Protects Mice from Imiquimod-induced Glomerulonephritis
9:00AM-11:00AM
Abstract Number: 0597
Telemedicine in Pediatric Rheumatology During COVID-19: The PR-COIN Experience
9:00AM-11:00AM
Abstract Number: 0897
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept
9:00AM-11:00AM
Abstract Number: 0601
The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 0819
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
9:00AM-11:00AM
Abstract Number: 0773
The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease
9:00AM-11:00AM
Abstract Number: 0754
The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs
9:00AM-11:00AM
Abstract Number: 0689
The Changing Epidemiology of Inpatient Gout and Associated Mortality: A 17-year National Study
9:00AM-11:00AM
Abstract Number: 0801
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
9:00AM-11:00AM
Abstract Number: 0824
The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study
9:00AM-11:00AM
Abstract Number: 0528
The Complex Relationship Between C4b Binding Protein, Warfarin and Antiphospholipid Antibodies
9:00AM-11:00AM
Abstract Number: 0688
The Discontinuation of Allopurinol in the Inpatient Setting and the Risk of Gout Flare: A Community-Hospital Experience
9:00AM-11:00AM
Abstract Number: 0929
The Effect of Mycophenolate Mofetil on Pulmonary Function Tests in Patients with Systemic Sclerosis-associated Interstitial Lung Disease, and the Difference Between the African Americans versus Non-African Americans
9:00AM-11:00AM
Abstract Number: 0618
The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus
9:00AM-11:00AM
Abstract Number: 0654
The Effects of Dietary Macronutrients on Serum Urate: A Secondary Analysis of the OmniHeart Trial
9:00AM-11:00AM
Abstract Number: 0607
The Evolution of Rheumatologist’s Practice in Response to the COVID19 Pandemic
9:00AM-11:00AM
Abstract Number: 0921
The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort
9:00AM-11:00AM
Abstract Number: 0589
The Ideal Mhealth Application for Rheumatoid Arthritis: Qualitative Findings from Stakeholder Focus Groups
9:00AM-11:00AM
Abstract Number: 0575
The Impact of an Integrated Care Management Program on Acute Care Utilization and Outpatient Appointment Attendance Among High-Risk Patients with Lupus
9:00AM-11:00AM
Abstract Number: 0685
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
9:00AM-11:00AM
Abstract Number: 0776
The Influence of Adipokine Profile and Periodontal Infection in Early Stages of Rheumatoid Arthritis and First-degree Relatives
9:00AM-11:00AM
Abstract Number: 0557
The Joint Association of Steps/day and Typical Sedentary Bout Length with Worsening Knee Cartilage Damage over Two Years: The MOST Study
9:00AM-11:00AM
Abstract Number: 0704
The Murine Ear Wound Cartilage Superhealer Trait, Mediated by the Gut Microbiome, Is Transgenerationally Heritable Following Cecal Transplantation
9:00AM-11:00AM
Abstract Number: 0570
The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0531
The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records
9:00AM-11:00AM
Abstract Number: 0805
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0562
The Relationship Between Heart Disease Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement
9:00AM-11:00AM
Abstract Number: 0684
The Shrinking Toe: A Sign of Crystal Dissolution During Urate Lowering Treatment of Severe Gouty Arthropathy
9:00AM-11:00AM
Abstract Number: 0553
The US Prevalence of Ulcerative Colitis Associated Peripheral Arthralgias and Arthritis: Data from the National Health & Nutrition Examination Survey (NHANES)
9:00AM-11:00AM
Abstract Number: 0545
The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series
9:00AM-11:00AM
Abstract Number: 0519
Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid
9:00AM-11:00AM
Abstract Number: 0808
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 0856
Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels
9:00AM-11:00AM
Abstract Number: 0730
To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
9:00AM-11:00AM
Abstract Number: 0739
Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pathologic Manifestations of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 0793
Topological Laser Capture Microscopy (LCM)-RNAseq to Map the Rheumatoid Arthritis (RA) Synovial Transcriptome
9:00AM-11:00AM
Abstract Number: 0584
Total Cost of Care for Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0924
Towards Systemic Sclerosis Rehabilitation via Videogames
9:00AM-11:00AM
Abstract Number: 0547
Transgender Patients in the Rheumatology Setting
9:00AM-11:00AM
Abstract Number: 0816
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
9:00AM-11:00AM
Abstract Number: 0855
Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study
9:00AM-11:00AM
Abstract Number: 0813
Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
9:00AM-11:00AM
Abstract Number: 0665
Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study
9:00AM-11:00AM
Abstract Number: 0572
Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial
9:00AM-11:00AM
Abstract Number: 0764
Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data
9:00AM-11:00AM
Abstract Number: 0784
Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0817
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
9:00AM-11:00AM
Abstract Number: 0664
Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
9:00AM-11:00AM
Abstract Number: 0872
Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia
9:00AM-11:00AM
Abstract Number: 0643
Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection
9:00AM-11:00AM
Abstract Number: 0555
Utilization and Adherence Among Infliximab Biosimilar Initiators in a U.S. National Commercial Insurance Database
9:00AM-11:00AM
Abstract Number: 0916
Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 0721
Validation of New Antirheumatic Drug Use as a Proxy for Increased JIA Disease Activity
9:00AM-11:00AM
Abstract Number: 0716
Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
9:00AM-11:00AM
Abstract Number: 0790
Vitamin D Polygenetic Risk Score and the Association with RA Autoantibodies Among First-Degree Relatives of RA Subjects
9:00AM-11:00AM
Abstract Number: 0633
Vitamin D Serum Status in a Cohort of COVID-19 Patients
9:00AM-11:00AM
Abstract Number: 0862
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
9:00AM-11:00AM
Abstract Number: 0655
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial
9:00AM-11:00AM
Abstract Number: 0850
What Does It Mean to Be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials
9:00AM-11:00AM
Abstract Number: 0726
Who Ordered the Stiff One? Characteristics of Polyarticular Juvenile Idiopathic Arthritis Patients Associated with the Presence and Increased Duration of Joint Stiffness
9:00AM-11:00AM
Abstract Number: 0760
X-rays Bone Erosions Are Uncommon in Anti-CCP Positive Individuals At-risk of Rheumatoid Arthritis with Musculoskeletal Symptoms Without Clinical Synovitis, and Do Not Predict the Development of Inflammatory Arthritis
10:00AM-10:50AM
Abstract Number: 0959
Altered Gut Microbiome in Dermatomyositis
10:00AM-10:50AM
Abstract Number: 0956
An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions
10:00AM-10:50AM
Abstract Number: 0963
Chronic Obstructive Pulmonary Disease Associated with Prolonged Opiate Use, Increased Short-Term Complications and the Need for Revision Surgery Following Total Knee Arthroplasty
10:00AM-10:50AM
Abstract Number: 0961
Development of a Pain Sensitivity Index to Examine the Transition from Intermittent to Constant Pain in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
10:00AM-10:50AM
Abstract Number: 0955
Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
10:00AM-10:50AM
Abstract Number: 0962
Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial
10:00AM-10:50AM
Abstract Number: 0946
ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin
10:00AM-10:50AM
Abstract Number: 0940
In Patients with Inflammatory Arthritides Central Pain Sensitization Is Strictly Associated with Functional Disability
10:00AM-10:50AM
Abstract Number: 0964
Is Meniscal Status in the Anterior Cruciate Ligament Injured Knee Associated with Change in Bone Surface Area? An Exploratory Analysis of Data from the KANON Trial
10:00AM-10:50AM
Abstract Number: 0948
Mass Cytometry Reveals Activation Heterogeneity of Circulating Neutrophils in Systemic Lupus Erythematosus
10:00AM-10:50AM
Abstract Number: 0941
MDHAQ/RAPID3 (multidimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data) Levels Are Elevated in Rheumatology Patients Who Meet 2011 Fibromyalgia (FM) or MDHAQ/FAST3 (fibromyalgia Assessment Screening Tool) Criteria
10:00AM-10:50AM
Abstract Number: 0957
Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis
10:00AM-10:50AM
Abstract Number: 0945
Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light
10:00AM-10:50AM
Abstract Number: 0944
Obstructive Sleep Apnea in Fibromyalgia Patients: A Meta-analysis
10:00AM-10:50AM
Abstract Number: 0943
Reliability and Validity Issues in Fibromyalgia Diagnosis
10:00AM-10:50AM
Abstract Number: 0949
SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation
10:00AM-10:50AM
Abstract Number: 0947
STING Gain-of-Function in Radio-resistant Cells Supports a Lymphocyte Dependent Auto-inflammatory Lung Disease
10:00AM-10:50AM
Abstract Number: 0960
The Risk of Venous Thromboembolism After Septic Total Knee Replacement (TKR) Revision Is Double the Risk After Aseptic TKR Revision: An Analysis of Administrative Discharge Data
10:00AM-10:50AM
Abstract Number: 0958
Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial
10:00AM-10:50AM
Abstract Number: 0942
Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study
11:30AM-1:00PM
Abstract Number: 0935
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Trial of BIIB059, an Anti-Blood Dendritic Cell Antigen 2 Antibody, in SLE
11:30AM-1:00PM
Abstract Number: 0937
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
11:30AM-1:00PM
Abstract Number: 0938
Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity
11:30AM-1:00PM
Abstract Number: 0939
Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial
11:30AM-1:00PM
Abstract Number: 0936
Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis
11:30AM-1:00PM
Abstract Number: 0934
Warfarin Use and Risk of Knee and Hip Replacements
3:00PM-3:50PM
Abstract Number: 0986
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
3:00PM-3:50PM
Abstract Number: 0978
Border-associated Macrophages Drive Recruitment of Immune Cells into the Choroid Plexus in Mice with Neuropsychiatric Lupus
3:00PM-3:50PM
Abstract Number: 0985
Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies
3:00PM-3:50PM
Abstract Number: 0987
Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study
3:00PM-3:50PM
Abstract Number: 0977
Expanded T Peripheral Helper Cells and Increased Pathologic B Cell Lung Infiltration in Pristane-induced Murine Lupus in the Absence of BCL6+ Tfh Cells
3:00PM-3:50PM
Abstract Number: 0975
Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage
3:00PM-3:50PM
Abstract Number: 0976
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
3:00PM-3:50PM
Abstract Number: 0972
Mapping Oligoclonally Expanded T Cells Within the Peripheral and Synovial Immune Landscape of Untreated ACPA+ Rheumatoid Arthritis Patients at the Single Cell Level
3:00PM-3:50PM
Abstract Number: 0973
Novel Network Tool Highlights Key Features Associated with Disease Pathotypes and Response to Treatment in Early Rheumatoid Arthritis
3:00PM-3:50PM
Abstract Number: 0970
Oxylipins Profiles During the Earliest Phases of Rheumatoid Arthritis: Associations with Clinical Stage and Treatment Outcomes
3:00PM-3:50PM
Abstract Number: 0974
Role of NR4A Nuclear Receptor Family in RA Synovial Ectopic Lymphoid Neogenesis Revealed by Single Cell Profiling
3:00PM-3:50PM
Abstract Number: 0971
Single-cell Profiling of Synovial Stromal Cells Reveals an Angiocrine Endothelium in Rheumatoid Arthritis
3:00PM-3:50PM
Abstract Number: 0979
The Identification of Shared and Unique Myeloid Cell States in Pre- and Post-nephritic Lupus Mouse Models, Sle.Yaa1 and NZBW
3:00PM-3:50PM
Abstract Number: 0988
Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis
3:00PM-3:50PM
Abstract Number: 0989
Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial
5:00PM-5:50PM
Abstract Number: 0967
Absence of Thy1 Associated with Severe Bone Loss in the TNF-transgenic (TNF-Tg) Mice Arthritis Model
5:00PM-5:50PM
Abstract Number: 0968
Combined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice
5:00PM-5:50PM
Abstract Number: 0966
Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3
5:00PM-5:50PM
Abstract Number: 0954
Dual-energy CT Predicts Mortality in Gout Patients: A 3-year Follow-up Cohort Study
5:00PM-5:50PM
Abstract Number: 0982
Genetics of Avascular Necrosis in Children and Adults with Systemic Lupus Erythematosus
5:00PM-5:50PM
Abstract Number: 0980
Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Time-trends, Healthcare Utilization and In-Hospital Mortality
5:00PM-5:50PM
Abstract Number: 0969
Investigating Murine Joint-Draining Lymphatics: Lineage Tracing and Single Cell RNA Sequencing Reveal Evidence That Popliteal Lymphatic Muscle Cells and Their Progenitors Represent Distinct Cell Types Divergent from Striated and Vascular Muscle Cells
5:00PM-5:50PM
Abstract Number: 0953
Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout
5:00PM-5:50PM
Abstract Number: 0981
Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic Status: The California Lupus Surveillance Project, 2007-2017
5:00PM-5:50PM
Abstract Number: 0984
Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity in SLE
5:00PM-5:50PM
Abstract Number: 0983
Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus
5:00PM-5:50PM
Abstract Number: 0952
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
5:00PM-5:50PM
Abstract Number: 0965
Repetitive Inhalant Lipopolysaccharide Exposure in the Setting of Arthritis Induction Potentiates Pro-Fibrotic Inflammatory Lung Disease in Mice
5:00PM-5:50PM
Abstract Number: 0950
The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders
5:00PM-5:50PM
Abstract Number: 0951
The Comparative Effect of Exposure to Various Risk Factors on the Risk of Hyperuricaemia: Diet Has a Weak Causal Effect
9:00AM-11:00AM
Abstract Number: 1265
2019 Lupus Classification Criteria Score Predicting Cost of Future Hospitalizations
9:00AM-11:00AM
Abstract Number: 1120
A Comparison of Opioid-Related Outcomes Among Commercially-Insured Osteoarthritis Patients Treated with Tramadol vs. Non-Tramadol Opioids
9:00AM-11:00AM
Abstract Number: 1091
A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD
9:00AM-11:00AM
Abstract Number: 1370
A Delayed Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
9:00AM-11:00AM
Abstract Number: 1317
A Large Agreement Between the Pain Points of the ACR 1990 Fibromyalgia Criteria and the MASES Enthesitis Score Is Observed in Patients with Axial Spondylitis, Including in Patients Without Concomitant Fibromyalgia
9:00AM-11:00AM
Abstract Number: 1126
A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study
9:00AM-11:00AM
Abstract Number: 1290
A Multitrait-Multimethod Matrix Approach to the Construct Validity of Patient Reported Outcomes Measurement Information System Computerized (PROMIS) Adaptive Tests (CAT) in Systemic Lupus Erythematous
9:00AM-11:00AM
Abstract Number: 1074
A Novel Autoantibody Recognizing a 65-kDa Protein Is Associated with Scleromyositis with Head Drop and/or Bent Spine
9:00AM-11:00AM
Abstract Number: 1388
A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1412
A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome
9:00AM-11:00AM
Abstract Number: 1090
Abnormal HDL Antioxidant Function Is Associated with Longitudinal Change in Lung Physiology in Dermatomyositis/Polymyositis Associated Lung Disease
9:00AM-11:00AM
Abstract Number: 1137
Access to Digital Health in an Urban Rheumatology Population
9:00AM-11:00AM
Abstract Number: 1353
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
9:00AM-11:00AM
Abstract Number: 1083
Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment
9:00AM-11:00AM
Abstract Number: 1429
An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US
9:00AM-11:00AM
Abstract Number: 1413
An Imbalance Between Regulatory and Inflammatory T Cell Subsets Distinguishes Systemic Autoimmune Rheumatic Disease Patients from Asymptomatic ANA+ Individuals
9:00AM-11:00AM
Abstract Number: 1240
An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1203
Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1333
Ankylosing Spondylitis Patients at Risk of Developing Aortic Valve Regurgitation, Need for Mandatory Echocardiography?
9:00AM-11:00AM
Abstract Number: 1016
Annual Cardiac or Orthopedic Procedure Volume in Gout versus Rheumatoid Arthritis: A National Time-trends Study
9:00AM-11:00AM
Abstract Number: 1073
Anti Melanoma Differentiation-associated Protein Gene 5 Antibody Titer Monitoring Is a Useful Indicator for Early Detection of Recurrence in Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis
9:00AM-11:00AM
Abstract Number: 1098
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
9:00AM-11:00AM
Abstract Number: 1427
Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach
9:00AM-11:00AM
Abstract Number: 1076
Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom
9:00AM-11:00AM
Abstract Number: 1059
Anti-mitochondrial Autoantibodies Are Associated with Cardiomyopathy, Dysphagia, and Features of More Severe Disease in Adult-onset Myositis
9:00AM-11:00AM
Abstract Number: 1064
Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis
9:00AM-11:00AM
Abstract Number: 1067
Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 1261
Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1284
Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability
9:00AM-11:00AM
Abstract Number: 1320
Are Coping Strategies, Anxiety and Depression Associated with Daily Physical Activity in Patient with Axial SpA?
9:00AM-11:00AM
Abstract Number: 1008
Assessing Improved Risk Prediction of Seropositive Rheumatoid Arthritis by Environmental, Genetic, and Preclinical Plasma Metabolite Factors
9:00AM-11:00AM
Abstract Number: 1096
Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis
9:00AM-11:00AM
Abstract Number: 1251
Assessing the Construct Validity of the Novel OMERACT Ultrasound Scoring System for Salivary Glands Target Lesions by Comparison with MRI in Patients with Sjögren’s Syndrome – An OMERACT Ultrasound Working Group Exercise
9:00AM-11:00AM
Abstract Number: 1236
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
9:00AM-11:00AM
Abstract Number: 1214
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
9:00AM-11:00AM
Abstract Number: 1285
Association of Frailty with Disability Is Not Attenuated by Lean Body Mass in Women with SLE
9:00AM-11:00AM
Abstract Number: 1127
Association of Health Literacy and Numeracy with Patient Reported Psychological Outcomes
9:00AM-11:00AM
Abstract Number: 1232
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)
9:00AM-11:00AM
Abstract Number: 1119
Association of Primary Insurance Status on Bilateral Knee Arthroplasty Utilization and Complications: A United States Nationwide Analysis
9:00AM-11:00AM
Abstract Number: 1263
Association of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and Damage Accrual in Long Standing Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1391
Associations Between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry
9:00AM-11:00AM
Abstract Number: 1238
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials
9:00AM-11:00AM
Abstract Number: 1196
Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors
9:00AM-11:00AM
Abstract Number: 1296
Associations of Metabolic Syndrome and Adipokines in SLE
9:00AM-11:00AM
Abstract Number: 1206
Associations of Vascular and Bone Status in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
9:00AM-11:00AM
Abstract Number: 1178
Associations of Walking Endurance and Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1007
Atopic Dermatitis and Risk of Incident Rheumatoid Arthritis: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 1095
Avascular Necrosis in the Hopkins Myositis Cohort: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 1060
B-cell-rich Inflammatory Myopathies in Adults: Striking Association with Connective Tissue Diseases
9:00AM-11:00AM
Abstract Number: 0996
Bacteria-Derived Indole Drives Autoimmune Arthritis by Altering B Cell Glycosylation of Autoantibodies
9:00AM-11:00AM
Abstract Number: 1228
Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials
9:00AM-11:00AM
Abstract Number: 1135
Barriers to Influenza Vaccination in Patients at a Tertiary Care Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 1362
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
9:00AM-11:00AM
Abstract Number: 1364
Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
9:00AM-11:00AM
Abstract Number: 1352
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
9:00AM-11:00AM
Abstract Number: 1045
Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.
9:00AM-11:00AM
Abstract Number: 1197
Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review
9:00AM-11:00AM
Abstract Number: 1229
Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1118
Bone Marrow Lesion Scores in Patients with Knee Osteoarthritis Undergoing Tibial Osteotomy: Reliability and Concurrent Validity of the Knee Inflammation MRI Scoring System (KIMRISS)
9:00AM-11:00AM
Abstract Number: 1336
Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases
9:00AM-11:00AM
Abstract Number: 1042
Building LSU Uveitis Registry ( BLUR ) Study – a Review of an Academic Rheumatology Center’s Experience and Approach to Uveitis
9:00AM-11:00AM
Abstract Number: 1400
cAMP Response Element Modulator (CREM)α Promotes PD-1- effector CD4+ T Cells in Psoriasis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1202
Cannabis Use Assessment and Its Impact on Pain in Rheumatic Diseases: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 1167
Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score
9:00AM-11:00AM
Abstract Number: 1328
Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis
9:00AM-11:00AM
Abstract Number: 1172
Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma
9:00AM-11:00AM
Abstract Number: 1179
Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study
9:00AM-11:00AM
Abstract Number: 1331
Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study
9:00AM-11:00AM
Abstract Number: 1108
Cartilage Biomarkers s-Coll2-1 and s-Coll2-1NO2 Are Associated with Knee Osteoarthritis MRI Features and Predict Disease Worsening
9:00AM-11:00AM
Abstract Number: 1318
Catastrophizing in Patients with Axial Spondyloarthritis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1411
CD8+ T Cell Subsets and Immune Checkpoint Profiles in Ankylosing Spondylitis Implicate Dysregulation of Cytotoxic T Lymphocytes (CTL)
9:00AM-11:00AM
Abstract Number: 1321
Central Sensitization, Disease Perception and Obesity Should Be Taken into Account When Interpreting Disease Activity in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1358
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
9:00AM-11:00AM
Abstract Number: 1382
Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
9:00AM-11:00AM
Abstract Number: 1071
Characteristics of Anti-Transcription Intermediary Factor 1-gamma Autoantibody Positive Dermatomyositis Patients in Singapore
9:00AM-11:00AM
Abstract Number: 1420
Characterization of ANCA-Associated Vasculitis Among African American Patients
9:00AM-11:00AM
Abstract Number: 1355
Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 1301
Characterizing How SLE Patients Access Health Information Pre and During COVID-19
9:00AM-11:00AM
Abstract Number: 1223
Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History
9:00AM-11:00AM
Abstract Number: 1397
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
9:00AM-11:00AM
Abstract Number: 1279
Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Erythematosus Patients in a Spanish Tertiary Hospital
9:00AM-11:00AM
Abstract Number: 1244
Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 1389
Clinical Characteristics and Treatment Outcome of a Cohort of Patients with Joint and Fascial Involvement in the Context of Chronic Graft versus Host Disease
9:00AM-11:00AM
Abstract Number: 1029
Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry
9:00AM-11:00AM
Abstract Number: 1040
Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand
9:00AM-11:00AM
Abstract Number: 1386
Clinical Correlates and Relevance of the UCLA GIT 2.0 Instrument for Indication for Esophagogastroduodenoscopy and Endoscopic Esophagitis in Real-life Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1419
Clinical Disease Might Be Divided into Two Phenotypes in ANCA Associated Vasculitis; Results of a Cluster Analysis
9:00AM-11:00AM
Abstract Number: 1158
Clinical Features and Outcomes in STING-Associated Vasculopathy with Onset in Infancy (SAVI)
9:00AM-11:00AM
Abstract Number: 1421
Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans
9:00AM-11:00AM
Abstract Number: 1379
Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
9:00AM-11:00AM
Abstract Number: 1418
Clinical Presentations and Follow-up Results of Granulomatosis with Polyangiitis: An Analysis of 8 Years Clinical Experience with 220 Patients from a National Referral Center
9:00AM-11:00AM
Abstract Number: 1327
Comorbidity Burden in Patients with Non-Radiographic Axial Spondyloarthritis at Least as High as in Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1357
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
9:00AM-11:00AM
Abstract Number: 1162
Comparison of Clinicopathologic and Imaging Features Between Chronic Nonbacterial Osteomyelitis and Its Mimickers: A Multi-national 450 Case-Control Study
9:00AM-11:00AM
Abstract Number: 1156
Comparison of Immunological Biomarkers and Lung Histology in Patients with Elevated IL18 – Pulmonary Alveolar Proteinosis and Recurrent Macrophage Activation Syndrome (IL-18PAP-MAS) and Other Inflammatory Lung Diseases
9:00AM-11:00AM
Abstract Number: 1144
Concerns and Behaviors of Patients with Common Autoimmune Rheumatic Diseases in the United States Early in the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: PP03
Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
9:00AM-11:00AM
Abstract Number: 1052
Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska
9:00AM-11:00AM
Abstract Number: 1084
Consumer-based Activity Trackers in Evaluation of Physical Function in Myositis Patients
9:00AM-11:00AM
Abstract Number: PP05
Coping Through Advocacy – My Story Living with Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 1339
COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
9:00AM-11:00AM
Abstract Number: 1274
COVID-19 in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1280
COVID-19 Infections May Increase the Risk of SLE Flares
9:00AM-11:00AM
Abstract Number: 1230
Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0999
CXCL13 Is a Key Driver for Migration and Differentiation of Regulatory B Cells
9:00AM-11:00AM
Abstract Number: 1061
Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers
9:00AM-11:00AM
Abstract Number: 1022
Declining In-hospital Mortality Gap in Lupus Compared to Non-lupus Hospitalizations: A National Study
9:00AM-11:00AM
Abstract Number: 1423
Declining In-Hospital Mortality in Vasculitis: A 17-year U.S. National Study
9:00AM-11:00AM
Abstract Number: 1291
Depressed Symptomatology Persists over Time in the Majority of Systemic Lupus Erythematosus Patients and Is Independent of Disease Activity
9:00AM-11:00AM
Abstract Number: 1062
Dermatomyositis: A Dermatology-Rheumatology Clinic Retrospective Analysis
9:00AM-11:00AM
Abstract Number: 1056
Descriptive Data Analysis of Patients with Anti Jo1 Syndrome (AJS) and Lung Involvement
9:00AM-11:00AM
Abstract Number: 1307
Detecting Subtle Changes in Fundoscopic Retinal Images in Patients with Axial Spondyloarthritis with Deep Learning
9:00AM-11:00AM
Abstract Number: 1147
Development of a Digital Toolkit to Improve Quality of Life of Patients with Systemic Lupus Erythematosus: A Pilot Study
9:00AM-11:00AM
Abstract Number: 1075
Diagnostic Utility of Myositis Antibodies in HyperCKemia: A University Affiliated Single Center Retrospective Study
9:00AM-11:00AM
Abstract Number: 1403
Differential Effect of Abatacept vs TNF Blockers, on the Frequency of Circulating Follicular Helper (Tfh) and Periperal Helper (Tph) T Cells in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1399
Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
9:00AM-11:00AM
Abstract Number: 0998
Differential Roles of TNFRI and TNFRII in the Morphology of Secondary Lymphoid Organs
9:00AM-11:00AM
Abstract Number: 1396
Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1380
Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Increases the Risk of Digital Ischemic Complications in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
9:00AM-11:00AM
Abstract Number: 1129
Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 1213
Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1295
Disease Activity and Mental Health in SLE Patients: A Cross-section Study with Self-Assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
9:00AM-11:00AM
Abstract Number: 1319
Disease Activity and Mental Health of as Patients: A Cross-section Study with Self-assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
9:00AM-11:00AM
Abstract Number: 1014
Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years
9:00AM-11:00AM
Abstract Number: 1401
Disease Mutation That Weakens ZAP70 Autoinhibition Enhances Responses to Weak and Self Ligands
9:00AM-11:00AM
Abstract Number: 1154
Distinct Gene Signature Predicts Strong Clinical Responses to Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 1278
Does Co-existing Systemic Lupus Erythematosus Affect Outcomes of Hospitalizations for Ischemic Stroke?
9:00AM-11:00AM
Abstract Number: 1334
Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study
9:00AM-11:00AM
Abstract Number: 0994
Does Tofacitinib Impact B Cell Functions?
9:00AM-11:00AM
Abstract Number: 1057
Earlier Cancer Diagnosis After Idiopathic Inflammatory Myopathy Onset Is Associated with Improved Long Term Survival – Results from Four European Cohorts
9:00AM-11:00AM
Abstract Number: 1343
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
9:00AM-11:00AM
Abstract Number: 1250
Early Sjögren Antibodies: Potential Biomarker for Abnormal Minor Labial Salivary Gland Biopsy in Juvenile Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1201
Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials
9:00AM-11:00AM
Abstract Number: 1101
Effect of Transcutaneous Vagal Nerve Stimulation in Erosive Hand Osteoarthritis: Results from an Open-label Non-randomized Pilot Trial
9:00AM-11:00AM
Abstract Number: 1011
Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
9:00AM-11:00AM
Abstract Number: 1217
Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells
9:00AM-11:00AM
Abstract Number: 1049
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
9:00AM-11:00AM
Abstract Number: 1416
Effects of the COVID-19 Pandemic on Patients Living with Vasculitis
9:00AM-11:00AM
Abstract Number: 1372
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement
9:00AM-11:00AM
Abstract Number: 1068
Efficacy of Early Initiation of Plasma Exchange Therapy for a Patient with Anti-MDA5 Autoantibody-Positive Dermatomyositis Developing Refractory Rapidly Progressive Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 1351
Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study
9:00AM-11:00AM
Abstract Number: 1053
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD) : A Single Center Study of 47 Patients- Extension Study
9:00AM-11:00AM
Abstract Number: 1363
Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
9:00AM-11:00AM
Abstract Number: 1369
Efficacy of Tildrakizumab in PsA: DAPSA Remission and Low Disease Activity in PASDAS Through Week 52
9:00AM-11:00AM
Abstract Number: 1356
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs
9:00AM-11:00AM
Abstract Number: 1342
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
9:00AM-11:00AM
Abstract Number: 1032
Epidemiology and Geographic Evaluation of ANCA-associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)
9:00AM-11:00AM
Abstract Number: 1023
Epidemiology and Sociodemographic Distribution of Upper Gastrointestinal Bleeding Among Medicaid Beneficiaries with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1138
Estimation of Clinically Important Differences in Patient-Reported Outcomes Measurement Information System (PROMIS) Measures in Juvenile Myositis
9:00AM-11:00AM
Abstract Number: 1405
Evaluating the Cellular Composition of Anti-synthetase Syndrome and Dermatomyositis Skin Lesions Using Image Mass Cytometry
9:00AM-11:00AM
Abstract Number: 1269
Evaluation of a Patient-reported Frailty Tool in Women with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1221
Evaluation of Methotrexate Efficacy and Exploration of Metabolites Associated with Disease Activity in Collagen-induced Arthritis Mouse Model
9:00AM-11:00AM
Abstract Number: 1302
Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations
9:00AM-11:00AM
Abstract Number: 1315
Exploring the Prevalence and Factors Associated with Fatigue in Axial Spondyloarthritis in a Multiethnic Asian Cohort in Singapore
9:00AM-11:00AM
Abstract Number: 1170
Exploring the Use of Von Willebrand Factor as a Disease Biomarker in a Cohort of Patients with Juvenile Scleroderma: A Pilot Study
9:00AM-11:00AM
Abstract Number: 1180
External Validation of a Multi-biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1283
Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry
9:00AM-11:00AM
Abstract Number: 1293
Factors Associated with Early Hospital Readmission in Systemic Lupus Erythematosus: Data from National Readmission Database
9:00AM-11:00AM
Abstract Number: 1183
Factors Associated with Incident Heart Failure Subtypes in Patients with Rheumatoid Arthritis Using Electronic Health Record Data
9:00AM-11:00AM
Abstract Number: 1314
Fatigue in Psoriatic Arthritis (PsA): Prevalence in Patients from the US and Europe, and Impact on Quality of Life and Work Productivity
9:00AM-11:00AM
Abstract Number: 1247
Features of Childhood Sjogren’s Syndrome: A Literature Review Based Cohort
9:00AM-11:00AM
Abstract Number: 1216
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study
9:00AM-11:00AM
Abstract Number: 1218
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
9:00AM-11:00AM
Abstract Number: 1215
Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
9:00AM-11:00AM
Abstract Number: 1292
Frequency and Predictors of Influenza Vaccine Hesitancy in Systemic Autoimmune Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1164
Frequency of Genetic Diagnosis in an Autoinflammatory Disease Natural History Protocol Cohort of Patients
9:00AM-11:00AM
Abstract Number: 1181
Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1402
Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1257
Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1077
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
9:00AM-11:00AM
Abstract Number: 1224
Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
9:00AM-11:00AM
Abstract Number: 1349
Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1344
Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
9:00AM-11:00AM
Abstract Number: 1310
Gut Microbiome Changes Are Different Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Disease Activity in Both Diseases
9:00AM-11:00AM
Abstract Number: 1174
HEADSS and Shoulders, Knees and Toes: Improving Sexual Orientation and Gender Identity Screening in the Pediatric Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 1157
Health and Socioeconomic Outcomes in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed for a Median of Fifteen Years
9:00AM-11:00AM
Abstract Number: 1422
Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data
9:00AM-11:00AM
Abstract Number: 1099
High Burden of Infections in Indian Patients with Idiopathic Inflammatory Myopathy: Validation of Observations from the MyoCite Dataset
9:00AM-11:00AM
Abstract Number: 1306
High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred with Anterior Uveitis and Chronic Back Pain
9:00AM-11:00AM
Abstract Number: 1414
Highly Polyfunctional Metabolically Altered Pathogenic T Cells Accumulate in the Synovial Tissue of RA Patients and Arthralgia Subject but Not Healthy Control Synovial Tissue
9:00AM-11:00AM
Abstract Number: 1078
Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate with Lung and Joint Involvement in Patients with Myositis
9:00AM-11:00AM
Abstract Number: 1140
How Did SARS-CoV2/COVID-19 Pandemic Affected Patients with Rheumatic Diseases in Latin America? A Regional Survey from PANLAR
9:00AM-11:00AM
Abstract Number: 1311
Identification of Clinical Phenotypes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis According to Peripheral Musculoskeletal Manifestations: A Cluster Analysis in the International ASAS-PerSpA Study
9:00AM-11:00AM
Abstract Number: 1338
Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study
9:00AM-11:00AM
Abstract Number: 1300
Identifying Cognitive Impairment in Patients with Systemic Lupus Erythematosus Using Hidden Markov Models: A Bayesian Approach
9:00AM-11:00AM
Abstract Number: 1176
Identifying Targets to Improve the Assessment of Psychosocial Risk Factors in Adolescent Patients: Perspectives from Pediatric Rheumatology Fellows in the United States and Canada
9:00AM-11:00AM
Abstract Number: 1332
Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?
9:00AM-11:00AM
Abstract Number: 1152
IL-18: A Biomarker That Reflects Disease Activity, Could It Be the Next Disease Activity Measure in Systemic Juvenile Idiopathic Arthritis?
9:00AM-11:00AM
Abstract Number: 1373
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
9:00AM-11:00AM
Abstract Number: 1107
IL1RN Polymorphism Predicts Weight Loss, Inflammatory Biomarker Changes and Knee Osteoarthritis Pain Relief After Bariatric Surgery
9:00AM-11:00AM
Abstract Number: 1097
Immunophenotypic Characterization of Myeloid Derived Supressor Cells (MDSCs) and Their Relationship to the Clinical Characteristics of Patients with Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 1065
Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis
9:00AM-11:00AM
Abstract Number: 1093
Impact of Blood Flow Restricted Strength Training on Myogenic Stem Cells and Myofiber Hypertrophy in Sporadic Inclusion Body Myositis Patients
9:00AM-11:00AM
Abstract Number: 1376
Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1207
Impact of Body Mass Index on Clinical Responses of Novel Subcutaneous Infliximab (CT-P13 SC) in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase I/III Randomized Controlled Trial
9:00AM-11:00AM
Abstract Number: 1367
Impact of Ixekizumab on Work Productivity in Non-Radiographic Axial Spondyloarthritis Patients: Results from the COAST-X Trial at 52 Weeks
9:00AM-11:00AM
Abstract Number: 1272
Impact of Remission and Low Disease Activity Status on Hospitalizations Among SLE Patients from the GLADEL Latin American Cohort
9:00AM-11:00AM
Abstract Number: 0992
Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment
9:00AM-11:00AM
Abstract Number: PP01
Impacting Change Through Facilitation and Advocacy for Lupus
9:00AM-11:00AM
Abstract Number: 1151
Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia
9:00AM-11:00AM
Abstract Number: 1142
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
9:00AM-11:00AM
Abstract Number: 1145
Implementation of Web-Based Patient-Reported Outcome Measures (PROMs) in SLE Clinical Care: A Multi-Center Prospective Cohort Study
9:00AM-11:00AM
Abstract Number: 1371
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs
9:00AM-11:00AM
Abstract Number: 1341
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
9:00AM-11:00AM
Abstract Number: PP07
Improving Communication with My Physician Drastically Improved My Health
9:00AM-11:00AM
Abstract Number: 1124
Improving Documentation Rates of Non-Pharmacologic Therapies for Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1184
In a Prospective RA Cohort, Higher Baseline Disease Activity Is an Independent Predictor of Decline in Left Ventricular Diastolic Function
9:00AM-11:00AM
Abstract Number: 1436
Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study
9:00AM-11:00AM
Abstract Number: 1182
Increased Prevalence of Carotid Atherosclerosis in Postmenopausal Women with Rheumatoid Arthritis: A Case Control Study
9:00AM-11:00AM
Abstract Number: 1220
Increased Serum Levels of Circulating Vimentin and Citrullinated Vimentin Are Differently Regulated by Tocilizumab and Methotrexate Monotherapies in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1010
Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
9:00AM-11:00AM
Abstract Number: 0990
Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
9:00AM-11:00AM
Abstract Number: 1089
Intermuscular Adipose Tissue in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1431
Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study
9:00AM-11:00AM
Abstract Number: 1111
Intra-Articular Mineralization on Knee CT Increases Risk of Knee Pain: The Multicenter Osteoarthritis Study
9:00AM-11:00AM
Abstract Number: 1113
Intrameniscal Signal Alterations Strongly Predict Destabilizing Meniscal Tears and Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 1404
Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
9:00AM-11:00AM
Abstract Number: 1222
Iron Management in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1305
Is the Occurrence of Acute Anterior Uveitis Linked Primarily to Ankylosing Spondylitis (AS) or to HLA-B27? Results of a 35-Year Follow-Up Family Study of a Swiss Cohort of Patients with AS
9:00AM-11:00AM
Abstract Number: 0995
Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome
9:00AM-11:00AM
Abstract Number: 1409
Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy
9:00AM-11:00AM
Abstract Number: 1254
Lack of Efficacy of Early Treatment with Hydroxychloroquine in a Group of Hispanics with Primary Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1406
LAG-3+ T Cells Are Diminished in Active Psoriatic Arthritis Patients and Their Restoration in Vitro Is Mediated by TNF Inhibitors
9:00AM-11:00AM
Abstract Number: 1198
Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1094
Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
9:00AM-11:00AM
Abstract Number: 1155
Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 1392
Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1003
Long-term Weight Changes and Risk of Rheumatoid Arthritis Among Women in a Prospective Cohort: A Marginal Structural Model Approach
9:00AM-11:00AM
Abstract Number: 1299
Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity
9:00AM-11:00AM
Abstract Number: 1260
Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus
9:00AM-11:00AM
Abstract Number: 1114
Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up
9:00AM-11:00AM
Abstract Number: 1277
Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: PP02
Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease
9:00AM-11:00AM
Abstract Number: 1297
Lupus Antibodies in Relation to Malignancy
9:00AM-11:00AM
Abstract Number: 1298
Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort
9:00AM-11:00AM
Abstract Number: 1365
Machine Learning-based Berlin Scoring of Magnetic Resonance Images of the Spine in Patients with Ankylosing Spondylitis: Analysis of Data from a Phase 3 Trial with Secukinumab
9:00AM-11:00AM
Abstract Number: 1116
Magnetic Resonance Imaging Structural Changes Correlated with Knee Extension: Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 1326
Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study
9:00AM-11:00AM
Abstract Number: 1256
Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production
9:00AM-11:00AM
Abstract Number: 1437
Measuring Disease Activity and Functional Status in Patients with Granulomatosis with Polyangiitis (Wegener’s) (GPA)
9:00AM-11:00AM
Abstract Number: 1408
Metabolic Reprogramming in Memory CD4+ T Cells Is Associated with Immune Cell Dysfunction During Aging
9:00AM-11:00AM
Abstract Number: 1103
Metacarpo-phalangeal Osteoarthritis Is Not Rare and Is Associated with Mechanical Rather Than Systemic Factors in Hand Osteoarthritis: An Observational Study from a Large Hospital-based Cohort
9:00AM-11:00AM
Abstract Number: 1009
Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method
9:00AM-11:00AM
Abstract Number: 1106
MMP Mediated Type I Collagen Degradation Is Associated with Erosive Hand Osteoarthritis in a Hospital-based Observational Cohort – the NOR-HAND Study
9:00AM-11:00AM
Abstract Number: 1325
Monoclonal Gammopathy in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1264
Mortality in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
9:00AM-11:00AM
Abstract Number: 1194
MUC5B Promoter Variant rs35705950 and Risk Stratification for Rheumatoid Arthritis – Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 1195
MUC5B rs35705950 and Rheumatoid Arthritis Associated Interstitial Lung Disease Progression
9:00AM-11:00AM
Abstract Number: 1266
Multivariate Risk Model Shows Different Risk Factors for Myocardial Infarction and Stroke in SLE
9:00AM-11:00AM
Abstract Number: 1415
Murine Roseolovirus Induces Autoimmune Disease and Development of Autoreactive T Cells and Autoantibodies
9:00AM-11:00AM
Abstract Number: PP04
My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life
9:00AM-11:00AM
Abstract Number: 1055
Myositis and Systemic Sclerosis Spectrum IPAF Patients Are More Likely to Respond Favorably to Immunosuppression
9:00AM-11:00AM
Abstract Number: 0993
N-linked Glycosylation of the Immunoglobulin Variable Domain Affects Antigen Binding and Autoreactive B Cell Activation
9:00AM-11:00AM
Abstract Number: 1013
National Burden of RA in Canada 1990-2017: Findings from the Global Burden of Disease Study 2017
9:00AM-11:00AM
Abstract Number: 1102
Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment
9:00AM-11:00AM
Abstract Number: 1360
New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study
9:00AM-11:00AM
Abstract Number: 1092
NMR-Based Serum Metabolomics, Is It Different in Clinico-Serological Clusters of Idiopathic Inflammatory Myositis?
9:00AM-11:00AM
Abstract Number: 1173
No Disease Progression After 36 Months Follow up in the Juvenile Systemic Scleroderma Inception Cohort
9:00AM-11:00AM
Abstract Number: 1234
Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab
9:00AM-11:00AM
Abstract Number: 0997
Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1159
Novel STING1 Mutations Including in the Transmembrane Linker Region Cause STING-associated Vasculopathy with Onset in Infancy (SAVI)
9:00AM-11:00AM
Abstract Number: 1036
Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital
9:00AM-11:00AM
Abstract Number: 1044
Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center
9:00AM-11:00AM
Abstract Number: 1043
Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center
9:00AM-11:00AM
Abstract Number: PP06
Only in My Dreams Can I Do the Things I Used to Do: Where There Is Research, There Is Hope
9:00AM-11:00AM
Abstract Number: 1281
Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
9:00AM-11:00AM
Abstract Number: 1021
Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status
9:00AM-11:00AM
Abstract Number: 1122
Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review
9:00AM-11:00AM
Abstract Number: 1121
Osteoarthritis in the Million Veterans Program: Integrating the Electronic Medical Record with Precision Medicine
9:00AM-11:00AM
Abstract Number: 1110
Osteoarthritis-Related Knee Inflammation Measured by Ultrasound Is Associated with Performance-Based Measures of Function
9:00AM-11:00AM
Abstract Number: 1226
Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK
9:00AM-11:00AM
Abstract Number: 1424
Outcomes of Hospitalizations for Acute Myocardial Infarction in Patients with ANCA Associated Vasculitis from the National Inpatient Sample
9:00AM-11:00AM
Abstract Number: 1390
Outcomes of Systemic Sclerosis Patients Who Were Primarily Admitted for Acute Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample
9:00AM-11:00AM
Abstract Number: 1019
Outdoor Air Pollution and Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1237
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
9:00AM-11:00AM
Abstract Number: 1085
Pain in Myositis Is Associated with the Disease Activity
9:00AM-11:00AM
Abstract Number: 1109
Pain in Women with Knee and/or Hip Osteoarthritis Is Related to Systemic Inflammation and to Adipose Tissue Dysfunction and Distribution: A Cross-sectional Metabolic Biomarkers Cohort Study
9:00AM-11:00AM
Abstract Number: 1030
Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy
9:00AM-11:00AM
Abstract Number: 1000
Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women
9:00AM-11:00AM
Abstract Number: 0991
Pathogenic, Glycolytic PD-1+ B Cells Accumulate in the Hypoxic RA Joint
9:00AM-11:00AM
Abstract Number: 1394
Pathway to Systemic Sclerosis: Concerning Patients’ Experiences During the Diagnostic Process
9:00AM-11:00AM
Abstract Number: PP08
Patient Participation in the COVID-19 Global Rheumatology Alliance as a Model for Involving Patients from the Ground Up
9:00AM-11:00AM
Abstract Number: 1133
Patient Perceptions of Diagnosis, Tests, Treatments, Adherence and the Impact on Their Disease Understanding and Participation in Research Studies
9:00AM-11:00AM
Abstract Number: 1316
Patient Perceptions of Fibromyalgia Symptoms and the Overlap with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1131
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
9:00AM-11:00AM
Abstract Number: 1130
Patient Perspectives on Biobanking and Data-linkage for Rheumatic Disease Research
9:00AM-11:00AM
Abstract Number: 1125
Patient Reported Impact of Lupus on Quality of Life
9:00AM-11:00AM
Abstract Number: 1081
Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 1241
Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
9:00AM-11:00AM
Abstract Number: 1210
Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
9:00AM-11:00AM
Abstract Number: 1248
Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort
9:00AM-11:00AM
Abstract Number: 1267
Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)
9:00AM-11:00AM
Abstract Number: 1185
Performance of the MBDA-based CVD Risk Score in RA Patient Groups of Clinical Interest
9:00AM-11:00AM
Abstract Number: 1303
Performance of Three Referral Algorithms for Diagnosing Axial Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and Colitis Cohort
9:00AM-11:00AM
Abstract Number: 1239
Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1286
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
9:00AM-11:00AM
Abstract Number: 1161
Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
9:00AM-11:00AM
Abstract Number: 1041
Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center
9:00AM-11:00AM
Abstract Number: 1385
Physical Therapy in Patients with Systemic Sclerosis: The Perspective of Physical Therapists on Current Delivery and Educational Needs
9:00AM-11:00AM
Abstract Number: 1146
Pilot Study of an Internet-Based Pain Coping Skills Training Program for Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1087
Plasma-derived Extracellular Vesicles Induced STING-mediated Proinflammatory Effects in Dermatomyositis
9:00AM-11:00AM
Abstract Number: 1395
Poor Maternal and Fetal Outcome in Indian Women with Systemic Sclerosis: Interview-based Study at a Tertiary Center in India
9:00AM-11:00AM
Abstract Number: 1006
Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort
9:00AM-11:00AM
Abstract Number: 1271
Post-Traumatic Stress Disorder (PTSD) and Risk of Systemic Lupus Erythematosus (SLE) Among Medicaid Recipients
9:00AM-11:00AM
Abstract Number: 1346
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1117
Prediction Model for Progression to Different Find-Grained MRI-Based Osteoarthritis Severity States: The Vancouver Longitudinal Study of Early Knee Osteoarthritis (VALSEKO)
9:00AM-11:00AM
Abstract Number: 1294
Prediction of Damage in SLE Using Unbiased Analysis of Large Datasets
9:00AM-11:00AM
Abstract Number: 1163
Predictors of Colchicine Response in Patients with Undefined Systemic Autoinflammatory Diseases
9:00AM-11:00AM
Abstract Number: 1288
Predictors of Frailty Identified by the Short Physical Performance Battery and Associations with Patient-reported Outcomes
9:00AM-11:00AM
Abstract Number: 1347
Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study
9:00AM-11:00AM
Abstract Number: 1323
Pregnancy in Axial Spondyloarthropathy: A Systematic Review & Meta-Analysis
9:00AM-11:00AM
Abstract Number: 1322
Prevalence and Associated Factors of Sleep Disorders in Patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
9:00AM-11:00AM
Abstract Number: 1025
Prevalence Estimates for Systemic Lupus Erythematosus over Four Decades
9:00AM-11:00AM
Abstract Number: 1426
Prevalence of ANCA-associated Vasculitis and Spatial Association with Quarries in a French Northeast Region: A Capture-recapture and Geospatial Analysis
9:00AM-11:00AM
Abstract Number: 1066
Prevalence of Cervical Dysplasia in Women with Antisynthetase Syndrome
9:00AM-11:00AM
Abstract Number: 1313
Prevalence of Extra-Articular Manifestations in Early Ankylosing Spondylitis versus Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Meta-Analysis of 1504 Patients
9:00AM-11:00AM
Abstract Number: 1134
Prevalence of Frailty and Associated Factors in a National Observational Cohort of Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1287
Prevalence of Morbidity Prior to Diagnosis of Incident Systemic Lupus Erythematosus in the Danish Population
9:00AM-11:00AM
Abstract Number: 1199
Prevalence of Subclinical Interstitial Lung Disease After a Mean Rheumatoid Arthritis Duration of 13 Years: Results from the French ESPOIR Cohort
9:00AM-11:00AM
Abstract Number: 1309
Prevalence of Undiagnosed Axial Spondyloarthritis Among Patients with Inflammatory Bowel Disease: A Secondary Care Cross-Sectional Study
9:00AM-11:00AM
Abstract Number: 1139
Primary Non-adherence in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1028
Probabilistic Linkage of a Cohort of Individuals with Symptoms Suggestive of Early Spondyloarthritis and the French National Healthcare Database
9:00AM-11:00AM
Abstract Number: 1435
Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1368
Proportions of Patients Achieving a Minimal Disease Activity State upon Treatment with Tildrakizumab in a Psoriatic Arthritis Phase 2b Study
9:00AM-11:00AM
Abstract Number: 1047
Prospective Analysis of a Cohort of Patients with Interstitial Lung Disease Associated with Connective Tissue Disease and Their Response to Immunosuppression with Mycophenolate Mofetil and Rituximab
9:00AM-11:00AM
Abstract Number: 1002
Prostate Cancer Risk Is Not Increased in Rheumatoid Arthritis After Accounting for Retention in a Health Care System
9:00AM-11:00AM
Abstract Number: 1439
Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1017
Racial and Ethnic Disparities in the Risk of Preterm Birth Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis with Varying Reference Groups
9:00AM-11:00AM
Abstract Number: 1231
Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years
9:00AM-11:00AM
Abstract Number: 1235
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
9:00AM-11:00AM
Abstract Number: 1105
RANK-L Activity: Understanding the Pathogenesis of Erosive Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1377
Raynaud’s Phenomenon and Systemic Sclerosis in Post-9/11 Deployed Veterans Receiving Care Veterans Health Administration Care
9:00AM-11:00AM
Abstract Number: 1253
Re-evaluation of the Extent of Lymphocytic Infiltration May Improve the Diagnostic Accuracy of Lip Biopsy in Primary Sjögren’s Syndrome (pSS)
9:00AM-11:00AM
Abstract Number: 1219
Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial
9:00AM-11:00AM
Abstract Number: 1031
Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab
9:00AM-11:00AM
Abstract Number: 1381
Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset
9:00AM-11:00AM
Abstract Number: 1088
Recruitment Rates of Virtual Remote Research (Tele-Research) in Myositis
9:00AM-11:00AM
Abstract Number: 1186
Red Cell Distribution Width and Absolute Lymphocyte Count Associate with Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1187
Red Cell Distribution Width Is Associated with ASCVD Risk Score and CVD in RA After Initiation of Methotrexate
9:00AM-11:00AM
Abstract Number: 1048
Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
9:00AM-11:00AM
Abstract Number: 1425
Reduced Risk of Cardiovascular Diseases Events with Renal Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System
9:00AM-11:00AM
Abstract Number: 1227
Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors
9:00AM-11:00AM
Abstract Number: 1037
Relationship Between Air Quality and Sarcoidosis Inflammatory Activity
9:00AM-11:00AM
Abstract Number: 1211
Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies
9:00AM-11:00AM
Abstract Number: 1020
Relationship Between Skin-related Quality of Life, Psychosocial Stress, and Race in Cutaneous Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1112
Relationship of Depth-Specific Subchondral Bone Mineral Density and Pain in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
9:00AM-11:00AM
Abstract Number: 1337
Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1168
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
9:00AM-11:00AM
Abstract Number: 1132
Reliability of Virtual Sources of Education for Patients with Vasculitis
9:00AM-11:00AM
Abstract Number: 1375
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?
9:00AM-11:00AM
Abstract Number: 1410
Resident Memory T Cells Persist in Joints of Anakinra-Treated Mice in Spontaneous Arthritis Model
9:00AM-11:00AM
Abstract Number: 1407
Resolvin D5 Modulates Th17/Treg Cell Differentiation and Suppresses Osteoclastogenesis
9:00AM-11:00AM
Abstract Number: 1141
Reversing Seasonal Decline of T2T Outcome in RA Patients Under Double Hits by Chinese New Year and COVID-19 Epidemic via Online Interaction with SSDM
9:00AM-11:00AM
Abstract Number: 1177
Rheumatic Diseases in Mexican Children and Their Psychosocial and Economic Impact on Caregivers
9:00AM-11:00AM
Abstract Number: 1046
Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis
9:00AM-11:00AM
Abstract Number: 1324
Risk Factors for Adverse Pregnancy Outcomes in Women with Spondyloarthritis: An Observational Study from Two European Multidisciplinary Pregnancy Clinics
9:00AM-11:00AM
Abstract Number: 1001
Risk of Malignant Melanoma and Nonmelanoma Skin Cancer in Rheumatoid Arthritis Patients Initiating Methotrexate versus Hydroxychloroquine
9:00AM-11:00AM
Abstract Number: 1005
Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs: A Multi-Database Comparative Safety Study
9:00AM-11:00AM
Abstract Number: 1417
Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study
9:00AM-11:00AM
Abstract Number: 1149
Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA)
9:00AM-11:00AM
Abstract Number: 1051
Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers
9:00AM-11:00AM
Abstract Number: 1438
Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)
9:00AM-11:00AM
Abstract Number: 1050
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center
9:00AM-11:00AM
Abstract Number: 1350
Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis from Two Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 1070
Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features
9:00AM-11:00AM
Abstract Number: 1069
Scleromyositis Is Associated with Nailfold Capillary Abnormalities Compared to Immune-Mediated Necrotizing Myopathy
9:00AM-11:00AM
Abstract Number: 1018
Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)
9:00AM-11:00AM
Abstract Number: 1366
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation
9:00AM-11:00AM
Abstract Number: 1340
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
9:00AM-11:00AM
Abstract Number: 1374
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
9:00AM-11:00AM
Abstract Number: 1361
Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naïve Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study
9:00AM-11:00AM
Abstract Number: 1243
Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression
9:00AM-11:00AM
Abstract Number: 1080
Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America
9:00AM-11:00AM
Abstract Number: 1188
Serum Anti-malondialdehyde-acetaldehyde IgA Antibody Concentration Improves Prediction of Coronary Atherosclerosis Beyond Traditional Risk Factors in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1200
Serum Anti-PAD4 and Anti-PAD3/4XR Antibodies in Rheumatoid Arthritis Associated-Interstitial Lung Disease Are Associated with Better Lung Function
9:00AM-11:00AM
Abstract Number: 1189
Serum High-sensitive Cardiac Troponin at Baseline Predict Cardiovascular Events in Rheumatoid Arthritis and Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1079
Sex Differences in Antibody Profile, Phenotype, and Treatment Response in a Racially Diverse Population with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 1190
Sex Differences in Cardiovascular Disease Prevention in Patients with Rheumatoid Arthritis: World-wide Data from the SURF-RA
9:00AM-11:00AM
Abstract Number: 1289
Sex Differences in Mental Health and Quality of Life and Their Impact in the Treatment of Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1072
Sexual Health Impairment in 62 Female Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 1387
Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction?
9:00AM-11:00AM
Abstract Number: 1262
Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE
9:00AM-11:00AM
Abstract Number: 1246
Sjogren’s Syndrome and Its Risk of Cervical Lesions
9:00AM-11:00AM
Abstract Number: 1255
Sjӧgren’s Syndrome Minor Salivary Gland Mesenchymal Stromal Cells Derived Deploy Intact Immune Plasticity and Display Myofibroblast-Like Properties
9:00AM-11:00AM
Abstract Number: 1245
Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1335
Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
9:00AM-11:00AM
Abstract Number: 1205
Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy
9:00AM-11:00AM
Abstract Number: 1191
Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1063
Spirulina Stimulates Inflammatory Cytokine Production Through the STING and TLR Pathways in Dermatomyositis in Vitro
9:00AM-11:00AM
Abstract Number: 1038
STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis
9:00AM-11:00AM
Abstract Number: 1268
Structural Validity of a Comprehensive Neuropsychological Battery for Assessment of Cognitive Impairment in Systemic Lupus Erythematosus: Exploratory Factor Analysis Confirms Six Cognitive Domains
9:00AM-11:00AM
Abstract Number: 1035
Study of Ocular Sarcoidosis and Clusters of Clinical Associations in a Series of 383 Patients with Systemic Sarcoidosis from a Single Hospital
9:00AM-11:00AM
Abstract Number: 1329
Subclinical Atherosclerosis Risk in Psoriatic Arthritis: Could It Be Prevented?
9:00AM-11:00AM
Abstract Number: 1330
Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study with 806 patients.
9:00AM-11:00AM
Abstract Number: 1192
Subclinical Coronary Calcification Associated with Long-term Cardiovascular Outcomes in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1136
Survey of Medical Cannabis Use in Lupus and Scleroderma
9:00AM-11:00AM
Abstract Number: 1393
Systemic Sclerosis: Subclinical Aterosclerosis and Morbimortality
9:00AM-11:00AM
Abstract Number: 1033
Systemic Treatment in Sarcoidosis. Study of 377 Patients from a Single University Hospital
9:00AM-11:00AM
Abstract Number: 1359
Targeted Serum Proteomic Analysis Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue Repair Modulation
9:00AM-11:00AM
Abstract Number: 1225
Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching Each Other If One of These Treatments Resulted in Lack of Efficacy
9:00AM-11:00AM
Abstract Number: 1128
The Diagnosis of Systemic Sclerosis as a Traumatic Experience: Patients’ Reactions to the Diagnostic Process
9:00AM-11:00AM
Abstract Number: 1086
The Diagnostic Value and Clinical Significance of Myositis-Specific Antibodies in Patients Suspected to Have Autoimmune Myopathies and/or Autoimmune Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1104
The Disability Associated with Hand Osteoarthritis Is Substantial in a Cohort of Post-menopausal Women : The QUALYOR Study
9:00AM-11:00AM
Abstract Number: 1354
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1428
The Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 1012
The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis
9:00AM-11:00AM
Abstract Number: 1100
The Hand Osteoarthritis Registry of New York University: Impacts of Gender and Obesity
9:00AM-11:00AM
Abstract Number: 1249
The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies
9:00AM-11:00AM
Abstract Number: 1259
The Impact of Antimalarial Agents on Traditional and Non-traditional Cardiovascular Markers in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 1282
The Impact of High Disease Activity as Measured by SLEDAI and Drug Burden on Healthcare Utilization, Quality of Life and Work Productivity in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 1273
The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients
9:00AM-11:00AM
Abstract Number: 1004
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1026
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 1143
The Influence of YouTube on Spreading Awareness and Patient Education Regarding Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1398
The Isolated Nucleolar Pattern ANA Antibody in a Systemic Sclerosis Patient Cohort
9:00AM-11:00AM
Abstract Number: 1440
The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1027
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2017
9:00AM-11:00AM
Abstract Number: 1123
The Patient Journey in Knee OA: Variations in Patient Characteristics and Treatment by Physician Specialty
9:00AM-11:00AM
Abstract Number: 1082
The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect
9:00AM-11:00AM
Abstract Number: 1308
The Presence of Spondyloarthritis Is Associated with Higher Clinical Disease Activity in Patients with Early Crohn’s Disease: Results of a Prospective Cohort Study
9:00AM-11:00AM
Abstract Number: 1015
The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)
9:00AM-11:00AM
Abstract Number: 1115
The Relation of MRI-Based Cartilage Lesions to Knee Replacement and Knee Pain Severity in Osteoarthritis: The Multicenter Osteoarthritis Study
9:00AM-11:00AM
Abstract Number: 1058
The Relationship of Different Muscle Enzymes in Adult Myositis Patients
9:00AM-11:00AM
Abstract Number: 1430
The Role of Lung Biopsy in Pediatric ANCA-associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1434
The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres
9:00AM-11:00AM
Abstract Number: 1148
The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA
9:00AM-11:00AM
Abstract Number: 1209
The Strength of IL-6/STAT3 Signal Inhibition by SAR S.c q2w Showed Significantly Higher Level Than That of TCZ S.c q2w but Lower Than TCZ S.c q1w
9:00AM-11:00AM
Abstract Number: 1169
Three-Dimensional Analysis of Facial Asymmetry in Craniofacial Scleroderma
9:00AM-11:00AM
Abstract Number: 1433
Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study
9:00AM-11:00AM
Abstract Number: 1432
Thyroid Disease in Patients with ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1024
Time Trends in the Incidence of Systemic Lupus Erythematosus: A 40-Year Study
9:00AM-11:00AM
Abstract Number: 1312
Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1383
Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
9:00AM-11:00AM
Abstract Number: 1039
Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis
9:00AM-11:00AM
Abstract Number: 1150
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis
9:00AM-11:00AM
Abstract Number: 1258
Trajectory of Damage Accrual in African-American vs. Caucasian Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1242
Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study
9:00AM-11:00AM
Abstract Number: 1160
Treatment Intensity and Impact on Bone Lesion Evolution and Distribution Patterns in Severe Chronic Recurrent Multifocal Osteomyelitis
9:00AM-11:00AM
Abstract Number: 1054
Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients
9:00AM-11:00AM
Abstract Number: 1270
Trend of Survival of a Cohort of Patients with Systemic Lupus Erythematosus over 25 Years
9:00AM-11:00AM
Abstract Number: 1034
Trend of Treatment Plans, and Outcomes of Therapy in Cardiac Sarcoidosis via Analysis of Standardized Uptake Values Score and Ejection Fraction Using a Cardiac PET-CT
9:00AM-11:00AM
Abstract Number: 1153
Trends in Timing of Biologic Use for Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry
9:00AM-11:00AM
Abstract Number: 1252
Ultrasound-guided Parotid Gland Biopsy in Cadavers Performed by Rheumatologists – an OMERACT Ultrasound Working Group Study
9:00AM-11:00AM
Abstract Number: 1171
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort
9:00AM-11:00AM
Abstract Number: 1378
Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
9:00AM-11:00AM
Abstract Number: 1275
Unexpected Changes in Physical and Psychological Measures Among Georgia Lupus Patients During the Early Weeks of the COVID-19 Pandemic in the United States, March 30–April 21, 2020
9:00AM-11:00AM
Abstract Number: 1193
Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies
9:00AM-11:00AM
Abstract Number: 1345
Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 1384
Usage, Needs and Preferences Regarding Physical Therapy in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1204
Use of Multi-Biomarker Disease Activity Scores to Assess Biosimilarity in a Phase 3 Randomized Controlled Trial Comparing Biosimilar Infliximab-qbtx (PF‑06438179/GP1111) with EU-Sourced Reference Infliximab in Patients with Active RA
9:00AM-11:00AM
Abstract Number: 1233
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
9:00AM-11:00AM
Abstract Number: 1166
Use of Rituximab to Treat COPA Syndrome: A Multi-Institutional Cohort
9:00AM-11:00AM
Abstract Number: 1175
Using a Patient-Engaged Approach to Identify Cross-Cutting Disease Factors Impacting Mental Health in Youth with Rheumatologic Disease
9:00AM-11:00AM
Abstract Number: 1276
Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery
9:00AM-11:00AM
Abstract Number: 1208
Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial
9:00AM-11:00AM
Abstract Number: 1304
Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Prospective French Nationwide Cohort
9:00AM-11:00AM
Abstract Number: 1165
Validation of Healthcare Claims Algorithms for Identification of Herpes Zoster Among Children with Autoimmune/Autoinflammatory Disease
9:00AM-11:00AM
Abstract Number: 1348
What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial
9:00AM-11:00AM
Abstract Number: 1212
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)
10:00AM-10:50AM
Abstract Number: 1460
“Can I Help You with Your RA Today?”: A Pilot Study on the User Experience with a Voice-Enabled Smartphone App to Virtually Monitor Disease Activity and Collect ePROs in Rheumatoid Arthritis
10:00AM-10:50AM
Abstract Number: 1453
A First in Class Therapeutic Nanoparticle for Specific Targeting of Anti-citrullinated Protein Antibody Ameliorates Serum Transfer and Collagen Induced Arthritis
10:00AM-10:50AM
Abstract Number: 1478
A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center
10:00AM-10:50AM
Abstract Number: 1481
A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations
10:00AM-10:50AM
Abstract Number: 1480
Abatacept for the Treatment of IgG4-Related Disease
10:00AM-10:50AM
Abstract Number: 1477
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
10:00AM-10:50AM
Abstract Number: 1454
B Cell-specific TLR7 Regulates Lupus in TLR9 Deficient Mice
10:00AM-10:50AM
Abstract Number: 1456
Exploring the RA Bone Marrow Niche by Single-cell Technology to Identify Long Lived ACPA+ Plasma Cells
10:00AM-10:50AM
Abstract Number: 1455
Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants
10:00AM-10:50AM
Abstract Number: 1461
Implementation, Feasibility and Acceptability of Take Charge, an Email Series to Increase Knowledge of Lupus Self-Management Skills
10:00AM-10:50AM
Abstract Number: 1479
Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
10:00AM-10:50AM
Abstract Number: 1458
Slower Current Walking Speed Is Associated with Progression in Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
10:00AM-10:50AM
Abstract Number: 1459
The Association of Frequent Knee Bending with Trajectories of Pain and Physical Function over 8 Years in Knee Osteoarthritis
10:00AM-10:50AM
Abstract Number: 1452
Transcriptomic Meta-analysis Reveals a Core Transcriptional Program in Murine B Cell Anergy and Implicates Immunometabolic Regulation as a Central Pathway in Maintaining Non-responsiveness of Autoreactive B-cells in Both Mouse and Man
10:00AM-10:50AM
Abstract Number: 1457
Two Minute Walking Distance and Other Timed Function Tests Are Superior to MMT-8 in Assessing Outcomes in Polymyositis and Dermatomyositis
11:30AM-1:00PM
Abstract Number: 1445
Citrulline Reactive B Cells Are Present in the Lungs of Risk RA and Early Untreated RA
11:30AM-1:00PM
Abstract Number: 1444
Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial
11:30AM-1:00PM
Abstract Number: 1442
Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial
11:30AM-1:00PM
Abstract Number: 1441
Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis
11:30AM-1:00PM
Abstract Number: 1443
High-dimensional Analyses of Checkpoint-inhibitor Related Arthritis Synovial Fluid Cells Reveal a Unique, Proliferating CD38hi Cytotoxic CD8 T Cell Population Induced by Type I IFN
11:30AM-1:00PM
Abstract Number: 1446
Pregnancy Outcomes in Patients with Interstitial Lung Disease
12:00PM-1:00PM
Abstract Number: PP11
“Knitting a Community of Hope”- Supporting, Empowering and Educating Those Living with Lupus, and Overlapping Conditions and Their Loved Ones via in Person and Virtual Support Groups That Include Art Therapy, and Wellness Techniques Is Key; Mental Health Is as Important as Physical Health
12:00PM-1:00PM
Abstract Number: PP09
An Integrative Approach to Managing Rheumatoid Arthritis (RA): Healing the Body, Mind & Spirit
12:00PM-1:00PM
Abstract Number: PP12
COVID-19, Racism, and Gender Discrimination: The Function of Stress in Widening the Gap in Health Disparities
12:00PM-1:00PM
Abstract Number: PP10
Patients with Relapsing Polychondritis (“RP”) and an Advocate Manufactured Custom Cloth Masks to Combat COVID-19: This Mask Project Provided a Sense of Purpose, Created Unity, Increased Awareness of RP, Facilitated Research, and Generated Hope
3:00PM-3:50PM
Abstract Number: 1522
Biomarkers of Hemodynamic Severity of Systemic-Sclerosis Associated Pulmonary Arterial Hypertension by Serum Proteome Analysis
3:00PM-3:50PM
Abstract Number: 1508
Blood-Brain Barrier Leakage in Systemic Lupus Erythematosus Is Associated with Gray Matter Loss and Cognitive Impairment
3:00PM-3:50PM
Abstract Number: 1511
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
3:00PM-3:50PM
Abstract Number: 1497
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
3:00PM-3:50PM
Abstract Number: 1500
Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation
3:00PM-3:50PM
Abstract Number: 1462
Intensity and Duration of Silica Exposure Increase Rheumatoid Arthritis Risk Among Coal Miners
3:00PM-3:50PM
Abstract Number: 1525
Intergenic HLA Variants in African American Patients with Systemic Sclerosis Regulate Expression of HLA-DRB1
3:00PM-3:50PM
Abstract Number: 1524
Interstitial Lung Disease, Kidney Inflammation and Myositis Are Induced by Transfer of PBMC Derived from Systemic Sclerosis Patients into Rag2-/-/ IL2rg-/- mice
3:00PM-3:50PM
Abstract Number: 1509
Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study
3:00PM-3:50PM
Abstract Number: 1507
Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort
3:00PM-3:50PM
Abstract Number: 1464
Multi-Variate Approach Including Serology and Genetics for an Improved Identification of Patients at Risk of Developing Rheumatoid Arthritis
3:00PM-3:50PM
Abstract Number: 1466
Multimorbidity in Rheumatoid Arthritis, Psoriatic Arthritis, Gout, and Osteoarthritis Within the Rheumatology Informatics System for Effectiveness (RISE) Registry
3:00PM-3:50PM
Abstract Number: 1501
Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria
3:00PM-3:50PM
Abstract Number: 1510
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
3:00PM-3:50PM
Abstract Number: 1498
Pregnancy Outcomes in Patients with Axial Spondyloarthritis – a First Analysis of a European Collaboration of Pregnancy Registries
3:00PM-3:50PM
Abstract Number: 1523
Pulmonary Cytokine, Chemokine and Growth Factor Profiles of Distinct Radiographic Patterns of Interstitial Lung Disease in Systemic Sclerosis
3:00PM-3:50PM
Abstract Number: 1526
Single Cell Analysis of Skin and Blood of Scleroderma Patients Towards Identification of New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets
3:00PM-3:50PM
Abstract Number: 1499
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
3:00PM-3:50PM
Abstract Number: 1465
The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0
3:00PM-3:50PM
Abstract Number: 1463
Threshold Level for Long-term Healthy Diet Adherence to Reduce the Risk of Rheumatoid Arthritis Among Women in a Prospective Cohort Using a Marginal Structural Model Approach
4:00PM-4:50PM
Abstract Number: 1483
A Randomised Controlled Trial Evaluating the Efficacy of Internet-based Exercises Aimed at Treating Knee Osteoarthritis (iBEAT-OA)
4:00PM-4:50PM
Abstract Number: 1449
Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement
4:00PM-4:50PM
Abstract Number: 1469
Characteristics of Adult Patients with Rheumatic Diseases During the COVID-19 Pandemic: Data from an International Patient Survey
4:00PM-4:50PM
Abstract Number: 1493
Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis
4:00PM-4:50PM
Abstract Number: 1467
Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
4:00PM-4:50PM
Abstract Number: 1484
Efficacy of Tocilizumab in Patients with Hand Osteoarthritis: Double Blind, Randomized, Placebo Controlled, Multicenter Trial
4:00PM-4:50PM
Abstract Number: 1471
Healthy Lifestyle and Risk of Rheumatoid Arthritis in Women: A Prospective Cohort Study
4:00PM-4:50PM
Abstract Number: 1450
Integrative Analysis of DNA Methylation and Gene Expression in Monocytes from Primary Antiphospholipid Syndrome Patients Identifies a Gene Expression Signature Associated with Their Atherothrombotic Phenotype
4:00PM-4:50PM
Abstract Number: 1482
Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis
4:00PM-4:50PM
Abstract Number: 1485
LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
4:00PM-4:50PM
Abstract Number: 1486
Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study
4:00PM-4:50PM
Abstract Number: 1451
Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE
4:00PM-4:50PM
Abstract Number: 1470
Machine Learning-Based Prediction of Knee Replacement in Persons with and Without Radiographic Osteoarthritis Using Clinical and Imaging Features of Osteoarthritis: The Multicenter Osteoarthritis Study
4:00PM-4:50PM
Abstract Number: 1496
Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
4:00PM-4:50PM
Abstract Number: 1494
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
4:00PM-4:50PM
Abstract Number: 1515
Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort
4:00PM-4:50PM
Abstract Number: 1513
Role of Platelet C4d in Thrombosis and Lupus Nephritis
4:00PM-4:50PM
Abstract Number: 1448
Single-cell RNA Sequencing of Livedo Reticularis Skin Reveals Endothelial Pathology in Antiphospholipid Syndrome
4:00PM-4:50PM
Abstract Number: 1468
The Association of Walking Speed from Short- and Standard-Distance Tests with Mortality Risk Among Adults with Radiographic Knee Osteoarthritis: Data from Johnston County Osteoarthritis Project, Osteoarthritis Initiative and Multicenter Osteoarthritis Study
4:00PM-4:50PM
Abstract Number: 1492
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes
4:00PM-4:50PM
Abstract Number: 1514
The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study
4:00PM-4:50PM
Abstract Number: 1516
The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership
4:00PM-4:50PM
Abstract Number: 1495
Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
4:00PM-4:50PM
Abstract Number: 1512
Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis
4:00PM-4:50PM
Abstract Number: 1447
Vitamin D Deficiency Enhances Antiphospholipid Antibody-Mediated Thrombosis in a Passive Immunization Mouse Model
5:00PM-5:50PM
Abstract Number: 1473
A Combination of Healthy Lifestyle Behaviors Reduce Risk of Incident Systemic Lupus Erythematosus in the Nurses’ Health Studies
5:00PM-5:50PM
Abstract Number: 1521
A Novel Gut-joint Migratory TCRab+ Cell Subset Relies on sphingosine-1-phosphate for Tissue Localization
5:00PM-5:50PM
Abstract Number: 1505
Antibodies Binding Ro/SSA and Muscarinic 3 Receptor in Sjogren’s Syndrome
5:00PM-5:50PM
Abstract Number: 1488
Application of the Knee Injury and Osteoarthritis Outcome Score Percentile Curves on Preoperative and up to 2 Years Postoperative Data of Patients Undergoing Total Knee Arthroplasty
5:00PM-5:50PM
Abstract Number: 1472
Assessing Causal Associations of Urate Levels with Type 2 Diabetes and Related Glycemic Traits Using Bidirectional Mendelian Randomization
5:00PM-5:50PM
Abstract Number: 1491
Association of a Leaky Gut but Not Microbial Dysbiosis with Obesity-related OA: A Translational Study
5:00PM-5:50PM
Abstract Number: 1487
Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Analyses: Data from the Osteoarthritis Initiative
5:00PM-5:50PM
Abstract Number: 1520
Characterisation of Rheumatoid and Psoriatic Arthritis Synovial Fibroblasts
5:00PM-5:50PM
Abstract Number: 1502
Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS)
5:00PM-5:50PM
Abstract Number: 1506
Correction of Sjögren’s Syndrome Fluid Secretion Deficits in Salivary Gland Acinar Cells by Aquaporin-1 Gene Transfer
5:00PM-5:50PM
Abstract Number: 1474
Early Peak of Cardiovascular Events Occurs Equally in Caucasians and African-American SLE but Is Attributed to Different Risk Factors
5:00PM-5:50PM
Abstract Number: 1504
Four Distinct Symptom-Based Clusters Identified from the Sjӧgren’s Foundation Survey
5:00PM-5:50PM
Abstract Number: 1519
Interleukin-17D, a Cytokine Derived from Stromal Cells, Attenuates Joint Inflammation
5:00PM-5:50PM
Abstract Number: 1517
Metabolic Regulation of Type 3 Innate Lymphoid Cells by Intestinal Bacteria-Derived Indoles in Ankylosing Spondylitis
5:00PM-5:50PM
Abstract Number: 1490
Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials
5:00PM-5:50PM
Abstract Number: 1475
Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study
5:00PM-5:50PM
Abstract Number: 1489
Relation of Pain Mechanisms to Development of Knee Pain in Osteoarthritis: The Multicenter Osteoarthritis Study
5:00PM-5:50PM
Abstract Number: 1518
The Role for Neutrophils in the Early Phases of Enthesitis in Spondyloarthritis
5:00PM-5:50PM
Abstract Number: 1476
Trends in Mortality and Cause-specific Mortality Among Patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada
5:00PM-5:50PM
Abstract Number: 1503
Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands Might Help to Avoid Unnecessary Lip Biopsy in Patients with Sicca Syndrome
9:00AM-11:00AM
Abstract Number: 1826
­Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
9:00AM-11:00AM
Abstract Number: 1869
“Rheum to Diagnosis”: Uncovering Impediments to Accurate Diagnosis of Non-radiographic Axial Spondylarthritis (nr-axSpA)
9:00AM-11:00AM
Abstract Number: 1555
18F-NaF PET/CT Identifies Active Calcium Uptake in Calcinosis Due to Dermatomyositis and Scleroderma
9:00AM-11:00AM
Abstract Number: 1636
8 Years Follow-Up of a Novel Autoinflammatory Disease: CD59 Malfunction Causes Hemolytic Anemia, Recurrent Guillain-Barre Syndrome, and Strokes in Pediatric Populations and Respond Well to Eculizumab and Pozelimab
9:00AM-11:00AM
Abstract Number: 1813
A Comprehensive Method to Study Environmental Chemicals in Serum in Patients with SLE
9:00AM-11:00AM
Abstract Number: 1650
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
9:00AM-11:00AM
Abstract Number: 1724
A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project
9:00AM-11:00AM
Abstract Number: 1797
A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA and Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years
9:00AM-11:00AM
Abstract Number: 1840
A Novel Biomarker Identifies Systemic Lupus Erythematous (SLE) Patients Who Benefit from Obexelimab (XmAb®5871) Treatment
9:00AM-11:00AM
Abstract Number: 1745
A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques
9:00AM-11:00AM
Abstract Number: 1796
A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment
9:00AM-11:00AM
Abstract Number: 1588
A Quality Improvement Project to Improve Bone Densitometry Ordering in Adult Patients on Chronic Glucocorticoids
9:00AM-11:00AM
Abstract Number: 1591
A Quality Improvement Project to Increase Vitamin D Prescribing for Pediatric Patients on Glucocorticoids
9:00AM-11:00AM
Abstract Number: 1633
A Randomized, Double-Blind, Placebo-Controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
9:00AM-11:00AM
Abstract Number: 1803
Ability of Innate, Adaptive, and TNF-Superfamily Immune Pathways to Characterize Disease Activity and Inform a Refined Lupus Disease Activity Immune in a Confirmatory Cohort of SLE Patients
9:00AM-11:00AM
Abstract Number: 1856
Abnormal DNA Methylation in CD4+T Cells Is Associated with Cardiovascular Risk in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1530
Activin a and Follistatin Alter Endothelial Cell and Rheumatoid Arthritis Synovial Fibroblast Adhesion and Interaction
9:00AM-11:00AM
Abstract Number: 1576
Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review
9:00AM-11:00AM
Abstract Number: 1593
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus: Results of a Quality Improvement Initiative
9:00AM-11:00AM
Abstract Number: 1706
Advanced Integrated Science Courses: A Novel Approach to Medical Student Science Education
9:00AM-11:00AM
Abstract Number: 1830
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
9:00AM-11:00AM
Abstract Number: 1838
Aerobic Exercise Improves Fatigue and Quality of Life in Women with Systemic Lupus Erythematosus (Preliminary Analysis)
9:00AM-11:00AM
Abstract Number: 1819
Altered Brain Functional Connectivity in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1836
Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1545
An Artificial Intelligence (AI) Assistant Identifying Spinal Diffuse Idiopathic Skeletal Hyperostosis on Plain X-rays: A Pilot Deep Learning Study
9:00AM-11:00AM
Abstract Number: 1801
An Engineered Extracellular Matrix‐rich Decellularized Substrate Based Podocytes Culture System to Study Intracellular Complement Production and Activation
9:00AM-11:00AM
Abstract Number: 1589
An Initiative to Improve Timely Glucocorticoid Tapering in Vasculitis
9:00AM-11:00AM
Abstract Number: 1860
An Integrative Approach to Identify Heritable and De Novo Genomic Variations in Psoriatic Arthritis Mutilans and Understand Its Systems Biology
9:00AM-11:00AM
Abstract Number: 1725
An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice
9:00AM-11:00AM
Abstract Number: 1647
An Oleuropein-based Dietary Supplement Improves Joint Function in Older People with High Knee Joint Pain
9:00AM-11:00AM
Abstract Number: 1942
Analysis of Vasculitis Patterns in Patients with Giant Cell Arteritis Compared to Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 1923
Angiographic Progression of Disease in Large-Vessel Vasculitis
9:00AM-11:00AM
Abstract Number: 1695
Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
9:00AM-11:00AM
Abstract Number: 1937
Aortic Aneurysm in Giant Cell Arteritis: A Nationwide Analysis
9:00AM-11:00AM
Abstract Number: 1691
Applied Geostatistics in Pediatric Rheumatology – Spatial Clustering of IgA Vasculitis
9:00AM-11:00AM
Abstract Number: 1882
Are There Any Clues to Predict Bamboo Spine in Axial Spondyloarthritis?
9:00AM-11:00AM
Abstract Number: 1556
Assessing Calcinosis in Dermatomyositis with Computed Tomography and Calcium Scoring
9:00AM-11:00AM
Abstract Number: 1612
Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
9:00AM-11:00AM
Abstract Number: 1615
Assessing Preparation for Care Transition Among Adolescents with Rheumatologic Disease: A Quality Assessment with Patient Survey
9:00AM-11:00AM
Abstract Number: 1579
Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response
9:00AM-11:00AM
Abstract Number: 1602
Assessing the Psychometric Properties of a Measure of Patient Empowerment with Patients with Arthritis
9:00AM-11:00AM
Abstract Number: 1903
Assessment of Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis : Preliminary Results
9:00AM-11:00AM
Abstract Number: 1726
Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice
9:00AM-11:00AM
Abstract Number: 1788
Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE
9:00AM-11:00AM
Abstract Number: 1540
Association Between Disease Activity and Left Ventricular Systolic Function in Patients with Rheumatoid Arthritis: A Case-Control Study
9:00AM-11:00AM
Abstract Number: 1800
Association of Air Pollution with Systemic Lupus Erythematosus Disease Activity in the Central Valley of California
9:00AM-11:00AM
Abstract Number: 1567
Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)
9:00AM-11:00AM
Abstract Number: 1853
Association of Gut Dysbiosis with Radiographic and Enthesis Involvement, Disease Activity and Duration in Axial Spondyloarthritis. Data from CASTRO Registry
9:00AM-11:00AM
Abstract Number: 1880
Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1922
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 1746
Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1790
Association of Telomere Length and the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) in Long Standing Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1729
Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
9:00AM-11:00AM
Abstract Number: 1582
Average Follow-up Time After Telemedicine Visit Is Longer Than Conventional Face-to-Face Visit in Outpatient Rheumatology Practice During COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 1832
Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population
9:00AM-11:00AM
Abstract Number: 1762
Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA
9:00AM-11:00AM
Abstract Number: 1653
Bilateral vs Unilateral Total Knee Arthroplasty: Racial Variation in Utilization and In-Hospital Major Complication Rates
9:00AM-11:00AM
Abstract Number: 1834
Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1831
Biomarkers Linked to Anti-IFN-I and Ustekinumab Suggest Distinct Mechanism of Action in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1763
Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1548
Blood Pressure, BMI and Sex Affect Optical Spectral Transmission Imaging Measurements of the Hands
9:00AM-11:00AM
Abstract Number: 1755
Body Mass Index Trajectory and Variability in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1590
Bone Health in ANCA – Associated Vasculitis Patients
9:00AM-11:00AM
Abstract Number: 1747
Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)
9:00AM-11:00AM
Abstract Number: 1575
CD6 Is a Target for Cancer Immunotherapy
9:00AM-11:00AM
Abstract Number: 1621
Cervical Cancer Screening Among Women with Systemic Lupus Erythematosus or Prescribed Tumor Necrosis Alpha-inhibitors Who Receive Outpatient Rheumatology Care
9:00AM-11:00AM
Abstract Number: 1550
Change in Tophus Size Measured with Dual-energy CT and Ultrasound: A 1-year Multicenter Follow-up Study
9:00AM-11:00AM
Abstract Number: 1817
Changes in Macular Capillary Network Measured with Optical Coherence Tomography-angiography in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1531
Characterization of Cytokine/chemokine Profile in Patient-derived M1/ M2 Macrophages to Identify Biomarkers for Genetically-defined Systemic Autoinflammatory Diseases
9:00AM-11:00AM
Abstract Number: 1945
Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 1558
Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib
9:00AM-11:00AM
Abstract Number: 1901
Clinical Characteristics of Importance to Outcome in Patients with Axial Spondyloarthritis: A Prospective Cohort Study
9:00AM-11:00AM
Abstract Number: 1572
Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases
9:00AM-11:00AM
Abstract Number: 1904
Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis
9:00AM-11:00AM
Abstract Number: 1863
Clinical History as Tool for Diagnosis and Classification of Patients with Ankylosing Spondylitis (Axial Spondyloarthritis): Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
9:00AM-11:00AM
Abstract Number: 1837
Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort
9:00AM-11:00AM
Abstract Number: 1640
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies
9:00AM-11:00AM
Abstract Number: 1641
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
9:00AM-11:00AM
Abstract Number: 1534
Combined Thermal and Ultrasound Imaging in Rheumatoid Arthritis Is Superior to Either Imaging Alone in Terms of Correlation with the 28-joint Disease Activity Score
9:00AM-11:00AM
Abstract Number: 1756
Comparable Long-Term Outcomes Among DAS28-ESR-based Remission Criteria and ACR/EULAR Definitions in Patients with Established Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1898
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1730
Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression
9:00AM-11:00AM
Abstract Number: 1648
Comparison of Methotrexate and Glucosamine in Primary Knee Osteoarthritis with Inflammation
9:00AM-11:00AM
Abstract Number: 1637
Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan
9:00AM-11:00AM
Abstract Number: 1868
Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
9:00AM-11:00AM
Abstract Number: 1871
Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthritis Caught Early Cohort
9:00AM-11:00AM
Abstract Number: 1810
Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine
9:00AM-11:00AM
Abstract Number: 1828
Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 1878
Consensus Definitions for MRI Lesions in the Spine of Patients with Axial Spondyloarthritis: First Analysis from the Assessments in SpondyloArthritis International Society Classification Cohort
9:00AM-11:00AM
Abstract Number: 1596
Coproduction of Care for Veterans with RA: Improving Elicitation and Documentation of Patient Goals
9:00AM-11:00AM
Abstract Number: 1859
Curdlan-induced Villous Permeability, Luminal Pathobiont Translocation to the Ileal Crypts, Ileitis and Arthritis Are Mitigated by Clostridia in Colonised Germ-free SKG Mice
9:00AM-11:00AM
Abstract Number: 1700
Curricular Implementation of the Rheumatic Disease Patient Expert Program: The Students’ Perspective
9:00AM-11:00AM
Abstract Number: 1610
Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India
9:00AM-11:00AM
Abstract Number: 1890
Daily Management of Patients with Axial Spondyloarthritis: Self-monitoring of Disease Activity with a Smartphone App Is Feasible – a Proof of Concept Study
9:00AM-11:00AM
Abstract Number: 1939
Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
9:00AM-11:00AM
Abstract Number: 1847
Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1740
Determinants of Influenza Vaccine Hesitancy in Rheumatoid Arthritis According to the WHO-SAGE Matrix
9:00AM-11:00AM
Abstract Number: 1902
Determinants of Physician Global Assessment and Influence of Contextual Factors in Early Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1622
Determining the Zoster Vaccination Rate Among Veterans on Chronic Immunosuppressive Therapy at the Southeast Louisiana Veterans Healthcare System – a Quality Indicator
9:00AM-11:00AM
Abstract Number: 1679
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1707
Development and Delivery of Continuing Education Interventions Promoting Shared Decision Making in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1701
Development and Validity Evidence for a Tool to Assess the Performance of Shoulder Injections
9:00AM-11:00AM
Abstract Number: 1879
Development of a Deep Learning Algorithm to Predict Positive MRI of the Sacroiliac Joints According to the ASAS Definition in Patients with Recent Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1731
Development of a Disease Activity Index for Rheumatoid Arthritis Patients Using the HandScan
9:00AM-11:00AM
Abstract Number: 1667
Development of Autoimmune Diseases and HLA Associations in Children with Neonatal Lupus and Their Unaffected Siblings
9:00AM-11:00AM
Abstract Number: 1870
Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
9:00AM-11:00AM
Abstract Number: 1877
Diagnosis of Axial Spondyloarthritis: A Primary Unmet Educational Need for Rheumatologists Is Interpretation of MRI
9:00AM-11:00AM
Abstract Number: 1539
Diagnostic Value of Ultrasound Halo Count and Halo Score in Giant Cell Arteritis: A Retrospective Study from Routine Care
9:00AM-11:00AM
Abstract Number: 1874
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1787
Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
9:00AM-11:00AM
Abstract Number: 1851
Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort
9:00AM-11:00AM
Abstract Number: 1529
Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients
9:00AM-11:00AM
Abstract Number: 1884
Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 1714
Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Real World Results from a Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 1764
Disease Modifying Anti-rheumatic Drug and Biologic Therapy in Pregnancy: A Single-center Mixed Methods Study
9:00AM-11:00AM
Abstract Number: 1571
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
9:00AM-11:00AM
Abstract Number: 1811
Distinctive Molecular Signatures Among Monocytes from Childhood- and Adult-onset Systemic Lupus Erythematosus: Clinical Involvement and Relevance of Sustained Anti-dsDNA Positivity
9:00AM-11:00AM
Abstract Number: L05
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 1907
DNASE1L3 R206C Polymorphism, a Systemic Sclerosis Risk Factor, Causes Impaired Digestion of Genomic DNA in Apoptosis-derived Extracellular Vesicles
9:00AM-11:00AM
Abstract Number: 1657
Do Comorbidities Limit Improvement in Pain and Physical Function After Total Knee Arthroplasty in Patients with Knee Osteoarthritis?
9:00AM-11:00AM
Abstract Number: 1662
Do Weight-bearing versus Non-weight-bearing Pain Reflect Different Pain Mechanisms in Knee Osteoarthritis?: The Multicenter Osteoarthritis Study
9:00AM-11:00AM
Abstract Number: 1611
Documentation of Pregnancy Counseling in SSA-Positive Patients of Childbearing Potential: A Cross-Sectional Study
9:00AM-11:00AM
Abstract Number: 1741
Does Preventive Care Matter? (in RA)
9:00AM-11:00AM
Abstract Number: 1538
Doppler Ultrasound Predicts Successful Discontinuation of Biological DMARDs in Rheumatoid Arthritis Patients in Sustained Clinical Remission
9:00AM-11:00AM
Abstract Number: 1815
Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1821
Early Assessment of Left Ventricular Assessment Using Speckle Tracking Echocardiography and It´s Relationship with Insulin Resistance in Women with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1735
Effect of Aerobic Land-based Exercise Intervention on Fatigue in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 1931
Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 1649
Effect of Knee Aspiration and Intra-articular Corticosteroid Injection on Gait Biomechanics and Strength Impairment in Patients with Signs of Inflammation Due to Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1607
Effectiveness of Dietary Counseling on Gout Management and Risk Factors for Metabolic Syndrome in Gout Patients
9:00AM-11:00AM
Abstract Number: 1748
Effects of Abatacept and Tumor Necrosis Factor Inhibitor on the Normal Glycosylated Hemoglobin Level in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1919
Efficacy & Safety of Tocilizumab in Giant Cell Arteritis: A Single Centre NHS Experience Using Imaging (Ultrasound and PET CT) as a Diagnostic and Monitoring Tool
9:00AM-11:00AM
Abstract Number: L03
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
9:00AM-11:00AM
Abstract Number: 1918
Efficacy and Safety of Methotrexate in Giant Cell Arteritis: Results from a Bicentric Portuguese Cohort Study
9:00AM-11:00AM
Abstract Number: 1651
Efficacy and Safety of Multiple Intra-articular Corticosteroid Injections for Osteoarthritis – a Systematic Review and Meta-analysis of Randomised Controlled Trials and Observational Studies
9:00AM-11:00AM
Abstract Number: 1920
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment
9:00AM-11:00AM
Abstract Number: 1926
Efficacy of Adjunctive Methotrexate in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Subanalysis of a Phase 3 Trial
9:00AM-11:00AM
Abstract Number: 1749
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis
9:00AM-11:00AM
Abstract Number: 1598
Efficacy of Universal Depression Screening in a Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 1855
Elevated Calprotectin Levels Reveal Loss of Vascular Pattern and Atrophy of Villi in Ileum Using Digital Chromo-endoscopy and Magnification Colonoscopy in Patients with Spondyloarthritis Without Inflammatory Bowel Disease
9:00AM-11:00AM
Abstract Number: 1666
Elucidating Research Priorities in Childhood-Onset Systemic Lupus Erythematosus: A Qualitative Study
9:00AM-11:00AM
Abstract Number: 1808
Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)
9:00AM-11:00AM
Abstract Number: 1908
Establishment of iPSc and Differentiated Endothelial Cells of Systemic Sclerosis Associated Pulmonary Arterial Hypertension ; Functional and Molecular Analysis
9:00AM-11:00AM
Abstract Number: 1634
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
9:00AM-11:00AM
Abstract Number: 1643
Evaluating Analgesic Response to Subcutaneous Tanezumab in Patients with Inadequate Treatment Response to Other Analgesics Based on Daily E-pain Diaries: A Pooled Analysis of 2 Randomized, Placebo-controlled Studies
9:00AM-11:00AM
Abstract Number: 1846
Evaluating the Risk of QT-prolongation Associated with Hydroxychloroquine Use with and Without Antidepressants in SLE Patients with Fibromyalgia
9:00AM-11:00AM
Abstract Number: 1693
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
9:00AM-11:00AM
Abstract Number: 1835
Evaluation of Low Dose Glucocorticoid Effects on Infection Occurrence in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 1883
Exercise Partially Explains the Impact of Body Mass Index on Disease Activity in Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1783
Experience of Pregnant Rheumatology Outpatients from a Tertiary Hospital in New York City During the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 1713
Exploring Novel Tenosynovitis and Combined Inflammation Imaging Outcomes: Results from a Randomized Controlled Trial in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1720
Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
9:00AM-11:00AM
Abstract Number: 1946
Fast-Track Giant Cell Arteritis Clinic Experience in the United States
9:00AM-11:00AM
Abstract Number: 1564
Feasibility of Ultra-low-dose, Short-duration, Total-body Evaluation of Inflammatory Arthritis Using uEXPLORER 18F-FDG PET/CT
9:00AM-11:00AM
Abstract Number: 1771
Fertility and Pregnancy Outcomes in Women with Spondyloarthritis: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 1528
Filgotinib Inhibits Monocyte Differentiation and Pro Inflammatoly Cytokine Production in Osteoblasts
9:00AM-11:00AM
Abstract Number: 1561
Findings Compatible with Axial Spondyloarthritis in Radiologist Reports
9:00AM-11:00AM
Abstract Number: 1827
Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 1751
Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center
9:00AM-11:00AM
Abstract Number: 1535
Frequency and Anatomic Distribution of Magnetic Resonance Imaging Lesions in the Sacro-iliac Joints of Healthy Subjects and Patients with Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1618
Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
9:00AM-11:00AM
Abstract Number: 1559
Fully Automatic Assessment of Nail Fold Capillaroscopy Software – Early Results
9:00AM-11:00AM
Abstract Number: 1779
Gap in Contraceptive Education to Females with Rheumatic Disease on Teratogenic Medications
9:00AM-11:00AM
Abstract Number: 1703
Gender Equity in Academic Rheumatology – Is There a Gender Gap at European Rheumatology Congresses?
9:00AM-11:00AM
Abstract Number: 1580
Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events
9:00AM-11:00AM
Abstract Number: 1862
Genetic Influences on Occurrence of Axial Spondyloarthritis (axSpA) in First-degree Relatives During a Prospective Study Lasting 35 Years
9:00AM-11:00AM
Abstract Number: 1669
Genetics of Age at Diagnosis in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1932
Giant Cell Arteritis – the Relationship Between the Extensiveness of Vasculitis and the Clinical Presentation
9:00AM-11:00AM
Abstract Number: 1682
Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1573
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
9:00AM-11:00AM
Abstract Number: 1736
Health Assessment Questionnaire Predicts All-Cause Mortality at One Year in Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1681
Hemophagocytic Lymphohistiocytosis (HLH) Gene Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)
9:00AM-11:00AM
Abstract Number: 1690
Henoch-Schönlein Purpura Nephritis: Different Histological Classifications, but Which One Is Most Strongly Associated to the Outcome of the Disease? Pilot Study of the Paediatric Rheumatology European Society Vasculitis Working Party
9:00AM-11:00AM
Abstract Number: 1620
Hepatitis B Screening Practices When Prescribing Tocilizumab or Tofacitinib in Real World Practice
9:00AM-11:00AM
Abstract Number: 1875
Heterogeneity Amongst Men and Women with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1799
High Fat-Diet as a Catalyst to Lupus Development and Autoimmunity in MRL/lpr Mice
9:00AM-11:00AM
Abstract Number: 1563
High Impact Sports Leads to Inflammatory Responses at Entheseal Sites Results of the BEAT Study (Badminton Enthesitis Arthrosonography Study)
9:00AM-11:00AM
Abstract Number: 1909
High-density Proteomic Analysis of Skin Blister Fluid and Plasma in Systemic Sclerosis Identifies Local and Systemic Differences for Key Proteins
9:00AM-11:00AM
Abstract Number: 1757
High-Intensity Interval Training Increases Rheumatoid Arthritis Cardiorespiratory Fitness in Association with Improvements in CD4+ T Cell and Skeletal Muscle Mitochondrial Metabolism
9:00AM-11:00AM
Abstract Number: 1864
How to Diagnose Axial Spondyloarthritis in 2020? A Data-Driven Estimation of the Disease Probability in Patients with a priori Different Likelihoods of the Diagnosis
9:00AM-11:00AM
Abstract Number: 1906
Hsp90 Inhibition Effectively Prevents Progression of Dermal Fibrosis and Induces Regression of Established Bleomycin-Induced Dermal Fibrosis
9:00AM-11:00AM
Abstract Number: 1844
Hydroxychloroquine and QTc Prolongation in a Cohort of SLE Patients
9:00AM-11:00AM
Abstract Number: 1833
Hydroxychloroquine and Vitamin D Both Reduce Proteinuria in SLE
9:00AM-11:00AM
Abstract Number: 1678
Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1594
Hydroxychloroquine Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
9:00AM-11:00AM
Abstract Number: 1848
Identification of Native and Citrullinated Autoantibodies to Psoriasis Related-antigen PsoP27 in Synovial Fluids of Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1849
Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study
9:00AM-11:00AM
Abstract Number: 1865
Identification of Parameters Associated with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS)
9:00AM-11:00AM
Abstract Number: 1704
Identifying Primary Care Clinician Knowledge Gaps and Needs in Rheumatologic Care for Rural Veterans
9:00AM-11:00AM
Abstract Number: 1671
Identifying Rare Genetic Variants in Childhood-onset Monogenic Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1798
IgE Anti-dsDNA Antibodies in Systemic Lupus Erythematosus Are Associated with Higher Disease Activity at the Baseline and in Longterm Follow-up
9:00AM-11:00AM
Abstract Number: 1818
IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1911
IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1
9:00AM-11:00AM
Abstract Number: 1570
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology
9:00AM-11:00AM
Abstract Number: 1577
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
9:00AM-11:00AM
Abstract Number: 1697
Immune Related Adverse Events from Checkpoint Inhibitor Therapy: Survey of Hospitalists’ Awareness and Experiences
9:00AM-11:00AM
Abstract Number: 1569
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
9:00AM-11:00AM
Abstract Number: 1619
Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center
9:00AM-11:00AM
Abstract Number: 1583
Impact of Telehealth Implementation on Practice Patterns and Electronic Health Record Utilization During COVID19
9:00AM-11:00AM
Abstract Number: 1685
Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe
9:00AM-11:00AM
Abstract Number: 1804
Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1568
Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study
9:00AM-11:00AM
Abstract Number: 1717
Impact of Treatments on Favorable Outcome over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort
9:00AM-11:00AM
Abstract Number: 1718
Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort
9:00AM-11:00AM
Abstract Number: 1891
Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
9:00AM-11:00AM
Abstract Number: 1712
Implementation of a Musculoskeletal Ultrasound (MSUS) Curriculum in an Academic Rheumatology Fellowship Within an Integrated Health System: A Four-Year Experience
9:00AM-11:00AM
Abstract Number: 1587
Improving Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus in an Internal Medicine Resident Clinic: A Quality Improvement Initiative
9:00AM-11:00AM
Abstract Number: 1592
Improving Documentation of Smoking Cessation Counseling Among Spondyloarthropathy Smokers
9:00AM-11:00AM
Abstract Number: 1624
Improving Pneumococcal Vaccination in Veterans with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1623
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
9:00AM-11:00AM
Abstract Number: 1778
Improving Teratogenic Medication Consent and Sexual Activity Screening in Adolescent and Young Females: A Pediatric Rheumatology Reproductive Health Initiative
9:00AM-11:00AM
Abstract Number: 1613
Improving Transition Policy Dissemination and Care Team Communication in Pediatric Rheumatology Clinic Through Standardization of Workflow and Electronic Health Record Documentation
9:00AM-11:00AM
Abstract Number: 1917
In Myositis Patients, Sjögren’s Syndrome Is Associated with Inclusion Body Myositis and with anti-cN1A Antibody Independently of the Myositis Subgroups
9:00AM-11:00AM
Abstract Number: 1940
In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached
9:00AM-11:00AM
Abstract Number: 1881
In Radiographic Axial Spondyloarthritis, Bridging Syndesmophytes Increase Risk of Facet Joint Ankylosis Development on the Same Vertebral Level While Facet Joint Ankylosis Does Not Increase Risk of Same Level Syndesmophytes Development
9:00AM-11:00AM
Abstract Number: 1705
In-Person Musculoskeletal Exam Demonstration by Rheumatologist More Effective Than Virtual PowerPoint Presentation in Teaching Internal Medicine Residents
9:00AM-11:00AM
Abstract Number: 1684
Increase in Emergency Department Visits and Hospitalizations, Decrease in Outpatient Visits Following Transition to Adult Rheumatologic Care
9:00AM-11:00AM
Abstract Number: 1858
Increased Proportion of TH17, TH22 and TC17 Cells and the Correlation to IL-22 and Clinical Parameters in Patients with Ankylosing Spondylitis from Northern Sweden
9:00AM-11:00AM
Abstract Number: 1721
Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
9:00AM-11:00AM
Abstract Number: L04
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
9:00AM-11:00AM
Abstract Number: 1843
Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids
9:00AM-11:00AM
Abstract Number: 1910
Integrated Molecular Analysis of Systemic Sclerosis Skin and Blood Highlights Significant Differences Between Major Autoantibody Subgroups
9:00AM-11:00AM
Abstract Number: 1852
Intestinal Permeability in the Adjuvant Induced Arthritis Model: Preliminary Study and Impact of NSAIDs
9:00AM-11:00AM
Abstract Number: 1795
Intracellular Homocysteine and Homocysteine Metabolites in Systemic Lupus Erythematosus (SLE)
9:00AM-11:00AM
Abstract Number: 1913
Investigation of the Cellular Mechanism for Estradiol-Induced Dermal Fibrosis
9:00AM-11:00AM
Abstract Number: 1708
Itching to Learn: Infusion Reactions Curriculum for Medicine Trainees
9:00AM-11:00AM
Abstract Number: 1565
Joint Cartilage Damage Evaluated by Ultrasound in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1549
Joint Damage and Malalignment Determine Articular Tenderness More Than Inflammation in Rheumatoid Arthritis, Psoriatic Arthritis or Osteoarthritis in Established Disease
9:00AM-11:00AM
Abstract Number: 1687
Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort
9:00AM-11:00AM
Abstract Number: 1857
KIR3DL2 Is Not Overexpressed on CD4+ T Cells and NK Cells in Patients with Axial Spondyloarthritis csDMARD and bDMARD Naive
9:00AM-11:00AM
Abstract Number: 1656
Knee OA Outcomes in Patients with Severe Obesity Following Bariatric Surgery or Total Knee Arthroplasty
9:00AM-11:00AM
Abstract Number: 1605
Knowledge of Biosimilars and Perceptions of Biosimilar Naming Conventions in Clinical Practice
9:00AM-11:00AM
Abstract Number: 1916
KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model
9:00AM-11:00AM
Abstract Number: 1915
Leptin Plays a Critical Role in Modulating Dermal Adipose Tissue, Inflammation and Skin Fibrosis
9:00AM-11:00AM
Abstract Number: 1585
Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 1899
Life Expectancy a Swiss Cohort of Patients with Ankylosing Spondylitis: A 35-Year Follow-up Study
9:00AM-11:00AM
Abstract Number: 1914
Long Non-coding RNA HOTAIR Induces GLI2 Expression Through Notch Signalling in Systemic Sclerosis Dermal Fibroblasts
9:00AM-11:00AM
Abstract Number: 1845
Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol: A Matched Case-Control Study
9:00AM-11:00AM
Abstract Number: 1632
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
9:00AM-11:00AM
Abstract Number: 1626
Long-Term Follow-Up of Renal Transplantation Due to Lupus Nephritis. Single Universitary Center Experience
9:00AM-11:00AM
Abstract Number: 1688
Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
9:00AM-11:00AM
Abstract Number: 1668
Long-Term Outcomes in Children Born to Anti-Ro and/or Anti-La Positive Mothers
9:00AM-11:00AM
Abstract Number: 1630
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 1805
Longitudinal Analysis of IFN Status and Disease Characteristics in SLE
9:00AM-11:00AM
Abstract Number: 1812
Longitudinal Blood DNA Methylation in a Multi-ethnic Cohort of SLE Patients
9:00AM-11:00AM
Abstract Number: 1750
Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial
9:00AM-11:00AM
Abstract Number: 1715
Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)
9:00AM-11:00AM
Abstract Number: 1670
Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset
9:00AM-11:00AM
Abstract Number: 1777
Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
9:00AM-11:00AM
Abstract Number: 1924
Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial
9:00AM-11:00AM
Abstract Number: 1680
Lupus Anticoagulant as a Predictor of Adverse Outcomes in Children with Venous Thromboembolism
9:00AM-11:00AM
Abstract Number: 1829
Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period
9:00AM-11:00AM
Abstract Number: 1770
Lupus Low Disease Activity State Protects Against Pre-Term Birth
9:00AM-11:00AM
Abstract Number: 1557
Lymphatics as a Biomarker of Joint Physiology: Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands
9:00AM-11:00AM
Abstract Number: 1732
Machine Learning Coupled with Patient Reported Outcome Data to Classify & Predict RA Disease Activity
9:00AM-11:00AM
Abstract Number: 1774
Making Decisions About Medication Use, Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Grounded Theory Study
9:00AM-11:00AM
Abstract Number: 1628
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
9:00AM-11:00AM
Abstract Number: 1629
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
9:00AM-11:00AM
Abstract Number: 1780
Maternal and Fetal Outcomes in Pregnant Women with Psoriatic Arthritis: A Systematic Literature Review
9:00AM-11:00AM
Abstract Number: 1767
Maternal Peripartum Outcomes Are Similar to the General Population in Rheumatoid Arthritis Pregnancies
9:00AM-11:00AM
Abstract Number: 1560
Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry
9:00AM-11:00AM
Abstract Number: 1886
Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH
9:00AM-11:00AM
Abstract Number: 1696
Measuring Quality Improvement from CME Participants: Results from the RAPID® CME Initiative
9:00AM-11:00AM
Abstract Number: 1658
Mediation of the Association Between Obesity and Osteoarthritis by Blood Pressure, Arterial Stiffness, and Subclinical Atherosclerosis
9:00AM-11:00AM
Abstract Number: 1839
Medication Adherence Barriers and Opportunities to Overcome Them Among Patients with SLE
9:00AM-11:00AM
Abstract Number: 1675
Microstructural Damage Is Associated with Age at Disease-onset and Cognitive Impairment in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1606
Mortality with Idiopathic Inflammatory Myositis in an Academic Hospital Setting: A Five-year Retrospective Study
9:00AM-11:00AM
Abstract Number: 1711
Musculoskeletal Sarcoidosis Learning Module for Internal Medicine Trainees: Developing a Rheumatology Curriculum
9:00AM-11:00AM
Abstract Number: 1823
Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience
9:00AM-11:00AM
Abstract Number: 1676
Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study
9:00AM-11:00AM
Abstract Number: 1581
Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review
9:00AM-11:00AM
Abstract Number: 1617
New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
9:00AM-11:00AM
Abstract Number: 1854
NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1631
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
9:00AM-11:00AM
Abstract Number: 1896
No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1912
Novel Role of Thy-1 (CD90) in the Pathogenesis of Skin Fibrosis
9:00AM-11:00AM
Abstract Number: 1642
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
9:00AM-11:00AM
Abstract Number: 1765
Obstetric Outcomes in Younger Women Less Than 21 Years of Age Compared to Women Between Age 21 and 25 Years with Rheumatic Disease
9:00AM-11:00AM
Abstract Number: 1921
Ongoing Vascular 18F-FDG Uptake Despite Clinical Remission in Patients Receiving Tocilizumab for Large Vessel Vasculitis-Giant Cell Arteritis: Single Universitary Center Experience of 30 Patients
9:00AM-11:00AM
Abstract Number: 1566
Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution
9:00AM-11:00AM
Abstract Number: 1553
Optical Tomography Can Accurately Diagnose Lupus Arthritis
9:00AM-11:00AM
Abstract Number: 1941
Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events
9:00AM-11:00AM
Abstract Number: 1841
Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus
9:00AM-11:00AM
Abstract Number: L01
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
9:00AM-11:00AM
Abstract Number: 1574
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
9:00AM-11:00AM
Abstract Number: 1603
P4 Index Correlates with RAPID3 and Disease-Specific Indices in Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA)
9:00AM-11:00AM
Abstract Number: 1655
Pain Reduction Post Total Knee Replacement in Opioid Users and Non-users
9:00AM-11:00AM
Abstract Number: 1769
Patient-reported COVID-19 Infection in Pregnant Women with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance Patient Experience Survey
9:00AM-11:00AM
Abstract Number: 1866
Patient-reported Impact of Axial Spondyloarthritis on Working Life. Results from the Spanish Atlas 2017
9:00AM-11:00AM
Abstract Number: 1728
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
9:00AM-11:00AM
Abstract Number: 1739
Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption
9:00AM-11:00AM
Abstract Number: 1733
Patients with Rheumatoid Arthritis and Comorbid Depression Have High Levels of RAPID3 (Routine Assessment of Patient Index Data) and FAST3 (Fibromyalgia Assessment Screening Index) on a Multidimensional Health Assessment Questionnaire (MDHAQ)
9:00AM-11:00AM
Abstract Number: 1742
Patients’ and Rheumatologists’ Perceptions on Preventive Intervention in Rheumatoid Arthritis and Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1892
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
9:00AM-11:00AM
Abstract Number: 1727
Patterns of Fatigue in Early RA over 10 Years: Results from the ESPOIR Cohort
9:00AM-11:00AM
Abstract Number: 1674
Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1885
Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial
9:00AM-11:00AM
Abstract Number: 1743
Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?
9:00AM-11:00AM
Abstract Number: 1627
Phase I Trial of High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients with Mild COVID-19: A Study in the Effects of Shifting Public Opinion on Patient Enrollment
9:00AM-11:00AM
Abstract Number: 1601
Pilot Testing Supports Utility of a Point-of-Care Dashboard to Enhance Patient and Clinician Partnerships in the Management of RA
9:00AM-11:00AM
Abstract Number: 1645
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
9:00AM-11:00AM
Abstract Number: 1792
Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
9:00AM-11:00AM
Abstract Number: 1625
Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center
9:00AM-11:00AM
Abstract Number: 1698
Polyarthritis Workup in Primary Care Setting : How Are We Doing?
9:00AM-11:00AM
Abstract Number: 1692
Poor Physical Activity Levels and Cardiorespiratory Fitness Among Patients with Childhood-Onset Takayasu Arteritis in Remission
9:00AM-11:00AM
Abstract Number: 1722
Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire
9:00AM-11:00AM
Abstract Number: 1752
Prediction of Responder and Non-responder to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Pilot Study with Integrative Cluster Analysis
9:00AM-11:00AM
Abstract Number: 1935
Predictors of Early Mortality for Giant Cell Arteritis at the Time of Diagnosis
9:00AM-11:00AM
Abstract Number: 1893
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
9:00AM-11:00AM
Abstract Number: 1716
Predictors of Unacceptable Pain and Unacceptable Pain with Low Inflammation in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1944
Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 1781
Pregnancy After Bariatric Surgery in Women with Rheumatic Diseases and Association with Adverse Birth Outcomes
9:00AM-11:00AM
Abstract Number: 1639
Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)
9:00AM-11:00AM
Abstract Number: 1758
Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data
9:00AM-11:00AM
Abstract Number: 1719
Prevalence and Trajectory of Erosions, Synovitis, and Bone Marrow Edema in Feet of Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1543
Prevalence of Ultrasound Findings Suggestive of Inflammatory Arthritis in Children with Skin Psoriasis (ChildEchoPso)
9:00AM-11:00AM
Abstract Number: 1673
Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
9:00AM-11:00AM
Abstract Number: 1635
Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database
9:00AM-11:00AM
Abstract Number: 1652
Progression of Knee OA with Use of Intra-articular Corticosteroids (CS) vs Hyaluronic Acid (HA)
9:00AM-11:00AM
Abstract Number: 1738
Promote Treat-to-Target for RA via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
9:00AM-11:00AM
Abstract Number: 1936
Prospective Analysis of Flow Velocity of the Central Retinal Artery in Newly Diagnosed Patients with Giant Cell Arteritis with Visual Symptoms and Controls
9:00AM-11:00AM
Abstract Number: 1928
Quantitative Ultrasound of Temporal, Axillary and Subclavian Arteries to Monitor Tocilizumab Treatment in Patients with Newly Diagnosed Giant Cell Arteritis: A 24 Week Analysis
9:00AM-11:00AM
Abstract Number: 1723
RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data
9:00AM-11:00AM
Abstract Number: 1702
RA-Related Knowledge and Skills of Rheumatology Fellows Among 20 US Academic Institutions
9:00AM-11:00AM
Abstract Number: 1644
Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1895
Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
9:00AM-11:00AM
Abstract Number: 1551
Rapid Effect of Tofacitinib in Reducing US Joint and Tendon Inflammatory Lesions of RA Patients: Data from a 24 Weeks Longitudinal Study
9:00AM-11:00AM
Abstract Number: 1683
Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
9:00AM-11:00AM
Abstract Number: 1600
Relationship Between Electronic Health Record Vendor and Performance on Patient-reported Outcome Quality Measures in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
9:00AM-11:00AM
Abstract Number: 1872
Relative Associations of Sociodemographic, Clinical and HLA-B Alleles with Enthesitis and Peripheral Arthritis in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1889
Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
9:00AM-11:00AM
Abstract Number: 1710
Remote Rheumapalooza: Reboot of a Foundational Rheumatology Curriculum for Pre-Clinical Medical Students in the Era of Virtual Learning
9:00AM-11:00AM
Abstract Number: 1672
Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 1791
Renal Tubular Complement C9 Deposition Is Associated with Renal Tubular Damage and Fibrosis in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1842
Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial
9:00AM-11:00AM
Abstract Number: 1786
Reproductive Health Outcomes in Women with RA and PsA
9:00AM-11:00AM
Abstract Number: 1554
Response to Tocilizumab in Large Vessel Vasculitis According to the Extent of Baseline 18F-FDG Vascular Uptake
9:00AM-11:00AM
Abstract Number: 1586
Rheum Service: Comprehensive Virtual Care During COVID-19
9:00AM-11:00AM
Abstract Number: 1759
Rheumatoid Arthritis Affects the Ossicular Joints: A Human Otopathologic Study
9:00AM-11:00AM
Abstract Number: 1761
Rheumatoid Arthritis Inpatient Mortality: An Analysis of the National Inpatient Sample
9:00AM-11:00AM
Abstract Number: 1694
Risk Factors Associated with Pneumocystis Jirovecii Pneumonia in Juvenile Myositis in North America
9:00AM-11:00AM
Abstract Number: 1775
Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies
9:00AM-11:00AM
Abstract Number: 1825
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1947
Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 1938
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: L02
Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study
9:00AM-11:00AM
Abstract Number: 1578
Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing
9:00AM-11:00AM
Abstract Number: 1547
Role of Artificial Intelligence in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 1784
Roles and Perspectives of Partners of Women with Rheumatoid Arthritis on Reproductive Decision Making: A Constructivist Grounded Theory Study
9:00AM-11:00AM
Abstract Number: 1776
Safety and Beneficial Effects of Hydroxychloroquine on Pregnancy Outcomes in Women with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1793
Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership
9:00AM-11:00AM
Abstract Number: 1677
Schizophrenia Genetics and Neuropsychiatric Features in Childhood-Onset Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1824
Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358
9:00AM-11:00AM
Abstract Number: 1809
Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters
9:00AM-11:00AM
Abstract Number: 1822
Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Patients with Active Lupus Nephritis: Correlation with Baseline Disease Characteristics and Response to Therapy
9:00AM-11:00AM
Abstract Number: 1820
Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity
9:00AM-11:00AM
Abstract Number: 1660
Sleep Disturbance and Pain Severity and Multi-site Pain: A Prospective 10.7-year Follow-up Study
9:00AM-11:00AM
Abstract Number: 1933
Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value
9:00AM-11:00AM
Abstract Number: 1665
Sociodemographic and Clinical Predictors of Childhood-Onset SLE Disease Activity in the Childhood Arthritis and Rheumatology Research Alliance Registry
9:00AM-11:00AM
Abstract Number: 1905
Soluble Guanylate Cyclase Reduced the Gastrointestinal Fibrosis in Bleomycin-induced Mouse Model of Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1887
Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?
9:00AM-11:00AM
Abstract Number: 1562
Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Clinical Remission Compared to Active Disease
9:00AM-11:00AM
Abstract Number: 1753
Substantial Work Limitations in Patients with Rheumatoid Arthritis Despite Optimal Treat-to-Target (T2T) Drug Therapy Intervention
9:00AM-11:00AM
Abstract Number: 1888
Successful Evaluation of Spinal Mobility Measurements with the Epionics SPINE Device in Patients with Axial Spondyloarthritis Compared to Controls
9:00AM-11:00AM
Abstract Number: 1608
Survey of Minimally-Invasive Ultrasound-Guided Synovial Biopsy Performed at Rheumatology Centres
9:00AM-11:00AM
Abstract Number: 1659
Synergistic Effect of Quadriceps Weakness and Obesity in Women at Risk of Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1661
Systematic Review and Meta-Analysis of the Prevalence of Neuropathic-Like Pain and Pain Sensitisation in People with Knee and Hip Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1616
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
9:00AM-11:00AM
Abstract Number: 1794
Systemic Lupus Erythematosus and Geomagnetic Disturbances: A Time Series Analysis
9:00AM-11:00AM
Abstract Number: 1638
Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients
9:00AM-11:00AM
Abstract Number: 1861
T Cells with IL-17A+ Signature in Psoriatic Arthritis Are of Different Subpopulations and Are Polyfuntional
9:00AM-11:00AM
Abstract Number: 1544
Tc99m Tilmanocept Imaging Is an Early Predictor of Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
9:00AM-11:00AM
Abstract Number: 1709
Teaching Clinical Application of Bayesian Reasoning in Rheumatology to Internal Medicine Residents and Medical Students
9:00AM-11:00AM
Abstract Number: 1584
Telemedicine Visits During COVID-19 Improved Clinic Show Rates
9:00AM-11:00AM
Abstract Number: 1609
The Accuracy of Administrative Health Data for Identifying Patients with Rheumatoid Arthritis: A Validation Study Using Medical Records in Western Australia
9:00AM-11:00AM
Abstract Number: 1850
The Association Between Imaging Sub-phenotypes of Psoriatic Arthritis and Gene Expression Profiles
9:00AM-11:00AM
Abstract Number: 1760
The Association Between the Risk of Venous Thromboembolism and Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Observational Study
9:00AM-11:00AM
Abstract Number: 1806
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1814
The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1734
The Challenge of Assessing Wellbeing from the Patients` Perspective in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1873
The Changing Profile of Ankylosing Spondylitis in the Biologic Era
9:00AM-11:00AM
Abstract Number: 1900
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1686
The COV-ASAKI Survey from the Pediatric Tuscany Network During COVID-19 Era
9:00AM-11:00AM
Abstract Number: 1807
The Extent of Tubulointerstitial Inflammation in Lupus Nephritis Identifies Two Distinctive Subgroups: Impact on Inflammation Characteristics and Prognosis in Patients with Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1604
The Impact of the COVID-19 Pandemic on Rheumatology Practice: A Study in 15 Arab Countries
9:00AM-11:00AM
Abstract Number: 1768
The Importance of Pregnancy Planning in Lupus Pregnancies
9:00AM-11:00AM
Abstract Number: 1532
The Non-psychotropic Phytocannabinoids Cannabigerol and Tetrahydrocannabinolic Acid Inhibit Rheumatoid Arthritis Synovial Fibroblast Function by Targeting the Wasabi Receptor TRPA1
9:00AM-11:00AM
Abstract Number: 1754
The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study
9:00AM-11:00AM
Abstract Number: 1943
The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 1654
The Relationship Between Patient-Reported Readiness for Total Knee Arthroplasty and the Likelihood of a Good Outcome at One Year
9:00AM-11:00AM
Abstract Number: 1542
The Role of Dual Energy Computed Tomography (DECT) in the Differentiation of Gout and Calcium Pyrophosphate Deposition Disease
9:00AM-11:00AM
Abstract Number: 1876
The Role of HLA B27 in Axial Spondyloarthritis: Prevalence and Performance as a Marker in an Argentinian Cohort
9:00AM-11:00AM
Abstract Number: 1744
The STAtins to Prevent Rheumatoid Arthritis (STAPRA) Trial: Clinical Results and Subsequent Qualitative Study, a Mixed Method Evaluation
9:00AM-11:00AM
Abstract Number: 1930
Thirty-Day Readmission Rate in Patients Who Were Initially Admitted for Active Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 1789
Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels
9:00AM-11:00AM
Abstract Number: 1527
Tofacitinib Inhibits Angiogenesis Through Its Opposite Effects on Pro- and Anti-angiogenic Factors
9:00AM-11:00AM
Abstract Number: 1699
Training Residents to ‘Choose Wisely’ When Testing for Antinuclear Antibodies
9:00AM-11:00AM
Abstract Number: 1897
Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis: Data from the National Inpatient Sample 2001-2014
9:00AM-11:00AM
Abstract Number: 1766
Trends of Pregnancy Outcomes in a Large Electronic Health Record Cohort of Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 1867
Two-Year Diagnostic Consistency in Patients with Chronic Back Pain Suspected of Axial Spondyloarthritis in Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
9:00AM-11:00AM
Abstract Number: 1927
Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity in GCA
9:00AM-11:00AM
Abstract Number: 1536
Ultrasound as an Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Early Rheumatoid Arthritis, TOVERA – a Longitudinal Study
9:00AM-11:00AM
Abstract Number: 1552
Ultrasound Doppler Enthesitis Shows Sensitivity to Change After Biological Therapy in Spondyloarthritis and Psoriatic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1925
Ultrasound Follow-up Examination of Intima-Media-Thickness of the Temporal and Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 1541
Ultrasound in Knee Osteoarthritis: Reader Performance, Sonographic Features, and Correlation with Radiographic Findings
9:00AM-11:00AM
Abstract Number: 1533
Ultrasound Joint Inflammation but Not Disease Activity Score at 28 Joints Is Reflective of the Severity of Joint Damage in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1546
Ultrasound, Magnetic Resonance Imaging and Radiography of the Fingers’ Joints of Psoriatic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1689
Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
9:00AM-11:00AM
Abstract Number: 1816
Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1614
Use of a Best Practice Alert to Encourage Transition Planning and Readiness
9:00AM-11:00AM
Abstract Number: 1597
Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
9:00AM-11:00AM
Abstract Number: 1782
Use of a Patient-reported Survey to Document Contraceptive Use and Interest in Pregnancy to Identify Patients with Unmet Pregnancy Prevention and Planning Needs
9:00AM-11:00AM
Abstract Number: 1785
Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1894
Use of Facebook and Electronic Patient Portal to Identify Axial Spondyloarthritis in Patients with Chronic Back Pain
9:00AM-11:00AM
Abstract Number: 1646
Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events
9:00AM-11:00AM
Abstract Number: 1537
Usefulness of Ultrasound Assessment of Sarcopenia in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1595
Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making
9:00AM-11:00AM
Abstract Number: 1772
Vaccinations of Infants Born to Mothers on TNF Inhibitors: Safe Administration of Live-vaccines Given Per the National Immunization Program
9:00AM-11:00AM
Abstract Number: 1929
Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systematic Review
9:00AM-11:00AM
Abstract Number: 1802
Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?
9:00AM-11:00AM
Abstract Number: 1664
Walking Energetics, Fatigue, and Physical Activity in People with Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1663
Walking for Exercise May Be Symptom and Structure Modifying for Those with Established OA and with Varus Alignment – Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 1737
What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study
9:00AM-11:00AM
Abstract Number: 1934
What Is the Significance of Periarterial Temporal Small Vessel Inflammation (SVI) on Temporal Artery Biopsy (TAB) in the Diagnosis of Vasculitis? A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 1599
Workflows for Collecting and Using Patient-reported Outcomes Across Rheumatology Practices
9:00AM-11:00AM
Abstract Number: 1773
Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
10:00AM-10:50AM
Abstract Number: 2046
Alterations in Circulating CD4+ T Cell Phenotypes in CCP+ Early RA and CCP+ At-risk Individuals by Mass Cytometry
10:00AM-10:50AM
Abstract Number: 1993
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
10:00AM-10:50AM
Abstract Number: 1984
Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort
10:00AM-10:50AM
Abstract Number: 2044
Complex, Dynamic Attributes of Antigen-specific T Cells in Rheumatoid Arthritis
10:00AM-10:50AM
Abstract Number: 1960
Cost-effectiveness of Surgical and Non-Surgical Weight Loss Programs for Morbidly Obese Patients with Knee Osteoarthritis
10:00AM-10:50AM
Abstract Number: 1961
Decreased Visits in RISE Practices Due to the SARS-CoV-2 Global Pandemic
10:00AM-10:50AM
Abstract Number: 1986
Determinants of Variation in Pediatric Systemic Lupus Erythematosus Care Delivery
10:00AM-10:50AM
Abstract Number: 1959
Epidemiology of Hospitalizations and Associated Mortality in Vasculitis: A National Study
10:00AM-10:50AM
Abstract Number: 1996
Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study
10:00AM-10:50AM
Abstract Number: 2043
Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis
10:00AM-10:50AM
Abstract Number: 1997
Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results
10:00AM-10:50AM
Abstract Number: 1995
Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study
10:00AM-10:50AM
Abstract Number: 1958
Patterns and Impact of Long-term Glucocorticoid Use on RA Patients at Risk for Major Adverse Cardiac Events
10:00AM-10:50AM
Abstract Number: 1987
Predictors of Adverse Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus Transitioning to Adult Care
10:00AM-10:50AM
Abstract Number: 2045
Resident Memory T Cells in Synovial Tissue Mediate Arthritis Flares
10:00AM-10:50AM
Abstract Number: 1994
Rheumatoid Arthritis Improvement After Exposure to an Anti-Inflammatory “ITIS” Diet Is Associated with Changes of Gut Microbiome and Systemic Metabolome
10:00AM-10:50AM
Abstract Number: 2047
Synovial CD8 T Cells in Rheumatoid Arthritis Exhibit High Antigen-independent Cytokine Production and Low Cytotoxic Potential
10:00AM-10:50AM
Abstract Number: 1983
Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
10:00AM-10:50AM
Abstract Number: 1962
Utilization of Telehealth Among Patients with Rheumatic Diseases in the Early Months of the COVID-19 Pandemic
10:00AM-10:50AM
Abstract Number: 1985
Validity and Reliability of Four Parent/Patient Reported Outcome Measures for Juvenile Idiopathic Arthritis
11:00AM-11:50AM
Abstract Number: 1991
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
11:00AM-11:50AM
Abstract Number: 2050
Autoantibodies Targeting Complement Receptors C3aR and C5aR1 Are Decreased in ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate
11:00AM-11:50AM
Abstract Number: 2048
Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
11:00AM-11:50AM
Abstract Number: 2024
Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial
11:00AM-11:50AM
Abstract Number: 2027
Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study
11:00AM-11:50AM
Abstract Number: 2023
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
11:00AM-11:50AM
Abstract Number: 2026
Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
11:00AM-11:50AM
Abstract Number: 2025
Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
11:00AM-11:50AM
Abstract Number: 2052
Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
11:00AM-11:50AM
Abstract Number: 1990
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
11:00AM-11:50AM
Abstract Number: 2051
Localized versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Database
11:00AM-11:50AM
Abstract Number: 1992
Longitudinal Evaluation of Axonal Dysfunction, Neuronal Markers and Serum Cytokines in Childhood-onset Systemic Lupus Erythematosus
11:00AM-11:50AM
Abstract Number: 2049
Nasal Bacteria Associated with Disease Activity and ANCA Levels in Granulomatosis with Polyangiitis
11:00AM-11:50AM
Abstract Number: 1989
NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin
11:00AM-11:50AM
Abstract Number: 1979
Participant Engagement and Adherence in an ArthritisPower Real-World Study to Capture Smartwatch and Patient-Reported Outcome Data Among Rheumatoid Arthritis Patients
11:00AM-11:50AM
Abstract Number: 1981
Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study
11:00AM-11:50AM
Abstract Number: 1978
Prevalence and Factors Associated with Patient-Physician Discordance Among RA Patients Initiating Advanced Therapy
11:00AM-11:50AM
Abstract Number: 1982
Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
11:00AM-11:50AM
Abstract Number: 1988
Skin Disease More Recalcitrant to Intervention Than Muscle Disease: A Long-Term Prospective Study of 184 Children with Juvenile Dermatomyositis
11:00AM-11:50AM
Abstract Number: 1980
Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Americans with SLE Through the Hablemos De Lupus Facebook Page
11:30AM-1:00PM
Abstract Number: L09
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
11:30AM-1:00PM
Abstract Number: L08
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
11:30AM-1:00PM
Abstract Number: L06
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
11:30AM-1:00PM
Abstract Number: L10
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
11:30AM-1:00PM
Abstract Number: L07
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
11:30AM-1:00PM
Abstract Number: L11
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
12:00PM-12:50PM
Abstract Number: 1957
A Single Cell Stromal Atlas Identifies Conserved Fibroblast Phenotypes Expanded in the Inflamed Synovium, Lung, Intestine, and Salivary Gland
12:00PM-12:50PM
Abstract Number: 2016
Baseline Serum Biomarker Levels Predict Spinal Radiographic Progression in Ankylosing Spondylitis Patients on TNF Inhibitor Therapy
12:00PM-12:50PM
Abstract Number: 1968
Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development
12:00PM-12:50PM
Abstract Number: 1967
Combating Rheumatologist Burnout: Use of Protocol Driven Medication Refill by Pharmacists
12:00PM-12:50PM
Abstract Number: 1956
Dysregulated Expression of the Long Non-coding RNA, LINC01871, Implicated in Sjögren’s Syndrome Pathogenesis
12:00PM-12:50PM
Abstract Number: 1964
Engaging Patients in the Development of a Quality Measure of Functional Status to Improve Care Among Patients with Rheumatoid Arthritis
12:00PM-12:50PM
Abstract Number: 1954
Genome-wide Association Study of Sjögren’s Syndrome Identifies Ten New Risk Loci
12:00PM-12:50PM
Abstract Number: 1971
Gut Microbiome Transplantation from MRL/MpJ Mice Prevents Post-Traumatic Osteoarthritis in C57BL6/J Mice
12:00PM-12:50PM
Abstract Number: 1955
High-throughput Identification of Functional Regulatory SNPs Associated with Systemic Lupus Erythematosus
12:00PM-12:50PM
Abstract Number: 1966
Improving Value Concordant Care Through Increased Use of Subcutaneous Methotrexate in Rheumatoid Arthritis
12:00PM-12:50PM
Abstract Number: 2017
Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis
12:00PM-12:50PM
Abstract Number: 1970
Mimicking Cytokine-driven Key Features of Arthritis Using a Human in Vitro 3D Joint Model
12:00PM-12:50PM
Abstract Number: 1972
NGF-Responsive Neurons Are Sensitized in Experimental Osteoarthritis
12:00PM-12:50PM
Abstract Number: 2015
Prevalence and Distribution of Peripheral Musculoskeletal Manifestations in Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis: Results of the International, Cross-sectional ASAS-PerSpA Study
12:00PM-12:50PM
Abstract Number: 1965
Reducing Delays for Biologic Medication Approval in Outpatient Rheumatology
12:00PM-12:50PM
Abstract Number: 1953
Somatic Mutations in a Single Residue of UBA1 Cause VEXAS, a Severe Adult-Onset Rheumatic Disease Presenting as Relapsing Polychondritis, Polyarteritis Nodosa, or Giant Cell Arteritis
12:00PM-12:50PM
Abstract Number: 2013
Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
12:00PM-12:50PM
Abstract Number: 1969
The Dynamics of Macrophage Sub-Populations in the Inflammatory Phase Following Joint Trauma
12:00PM-12:50PM
Abstract Number: 2014
The Relative Diagnostic Utility of Inflammatory Back Pain Criteria in an Inception Cohort of Patients with Psoriasis, Iritis, and Colitis Presenting with Undiagnosed Back Pain
12:00PM-12:50PM
Abstract Number: 1963
Variation in Quality of Care Among Patient Sociodemographic Groups in RISE Practices
3:00PM-3:50PM
Abstract Number: 1952
Activated Memory T Cells Produce Ligands That Cause NF-κB-dependent Inflammatory Activation of the Endothelium: Identification of Novel Therapeutic Targets
3:00PM-3:50PM
Abstract Number: 2001
Adverse Effects of Low Dose Methotrexate: Adjudicated Hematologic Outcomes in a Large Randomized Double-blind Placebo-controlled Trial
3:00PM-3:50PM
Abstract Number: 1949
CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro
3:00PM-3:50PM
Abstract Number: 2036
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
3:00PM-3:50PM
Abstract Number: 1977
Delivering Fracture Prevention Through Telemedicine: A Process Evaluation
3:00PM-3:50PM
Abstract Number: 1950
Elevated Serum Gasdermin D N-terminal Implicates Macrophage Pyroptosis in Adult-onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis
3:00PM-3:50PM
Abstract Number: 2035
Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design
3:00PM-3:50PM
Abstract Number: 2037
Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts
3:00PM-3:50PM
Abstract Number: 1976
High Disease Activity Is Associated with Incident Osteoporotic Fractures Among Veterans with Rheumatoid Arthritis
3:00PM-3:50PM
Abstract Number: 1999
Hydroxychloroquine Is Not Cardiotoxic in Patients with Rheumatoid Arthritis
3:00PM-3:50PM
Abstract Number: 1948
Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes
3:00PM-3:50PM
Abstract Number: 2002
Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib
3:00PM-3:50PM
Abstract Number: 2033
Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
3:00PM-3:50PM
Abstract Number: 1951
Possible Involvement of Fractalkine/CX3CR1 Axis in Peripheral CD14++CD16+ Monocytes in Disease Development of Patients with Systemic Lupus Erythematosus
3:00PM-3:50PM
Abstract Number: 1975
Predicting Bone Mineral Density of Lumbar Vertebrae by Assessing Plain Film with Deep Learning
3:00PM-3:50PM
Abstract Number: 2034
Resolving Phenotypic and Prognostic Differences in Interstitial Lung Disease Related to Systemic Sclerosis by Computed Tomography-based Radiomics
3:00PM-3:50PM
Abstract Number: 2000
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
3:00PM-3:50PM
Abstract Number: 1998
Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis
3:00PM-3:50PM
Abstract Number: 1973
Treatment Sequences with Romosozumab Before or After Antiresorptive Medication
3:00PM-3:50PM
Abstract Number: 1974
Validation of a Deep Learning Based Algorithm to Diagnose Vertebral Compression Fractures
4:00PM-4:50PM
Abstract Number: 2042
A Low FODMAP Diet Is Not Associated with Decreased GI Symptoms or Changes in GI Microbial Composition in Patients with Systemic Sclerosis
4:00PM-4:50PM
Abstract Number: 2038
Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis
4:00PM-4:50PM
Abstract Number: 2004
Circulating Biomolecules as Potential Biomarkers of Early and Establishedresponse to TNFi Therapy in Rheumatoid Arthritis Patients
4:00PM-4:50PM
Abstract Number: 2040
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
4:00PM-4:50PM
Abstract Number: 2041
Disease Features of Systemic Sclerosis Are Associated with Alterations in Gastrointestinal Microbial Composition in Two Independent Cohorts
4:00PM-4:50PM
Abstract Number: 2005
Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis
4:00PM-4:50PM
Abstract Number: 2006
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
4:00PM-4:50PM
Abstract Number: 2003
Individualized Prediction of Response to Methotrexate Treatment in Patients with Rheumatoid Arthritis: A Pharmacogenomics-driven Machine Learning Approach
4:00PM-4:50PM
Abstract Number: 2028
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
4:00PM-4:50PM
Abstract Number: 2039
Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma
4:00PM-4:50PM
Abstract Number: 2029
Therapeutic Drug Monitoring Compared to Standard Treatment of Patients Starting Infliximab: Results from a Multicenter Randomized Controlled Trial of 400 Patients
4:00PM-4:50PM
Abstract Number: 2032
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis
4:00PM-4:50PM
Abstract Number: 2030
Treatment with Selective Cyclooxygenase-2 Inhibitors Is Associated with Inhibition of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
4:00PM-4:50PM
Abstract Number: 2031
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
4:00PM-4:50PM
Abstract Number: 2007
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-Severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate
5:00PM-5:50PM
Abstract Number: 2012
A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate
5:00PM-5:50PM
Abstract Number: 2018
Development and Validation of an Artificial Intelligence Approach for the Detection of Radiographic Sacroiliitis
5:00PM-5:50PM
Abstract Number: 2022
Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – Results from a Prospective Study Using PET-MRI of SIJ and Spine
5:00PM-5:50PM
Abstract Number: 2011
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
5:00PM-5:50PM
Abstract Number: 2019
Preliminary Definition of a Positive MRI for Active Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis
5:00PM-5:50PM
Abstract Number: 2020
Preliminary Definition of a Positive MRI for Structural Lesions in the Sacroiliac Joints in Axial Spondyloarthritis
5:00PM-5:50PM
Abstract Number: 2008
Should We Use Glucocorticoid in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
5:00PM-5:50PM
Abstract Number: 2010
Stable versus Tapered and Withdrawn Treatment with Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Remission: A Randomized, Open-Label, Phase 4, Non-Inferiority Trial
5:00PM-5:50PM
Abstract Number: 2021
The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
5:00PM-5:50PM
Abstract Number: 2009
Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study

« View all sessions from this meeting